



# OKLAHOMA State Department of Health

## OKLAHOMA CENTRAL CANCER REGISTRY

### CANCER DATA REPORTING MANUAL

Updated for 2024



**OKLAHOMA**  
State Department  
of Health

This publication was issued by the Oklahoma State Department of Health (OSDH), an equal opportunity employer and provider. A digital file has been deposited with the Publications Clearinghouse of the Oklahoma Department of Libraries in compliance with section 3-114 of Title 65 of the Oklahoma Statutes and is available for download at <https://digitalprairie.ok.gov/digital/collection/stgovpub>. | Issued May 2024

**OKLAHOMA STATE DEPARTMENT OF HEALTH**

Website: <http://www.oklahoma.gov/health>

**Keith Reed, RN, MPH, CPH  
Commissioner of Health**

**Derek Pate, DrPH  
Center for Health Statistics Director**

**Meagan Carter, MS  
State Cancer Registry Program Manager**

**OKLAHOMA CENTRAL CANCER REGISTRY**

Website:

<https://oklahoma.gov/health/health-education/chronic-disease-prevention/oklahoma-central-cancer-registry-occr.html>

Oklahoma State Department of Health  
Center for Health Statistics  
123 Robert S. Kerr Ave  
Oklahoma City, OK 73102-6406  
Phone: (405) 426-8030  
Fax: (405) 900-7604

## OCCR STAFF

Meagan Carter, MS  
State Cancer Registry Program Manager  
[meagan.carter@health.ok.gov](mailto:meagan.carter@health.ok.gov)  
405-426-8742

Christy Dabbs, AA, ODS-C  
Data Manager  
[christyd@health.ok.gov](mailto:christyd@health.ok.gov)  
405-426-8012

Sandie James Steen, ODS-C  
Education & Training Specialist  
[sandra.steen@health.ok.gov](mailto:sandra.steen@health.ok.gov)  
405-426-8012

Judy Hanna, HT (ASCP), ODS-C  
Pathology Laboratories Specialist  
[judyh@health.ok.gov](mailto:judyh@health.ok.gov)  
405-426-8013

Lisa Fulkerson, RMA  
Facility Consultant, Large Hospitals  
[lisaf@health.ok.gov](mailto:lisaf@health.ok.gov)  
405-426-8015

Vacant  
Facility Consultant, Ambulatory Surgery  
Center & Dermatology Office  
[occr@health.ok.gov](mailto:occr@health.ok.gov)

Megan Ryan, AAS  
Facility Consultant, Treatment Center &  
Physician Office  
[megan.ryan@health.ok.gov](mailto:megan.ryan@health.ok.gov)  
405-426-8169

Leslie Dill  
Facility Consultant, Small Hospitals  
[leslied@health.ok.gov](mailto:leslied@health.ok.gov)  
405-426-8017

## **ACKNOWLEDGEMENTS**

The Oklahoma Central Cancer Registry would like to acknowledge the technical references used in writing this manual.

- Standards for Oncology Registry Entry (STORE) 2024
- International Classification of Diseases for Oncology Third Edition (ICD-O-3)
- NAACCR Data Standards and Data Dictionary, Volume II – Version 24
- SEER Program Coding and Staging Manual 2024
- SEER 2024 Solid Tumor Rules, 2024 Update
- SEER Hematopoietic and Lymphoid Neoplasm Database and Coding Manual
- Grade Coding Instructions and Tables v3.1, published October 2024
- SSDI Manual v3.1, published October 2024

Table of Contents

OKLAHOMA STATE DEPARTMENT OF HEALTH .....2

    OCCR Staff .....3

    Acknowledgements.....4

SECTION 1.....9

INTRODUCTION TO CANCER REPORTING .....9

    Acronyms.....12

    Terms Common to Cancer Data reporting.....13

    Coding Primary Site and Histology.....15

    Cancer Registry Resources for Cases diagnosed Beginning 2018 .....16

SECTION 2.....22

STANDARDS FOR CONFIDENTIALITY, DISCLOSURE OF DATA AND DATA QUALITY .....22

    HIPAA.....23

    Confidentiality Policies.....23

    Information Requests.....23

    Disclosure Of Data.....24

    OCCR Computer Security .....24

    Paper Records .....25

    Handling of Data in the Field.....25

    Hard Copies of Medical Records .....25

    Quality Assurance .....26

SECTION 3.....28

REPORTABLE DISEASES AND CASEFINDING .....28

    Reportability.....29

    Reportable Diseases.....29

    Non-Reportable Diseases.....31

    Diagnosis – Pathological vs Clinical.....32

    Ambiguous Terminology For determining reportability .....32

    Differential Diagnosis .....33

    Casefinding.....34

    Multiple Primaries and Histologies .....36

    OCCR Coding and Staging Requirements by Manual & Diagnosis Year.....38

SECTION 4.....39

REPORTING REQUIREMENTS .....39

    Timeliness.....40

    Submission Schedule.....40

SECTION 5.....41

PATIENT INFORMATION.....41

    Reporting Facility Number .....42

    Type of Reporting Source.....42

    Date of First Contact .....44

    Accession Number.....45

    Medical Record Number .....46

    Class of Case.....46

    Last Name.....48

    First Name .....49

    Middle Name.....49

Name-Birth Surname .....	50
Alias Name .....	50
Street Address at Diagnosis .....	51
Address at Diagnosis – Supplemental.....	52
City at Diagnosis .....	52
State at Diagnosis.....	53
Postal Code at Diagnosis .....	53
County at Diagnosis.....	53
Country at Diagnosis .....	54
Social Security Number .....	54
Date of Birth .....	55
Birthplace – State.....	56
Birthplace – Country .....	56
Race 1–5 .....	56
Spanish/Hispanic Origin .....	58
Sex .....	59
Text Usual Occupation .....	60
Text Usual Industry .....	61
Tobacco Use Smoking Status .....	61
Text–Remarks.....	62
Sequence Number.....	63
Primary Payer at Diagnosis .....	64
Medicare Beneficiary Identifier .....	64
SECTION 6.....	66
CANCER INFORMATION .....	66
Date of Initial Diagnosis .....	67
Estimating Dates .....	68
Morphology ICD-O-3: Type and Behavior .....	69
Primary Site .....	71
Grade Clinical .....	73
Grade Pathological.....	73
Grade Post Therapy Clin (yc).....	74
Grade Post Therapy Path (yp) .....	75
Laterality .....	75
Lymphovascular Invasion.....	77
Diagnostic Confirmation .....	78
Primary Site Text .....	79
Histology Text.....	80
Pathology Text.....	80
Physical Exam Text .....	81
X-ray/Scan Text .....	82
Lab Tests Text.....	83
Scopes Text.....	84
SECTION 7.....	86

STAGING .....	86
SEER Summary Stage 2018.....	87
Text Staging.....	89
Site-Specific Data Items (SSDI) .....	89
STAGE PROGNOSTIC FACTORS.....	91
Tumor Size Summary .....	91
SECTION 8.....	95
SOLID TUMOR RULES .....	95
History of the Multiple Primary and Histology Coding Rules and Solid Tumor Rules .....	96
Using the Solid Tumor Rules .....	96
SECTION 9.....	98
ABSTRACTING TREATMENT DATA.....	98
Text Requirements.....	99
First Course of Treatment .....	99
Diagnostic Procedure .....	100
Date of Diagnostic Procedure .....	101
DX Procedures Text.....	102
Date 1 <sup>st</sup> Course RX CoC.....	103
RX Summary – Scope of Reg LN Surgery.....	104
Regional Nodes Positive.....	107
Regional Nodes Examined.....	109
RX Date - Surgery .....	111
RX Summ--Surg Prim Site 03-2022.....	111
RX Summ--Surg Prim Site 2023 .....	113
Rx Date - Most Definitive Surgical Resection of The Primary Site .....	113
Reason for No Surgery of Primary Site .....	114
RX Summ--Surg Other Regional/Distant .....	115
Text Surgery .....	116
Date Radiation Started.....	117
Radiation Treatment Modality Phase I .....	117
Text Radiation (Beam & Other).....	118
RX Summary - Surgery/Radiation Sequence .....	119
Reason for No Radiation .....	120
Date Chemotherapy Started .....	121
RX Summ--Chemo .....	121
Text Chemo .....	123
Date Hormone Therapy Started.....	123
RX Summ – Hormone Therapy.....	124
Text Hormone .....	125
Date BRM (Immunotherapy) Started.....	126
RX Summ – BRM (Immunotherapy).....	126
Text – BRM (Immunotherapy) .....	127
RX Summ – Hematologic Transplant/Endocrine Procedure .....	128
RX Summary Systemic/Surgery Sequence .....	130
Date Other Treatment Started.....	131

Other Treatment .....	131
Text Other Treatment .....	133
RX Summ – Treatment Status .....	133
Date Case Completed.....	134
Abstracted By .....	134
SECTION 10.....	135
ABSTRACTING FOLLOW-UP DATA .....	135
Date of Last Contact or Date of Death .....	136
Vital Status .....	136
Place of Death – State .....	137
Place of Death – Country .....	137
Follow-Up Source .....	138
SECTION 11.....	139
DATA REVIEW GUIDLEINES .....	139
APPENDIX A – Reporting Laws and HIPAA .....	141
Federal Legislation .....	142
Oklahoma Legislation .....	142
Health Insurance Portability and Accountabiity Act (HIPAA) .....	142
APPENDIX B – Instructions for Lymphatic & Hematopoietic Diseases .....	143
APPENDIX C – SEER Country and State Codes .....	146
APPENDIX D – Common Abbreviations.....	156
APPENDIX E – 2024 Changes and Updates .....	180
APPENDIX F – Required Data Items .....	185
APPENDIX G – Texting Table .....	190



# **SECTION 1**

# **INTRODUCTION TO CANCER REPORTING**

## A BRIEF HISTORY OF THE OKLAHOMA CENTRAL CANCER REGISTRY (OCCR)

### 1991

The Oklahoma legislature recognized the need for defining the cancer burden in Oklahoma. Oklahoma Statute Title 63 Public Health and Safety, Title 310, Chapter 567 [[Appendix A](#)] established the existence of the Oklahoma Central Cancer Registry (OCCR) under the control of the Oklahoma State Department of Health. The inclusion of data necessary for epidemiologic surveys and scientific research along with other data necessary to further the recognition, prevention, control, treatment and cure of cancer, precancerous and tumorous disease was mandated. Unfortunately, no funding was provided.

### 1992

The National Program of Cancer Registries (NPCR) is established by US Public Law 102-515, [[Appendix A](#)] administered by US Centers for Disease Control and Prevention (CDC). The law authorizes the CDC to provide funds and technical assistance to states and territories to improve existing cancer registries and implement registries where none existed.

### 1994

NPCR began providing financial support and technical assistance to state health departments for statewide, population-based cancer registries. This funding, along with an emergency amendment by the Oklahoma State Legislature to fund a state cancer registry led to the official establishment of the OCCR in 1995, with a reference date of data submission of January 1, 1997. Cancer cases occurring prior to the reference date are not required to be reported.

Cancer registries are data systems for collecting, storing, and managing information about people with cancer. Registries are essential for cancer surveillance, research, and development of effective cancer treatment. For cancer data to be useful, it must be accurate, timely and complete. This manual was developed to assist in generating reliable cancer data.

The importance of quality cancer data reporting and the role of cancer registries can be summed up by the following:

Measures of cancer survival at the population level rely on our extensive surveillance infrastructure, particularly a national network of high-quality cancer registries. These cancer survival measures offer new insights into the need to address inequities in cancer diagnosis, treatment, and survivorship. Together with data regarding cancer incidence and death rates, cancer survival measures provide a comprehensive picture of the burden of cancer in a population and support public health efforts to prevent new cancers, extend survival and quality of life after a cancer diagnosis, and reduce cancer health disparities.<sup>1</sup>

---

<sup>1</sup> <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5846186/>

The Oklahoma Central Cancer Registry (OCCR) is able to provide outstanding data to the North American Association of Central Cancer Registries (NAACCR) and the National Program of Cancer Registries (NPCR) due to the collective efforts of all Oklahoma cancer reporters, including the highest certification from NAACCR, **Gold Standard for Quality, Completeness and Timeliness** for the past 8 years.

## ACRONYMS

ACoS–American College of Surgeons

ACS–American Cancer Society

AJCC–American Joint Committee on Cancer

CDC–Centers for Disease Control and Prevention

CoC–Commission on Cancer (of the American College of Surgeons)

CCR–Central Cancer Registry

CTR–Certified Tumor Registrar

DOH–Department of Health

DVR–Division of Vital Records

EDITS–Exchangeable-edits, Data–dictionary, and Information Translation Standard

EOD–Extent of Disease

FIPS–Federal Information Processing System

HIPAA–Health Insurance Probability and Accountability Act

ICD-O-3–International Classification of Diseases for Oncology, Third Edition, 2000

JC–Joint Commission (previously JCAHO Joint Commission on Accreditation of Healthcare Organizations)

NAACCR–North American Association of Central Cancer Registries

NCDB–National Cancer Data Base

NCI–National Cancer Institute

NCRA–National Cancer Registrars Association

NIH–National Institutes of Health

NPCR–National Program of Cancer Registries, CDC

OCCR–Oklahoma Central Cancer Registry

OCRA– Oklahoma Cancer Registrars Association

SEER–Surveillance, Epidemiology, and End Results a Program of NCI

SS – Summary Stage

STORE – Standards for Oncology Registry Entry

TNM–Tumor, Nodes, Metastasis (staging system of AJCC and UICC)

WHO – World Health Organization

## TERMS COMMON TO CANCER DATA REPORTING

**Abstract** – A review of detailed medical records, summarized in an organized reportable form for each incident of malignancy.

**Cancer/Cancerous** – A collection of diseases in which body cells multiply without stopping. Most cancer can form masses called tumors and spread into surrounding tissues. The cells can also travel throughout the body via blood vessels and the lymphatic system where additional tumors can develop. Leukemias, cancers of the bone marrow and blood, generally do not form tumors. Another term for cancer is malignancy.

**Clinic** – Any licensed medical facility serving persons on an outpatient basis, which provides a diagnosis and/or treatment of cancerous and precancerous conditions.

**Cytology** – The study of cells under microscope to aid in diagnosing diseases and conditions.

**Diagnostic Services** – Any service that identifies the nature of an illness including cancerous diseases or precancerous diseases by examination including, but not limited to, imaging, laboratory testing.

**Facility** – A general term used for any licensed or certified medical establishment that provides patient care on an inpatient or outpatient basis including diagnostic services and/or treatment of cancerous and precancerous conditions.

**Hematopoiesis & Hematopoietic System** – Relating to the production of blood (blood cells, plasma etc.) and the organs and tissues, primarily the bone marrow, spleen, tonsils, and lymph nodes involved in the production of blood.

**Histology** – The microscopic study of biologic tissue. Histology in cancer reporting includes, but is not limited to, morphology, grade, and behavior.

**Hospital** – A licensed healthcare institution equipped and staffed for the purpose of diagnosing and treating patients with cancer, including medical and surgical care on an inpatient or outpatient basis.

**Hospital Identifier** – A unique code assigned by the OCCR to each reporting facility in Oklahoma for identification of cancer cases reported from each facility.

**In Situ** – A group of abnormal cells that remain where they first formed within the body. These abnormal cells may become invasive and spread into nearby tissue.

**Laboratory** – A facility providing a wide range of procedures that aids physicians in carrying out the diagnosis, treatment, and management of cancer. This includes, but is not limited to, histopathology (examination of tissue), cytopathology (examination of fluids), and hematology (examination and characterization of blood) related to both cancerous and precancerous conditions.

**Lymphoid** – Relating to the lymphatic system including lymph, lymph nodes, bone marrow, and other lymphatic tissue that produces lymphocytes (a type of white blood cells).

**Pathologist** – A physician certified by the American Board of Pathology and licensed by the state to carry out pathologic examination of bodily tissues. This includes the diagnosis of cancerous and precancerous conditions.

**Physician** – Any person who has completed a course of medical training resulting in a medical degree and licensed by the Oklahoma Board of Medical Licensure and Supervision or the Oklahoma Osteopathic Board of Examiners to practice medicine.

**Precancerous Condition** – A disease process exhibiting abnormal cells with an increased risk of developing into cancer.

**Registry** – A computerized system for collecting and compiling cancer data in a standard format, with the functional ability to merge data from various sources and perform correlations among a variety of data elements. Summary reports and statistical analysis reports can be generated from registry data.

**Solid Tumor** – A tumor that develops in body tissue other than lymphoid tissue, bone marrow or blood. Examples include bone, skin, and organs.

**Stage of Disease** – Stage defines the extent of a patient’s malignancy and can change throughout the disease process. This includes disease limited to localized tissue, invasion from the original tumor into surrounding tissue, invasion of regional lymph nodes (usually lymph nodes in the typical draining pathway of the primary site of disease) and distant spread (distant metastasis) including distant tissue and distant lymph nodes.

**TNM** – The three components of tumor staging: T – tumor, N – nodes (regional lymph nodes), and M – metastasis.

**Treatment Services** – The delivery of therapeutic services for cancerous disease or precancerous conditions, performed in a medical facility.

**Tumor/Tumorous** – A circumscribed, non-inflammatory growth arising from existing tissue but growing independently of the normal rate or structural development of such tissue and serving no physiological function. Tumors may or may not be malignant.

Additional cancer related definitions can be found on the NCI website and the SEER Glossary for Registrars.

<https://www.cancer.gov/publications/dictionaries/cancer-terms/>

<https://seer.cancer.gov/seertools/glossary/>

## CODING PRIMARY SITE AND HISTOLOGY

Primary site and histology are the backbones of accurate cancer abstracting. Along with date of diagnosis, data items are generated based on combinations of primary site and histology; therefore, coding these two items correctly is crucial. The standard setters for coding primary site and histology for cancer reporting in the United States are SEER and the CoC.

### PRIMARY SITE

According to the SEER Program Coding and Staging Manual 2021, the principal resource for coding primary site (topography) is the [International Classification of Disease for Oncology, Third Edition \(ICD-O-3\)](#). The Solid Tumor Rules manual is used in conjunction with the ICD-O-3 for additional primary site coding guidance for cancers with site specific modules, including Head and Neck, Breast, Lung, and others. The full list can be found in [Section 8, Solid Tumor Rules](#).

**Exception** – Since 2010 primary site for hematopoietic and lymphoid neoplasms is coded according to the SEER [Hematopoietic and Lymphoid Neoplasm Database](#) and [Coding Manual](#).

*Note – although the ICD-O-3 had updates for coding morphology/histology for 2023, no topography codes were changed.*

### HISTOLOGY

Beginning January 1, 2001, ICD-O 3 was the primary resource for coding the correct histology/morphology for all cancer cases. As of January 1, 2018, the Solid Tumor Rules are the primary source for coding histology for the following sites:

- Breast
- Colon (includes rectosigmoid and sigmoid colon)
- Cutaneous Melanoma (beginning 1/1/2021)
- Head & Neck
- Kidney
- Lung
- Malignant CNS and Peripheral Nerves
- Non-malignant CNS
- Urinary Sites (includes bladder, renal pelvis, ureter, etc.)
- Other Sites (beginning 01/01/2023)

The Solid Tumor Rules will continue to be the first manual to consult when coding histology for the above-mentioned sites for diagnosis year 2024, followed by these resources listed in priority order:

1. ICD-O 3.2: <https://www.naaccr.org/icdo3/>
2. SEER Inquiry System: <https://seer.cancer.gov/seer inquiry/index.php>
3. Ask a SEER Registrar: <https://seer.cancer.gov/registrars/contact.html>

**Exception** – as with coding primary site, hematopoietic malignancies (leukemia, lymphoma, etc.) have their own set of rules for coding histology/morphology. Please refer to the [SEER Hematopoietic and Lymphoid Neoplasm Database](#) and [Coding Manual](#).

## CANCER REGISTRY RESOURCES FOR CASES DIAGNOSED BEGINNING 2018

### 1. International Classification of Diseases for Oncology (ICD-O) Manuals

**Use:** To determine applicable codes for primary site (topography) and histology (morphology) of solid tumors.

**ICD-O-3.1** is currently available only in PDF form. The PDF or printed of ICD-O-3, 1<sup>st</sup> revision (“purple” book) versions are still valid for coding primary site. The book has three main sections: topography, morphology, and the alphabetic index. The grade information is **obsolete**. Use only for coding primary site in conjunction with the Solid Tumor Rules manual. ICD-O-3.1 and 3.2 should only be used as the second resource for assigning histology as previously instructed. ICD-O-3 has been obsolete for hematopoietic and lymphoid neoplasms since 2010. The source for coding primary site for these conditions is the SEER hematopoietic and lymphoid neoplasm database and coding manual.

**ICD-O-3.2** are secondary resources for coding histology. ICD-O-3.1 is applicable from diagnosis year 2018 through 2020. ICD-O-3.2 is applicable for diagnosis year 2021 and forward for solid tumors. It is important to use the correct manual for the diagnosis year being abstracted as major changes were implemented in both versions. The North American coding guidelines and supplemental tables are available on the NAACCR website. Currently there is no PDF or printed book available for version 3.2, only the spreadsheet available at the link below.

ICD-O-3.2 2024 revisions:

<https://www.naaccr.org/icdo3/>

See previous guidelines, at the link above, for historical revisions.

### 2. American Joint Committee on Cancer (AJCC) Cancer Staging Manual, 8th Edition, 3<sup>rd</sup> Printing (Effective for cases diagnosed January 1, 2018, and after)



*Note: OCCR does not require AJCC TNM staging. This information is included for informational purposes and for facilities who wish to assign AJCC staging or who are required to assign it for other standard setters.*

**Use:** To determine TNM Stage and Stage Grouping

TNM staging is a process for determining the severity of cancer. Each letter stands for a different part of the staging formula. T defines the tumor's size and extension into nearby tissue; N defines spread into regional lymph nodes and M defines metastasis (spread of cancer to other parts of the body).

TNM stages are categorized by clinical stage and pathological stage. Clinical Staging determines how much cancer there is based on the physical examination, imaging tests, endoscopies, and biopsies of affected areas prior to any cancer treatment. Pathologic staging can only be determined for patients who have had surgery to remove a tumor or explore the extent of disease. Pathologic staging combines the results of both the clinical staging with surgical results such as operative findings from the surgeon and pathology reports from the resected specimen.

Each primary site has a chapter within the TNM Manual; however, there are guidelines in **chapter one** that must be read before moving on to site specific chapters.

The current AJCC Cancer Staging Manual is available by purchase only. The 1<sup>st</sup> edition through 7<sup>th</sup> edition AJCC manuals are available for free as scanned PDFs here:

<https://cancerstaging.org/references-tools/deskreferences/Pages/default.aspx>

Free training webinars are available from AJCC on how to use the manual:

<https://www.facs.org/quality-programs/cancer/ajcc/staging-education/registrar>

Beginning in 2021, as each chapter is revised, it will be released in **Kindle format and paperback**. AJCC is transitioning from "editions" to "versions". There are no plans currently to release a Version 9 printed book containing all chapters. The first chapter revised and released in Version 9 electronic format was Cervix Uteri.

[FAQ for Version 9 Cancer Staging System](#)

### 3. Standards for Oncology Registry Entry (STORE) Manual

<https://www.facs.org/Quality-Programs/Cancer/NCDB/call-for-data/cocmanuals>

The current STORE manual is for cases diagnosed beginning 1/1/2024. Previous editions are also available at the above website and should be used for the applicable diagnosis year.

**Use:** Utilized by the OCCR for coding instructions.

This manual provides instructions and standards for coding and should be the first manual referenced to determine applicable codes, unless indicated otherwise.

**4. SEER Program Coding & Staging Manual diagnosis year 2024**

<https://seer.cancer.gov/tools/codingmanuals/index.html>

Previous editions are available here:

<https://seer.cancer.gov/tools/codingmanuals/historical.html>

**Use:** Utilized by the OCCR for coding instructions.

This manual provides instructions and standards for coding and should be the second manual referenced to determine applicable codes, unless indicated otherwise.

**5. CTR Guide to Coding Radiation Therapy Treatment version 6.0 January 2024**

Appendix R of the 2024 Store manual linked above.

**Use:** Coding radiation data items for 01/01/2018 and forward

The method of collecting radiation data items changed significantly in 2018. This manual provides extensive instructions on how to code the data and provides comprehensive case studies with the intent to provide coding examples for 95% of the most common scenarios cancer registrars will encounter.

**6. NAACCR v24A Edit Detail Report**

<https://www.naacr.org/standard-data-edits/>

**Use:** Understand and resolve edits.

The NAACCR v24B Edit Detail Report is a document describing each edit in the metafile, which data items are included in each edit and the edit logic. If an error occurs when running edits on an abstract, this document can be helpful in understanding why it occurred and how to resolve it.

*Note:* Be sure you are using the edit detail report that corresponds to the version of the edit metafile in your software. Edit metafile versions are indicated by a number followed by a letter if the version has been revised. As of the writing of this manual, v24B is the most current version available. If you are unsure what version your software is using, please contact the software vendor.

**7. SEER Summary Stage 2018, v3.1 (published October 2023)**

(Effective for cases diagnosed January 1, 2018, and forward)

<https://seer.cancer.gov/tools/ssm/>

*Note:* SEER Summary Stage is the staging system used by the Oklahoma Central Cancer Registry and is a required data item.

**Use:** To determine SEER Summary Stage.

Summary stage is the most basic way of categorizing how far a cancer has spread from its point of origin. The 2018 Summary Staging Manual includes all anatomical sites including lymphoma and leukemia. All information in the medical record is used to establish stage and does not limit staging based on whether or not the patient has had primary site surgery. The manual includes a general instructions chapter along with modules for each specific site. As with all cancer coding manuals, the **general instructions** must be reviewed **first** to avoid coding errors.

*Note:* SEER Summary Stage is also included in SEER\*RSA. However, general instructions are only available in the summary stage manual.

## 8. NAACCR Site Specific Data Items (SSDI) v3.1

(Effective for cases diagnosed January 1, 2018, for software converted to NAACCR v24)

<https://apps.naacr.org/ssdi/list/>

**Use:** Provides instructions for coding Site-Specific Data Items

The SSDI Manual is the primary resource for documentation and coding instructions for site-specific data items introduced in 2018. There are two versions available at the above web address. Version 3.0 for use with NAACCR v23 layout, diagnosis years 2018 forward and version 3.1 for use with NAACCR v24 layout, diagnosis years 2018 forward. The individual version selections are above and to the right of the blue “Resources” box on the web page. Within the blue area there are links for the SSDI manual, appendices, grade manual and a change log. Review the opening chapters of the manual before moving on to individual schemas (primary site groupings) to learn about timing for collecting SSDIs and general rules for entering lab values and other measurements. The individual schemas are also listed in the manual. Once you have become familiar with SSDIs, you may wish to reference the interactive cancer schema list on the SSDI webpage.

*Note:* Schema instructions take priority over the general instructions when they differ from the general instructions. SSDI individual schema information is also included in SEER\*RSA. However, general instructions are only available in the SSDI manual.

## 9. 2018 Grade Coding Instructions and Tables (Grade Manual) v3.1

(Effective for cases diagnosed January 1, 2018, for software converted to NAACCR v24)

<https://apps.naacr.org/ssdi/list/>

**Use:** Coding instructions for Grade data items.

The Grade Coding Instructions and Tables (Grade Manual) is the primary resource for documentation and coding instructions for Grade. Before using the Grade Manual as a coding reference, it is important to **review the introductory materials and general instructions of the manual** carefully. These reflect several important changes in the collection of Grade data items, including use of AJCC–recommended grade tables where applicable, and the introduction of Clinical, Pathological and Post–Therapy Grade data items.

*Note:* Grade data items are also included in SEER\*RSA. However, general instructions are only available in the Grade manual.

#### 10. SEER Solid Tumor Rules

<https://seer.cancer.gov/tools/solidtumor/>

**Use:** To determine the appropriate histology code and whether a tumor is considered one or multiple primaries based on its site, histology, and in some cases, date of diagnosis.

The 2018 Solid Tumor coding rules replace the 2007 Multiple Primary and Histology (MP/H) rules for most sites. Unlike the previous MPH rules, The Solid Tumor Rules are only available in text format. Within the solid tumor rules, the multiple primary rules are used to determine the number of primaries. The histology coding rules are used to determine histology. The rules are hierarchical and must be followed in order. Use the first rule that applies and then **stop**, do not go any further.

*Note:* The rules do not apply to hematopoietic primaries (lymphoma and leukemia) of any site. Use the Hematopoietic and Lymphoid Neoplasm Coding Manual for determining multiple primaries and histology.

#### 11. SEER Hematopoietic and Lymphoid Neoplasm Database and Coding Manual

<https://seer.cancer.gov/tools/heme/>

**Use:** To determine primary site, histology, reportability, and multiplicity of hematopoietic and lymphoid neoplasms.

The Database contains abstracting and coding information for all hematopoietic and lymphoid neoplasms (9590/3–9992/3). The Coding Manual provides reportability instructions and rules for determining the number of primaries, the primary site and histology, and the cell lineage or phenotype.

#### 12. SEER Rx–Interactive Antineoplastic Drugs Database

<https://seer.cancer.gov/seertools/seerrx/>

**Use:** To research drugs or regimens used in treating cancer.

Utilize the search field to look for the drug or regimen in question. Select the name for more information about the drugs' category, type of cancer the drug is usually used for and if it is reportable.

### 13. NAACCR Data Dictionary Version 24

<https://apps.naaccr.org/data-dictionary/data-dictionary/version=24/chapter-view/>

**Use:** To provide a rationale for collecting a data item and for using the codes listed.

The NAACCR Data Dictionary Version 24 provides a description of each data item, along with the specific codes and definitions for data collection for 2023. Other versions are available for NAACCR record layout 22 and 23 . Earlier versions are available by request to NAACCR.

The NAACCR Data Standards and Data Dictionary web page was updated in 2023. A [demo](#) can be viewed on how to navigate and use the new website on the data [dictionary homepage](#).

# **SECTION 2**

## **STANDARDS FOR CONFIDENTIALITY, DISCLOSURE OF DATA AND DATA QUALITY**

## HIPAA

The Federal government addressed disclosure of confidential data within the Health Insurance Portability and Accountability Act of 1996 (HIPAA) enacted by Federal Public Law 104–191 and implemented beginning April 24, 2003. It provides access to protected health information without individual authorization for Health Care Operations that involve quality assessment and improvement activities. It also authorizes the release of data sets for the purpose of research and public health. The complete law can be found here: <https://www.hhs.gov/hipaa/index.html>

## CONFIDENTIALITY POLICIES

### Confidentiality

The OCCR program director has ultimate responsibility for maintaining confidentiality and compliance with Oklahoma state law and federal HIPAA guidelines. OCCR is bound by the rules of confidentiality as set forth by state laws, administrative rules, and this manual. Each staff member must sign a confidentiality agreement. Other departments, sections, or programs within the Oklahoma state department of health that are outside the OCCR and have a need for registry data, must also sign confidentiality agreements. The agreement describes their obligation regarding confidential data, documents that they have read this section of our confidential policy and acknowledges that the penalty for not complying constitutes commission of a class a misdemeanor with discipline in accordance with state policies. A copy of the confidentiality agreement is available upon request.

## INFORMATION REQUESTS

### Oklahoma Reporting Facilities

Requests from Oklahoma reporting facilities for data from the facility registry may be made by phone or in writing. Confidential information may be released to health care providers and institutions directly involved in the care of the patient.

The State Registry may release confidential data to treating hospitals for the purpose of patient follow-up. All requests for follow-up must follow 63 O.S., 1–551.1 and 1–552. Confidential data is information that can be used to identify a specific patient.

### Research Activities

Research activities are monitored by the Program Director who ensures that only relevant activities are undertaken. Data from the State Registry may be used in research projects upon approval. Such uses include survival statistics, epidemiological studies, planning of services, controlling the disease, and assessing the effects of intervention. Because any information that specifically identifies a healthcare professional is confidential, researchers must sign a confidentiality statement. This statement confirms their agreement to maintain patient confidentiality, cite the source of the data in any presentation or

publication, and provide the OCCR with copies of any publication or presentation prior to release. Violation of any part of the agreement shall prevent further access to the data and result in a letter of reprimand to the chief executive officer of the researcher's institution and other researchers at the institution may be denied access to data for an indeterminate time.

Article 5 of the Public Health Code under Oklahoma Statute Title 63 protects the identity of patients and physicians reported to the Oklahoma Central Cancer Registry through data submission. Written consent is required for the release of confidential information. The Commissioner of Health may authorize release of information for research activity in the interest of public health and welfare. Researchers must protect the confidentiality of patients. Only by obtaining the physician's signature, and a "release of confidential medical information" form from the patient, can a researcher request additional information or patient participation in a research project.

Research data will be provided only upon written request that **must** include:

- The exact purpose for the data requested.
- Agreement that the data will not be used for purposes other than agreed upon at the time of release.
- Data will not be released to unauthorized individuals or parties.
- Data that is no longer needed for the designated purpose will be returned or destroyed.

Confidential cancer registry data will **never** be made available to any institution for the purpose of recruiting new clients.

### **Cancer Patients**

If an individual were to call and ask if there is data in the state cancer registry about them, they would not be given any information. They will be referred to their treating physician for this information.

Data on deceased persons held in the cancer registry are subject to the same data release restrictions as those for the living.

## **DISCLOSURE OF DATA**

State law stipulates that patient data may be shared with other registries, private or governmental, within or outside of the state, provided that a reciprocal data sharing agreement, approved by the Commissioner of Health, is implemented with that registry.

## **OCCR COMPUTER SECURITY**

The Program Director is responsible for ensuring the overall security of the computer system. This includes verifying that only authorized individuals have access. Employees are strictly forbidden from releasing any information regarding codes, numbers, or names used to access the computer except to authorized individuals. **Failure to comply with the provision is grounds for immediate dismissal.**



Gaining access to confidential patient information is a four-tier security process. The first tier of protection is badge-only access to the OCCR's work environment. Visitors to the area are registered at the Oklahoma Commons reception desk and must be escorted by authorized OCCR employees. The second tier is the user login name and password for accessing OCCR computers. The password must be changed on a regular basis and must meet specific security measures to be valid. The third level of protection is provided by limited access to the network server where the OCCR database resides. Access is granted only to staff with authorized clearance. Finally, tier four is password access to the Rocky Mountain Cancer Data Systems (RMCDs) software. Only those individuals for whom access to the database is essential will be assigned usernames and passwords.

Read only access to **non-confidential** portions of RMCDs data can be granted to non-essential department users for research purposes.

## PAPER RECORDS

The need for paper records in today's environment is very limited. However, computer printouts of data with protected health information (PHI) are treated as medical records and all confidentiality procedures and rules apply. All personnel with a potential need for confidential paper records have locking file cabinets at their disposal as well as locked offices.

The Oklahoma State Department of Health (OSDH) server on which RMCDs is installed is backed up on a regular basis by the Office of Management and Enterprise Services.

### Handling of Data in the Field

Staff working in the field are discouraged from transporting any confidential information such as abstract forms or data disks. If confidential information must be transported in printed format, precautions are taken to protect the information. It will be carried in a locked briefcase, which will never be left unattended unless it is within a secure locked enclosure.

When a site visit is made, the abstract forms being discussed will be shown or discussed only with the individual responsible for initially submitting the abstract form or their supervisor and our OCCR staff member.

## HARD COPIES OF MEDICAL RECORDS

Medical records should **always** be submitted electronically. If absolutely necessary, documents containing confidential patient information may be sent by mail or courier service following these guidelines:

- Notify the recipient at OCCR prior to mailing them a package so they will be on alert.

- Securely enclose the records in tear resistant, tamper-proof packaging. **Do not** use thin pasteboard envelopes regardless of the carrier or class of mail. OCCR is not responsible for torn or lost packaging containing patient information.
- Always use tracking codes to determine if the package has reached its destination.
- Keep a copy of the records, or, at the very least, a listing of patient names and/or medical record numbers included in the mailing in the event there is a problem with package delivery.
- Address the package **exactly** as indicated below to ensure delivery to the proper person.

Center for Health Statistics  
Oklahoma Central Cancer Registry  
Name of cancer registry staff person receiving mail  
Oklahoma State Department of Health  
123 Robert S Kerr Ave STE 1702  
Oklahoma City, OK 73102-6406

## QUALITY ASSURANCE

OCCR follows quality assurance procedures established by SEER, the CDC NPCR, and NAACCR. This includes both internal and external processes to ensure the reliability, completeness, consistency, and comparability of Oklahoma reported data.

### Submission Review

The OCCR uses the CDC's Registry Plus™ Web Plus online software for facilities to upload their abstracted cancer cases. Prior to submission, abstracts must be run through current NAACCR edits to check for errors. All errors must be corrected prior to upload. Submitted data is processed through a set of edits at the central registry to ensure that it meets accuracy standards. The OCCR rejects uploaded case files if they do not clear 100% of the edits. Edits must be corrected before the case files can be resubmitted and accepted by the central cancer registry.

### Facility Training

OCCR staff provides training and education for Oklahoma cancer reporters via online training, Microsoft TEAMS video conference and telephone. Training encompasses the following topics:

- Use of RMCDS and Web Plus
- Casefinding and reportability
- Abstracting process and required data items
- Technical assistance

## Casefinding Audit

Each year, OCCR staff conducts casefinding audits to assess a facility's adherence to completeness requirements. Facilities will be selected randomly or specifically due to a significant reduction in reported cases. The auditor(s) will systematically review a facility's disease index and/or hospital discharge data, compare it with submitted cases from the facility in the OCCR database and determine if the audited facility has submitted all reportable cancers. A second method of auditing could involve an on-site visit to a facility to review the medical record for reportable cases. The purpose of an audit is threefold: to identify problem areas affecting a facility's casefinding process, provide advice on improving the process, and to aid in assessing the completeness of OCCR data.

## Reabstraction Data Quality Audits

The OCCR staff performs annual reabstraction audits. A reabstraction audit is a method for assessing the quality of a facility's abstracted data and text documentation. Facilities can be selected randomly, chosen when new abstractors are hired, chosen if text is consistently inadequate, or if patterns of inaccurate coding have been identified. Randomized cases from the selected facility's uploaded data will be reabstracted. If the intent of the audit is to evaluate text documentation, the chosen cases will be reabstracted based solely on the text provided by the audited facility. Cases that cannot be completely abstracted with text-only documentation will be reviewed with the facility abstractor and coaching on improvement will be provided. If the intent of an audit is to evaluate accuracy of coding, the audited facility will be notified of the selected cases and will be instructed on how to provide the necessary records to the auditor. Currently, medical records will need to be submitted to the OCCR. A second method of auditing could involve an on-site audit.

## Death Clearance

Death clearance is conducted annually to improve data completion and accuracy. The OCCR matches yearly incidence of cancer documented in the database against cancer deaths reported to the Oklahoma Division of Vital Records. If a match is found, the date of death and underlying cause of death are updated in the registry database. Any person with a documented, reportable cancer as a cause of death, and not listed in the OCCR database, must be investigated to identify potentially missed incidence of cancer. When a facility is listed on the death certificate as place of death, the OCCR uses this information for follow-back to the listed facility. Hospital discharge data is also used to identify possible follow-back sources.

Facilities are required to review all death clearance follow-back cases to determine if they have missed a reportable malignancy. In Oklahoma, a patient who dies with active cancer at a reporting facility must be reported to OCCR as a class of case 32 unless previously reported. The information required on a class of case 32 death includes demographics, date of diagnosis (or best estimate), type of cancer (primary site/histology) and any other readily available information about the cancer. If a case is determined to be non-reportable, facilities will be required to provide information from their medical record to assist the OCCR with reconciling the case. This includes an estimated date of diagnosis, as well as any information regarding another facility or a physician that may have treated the patient.

# **SECTION 3**

# **REPORTABLE DISEASES AND CASEFINDING**

Oklahoma requires that all hospitals, clinics, laboratories, pathologists, physicians, dentists, or facilities providing diagnostic or treatment services in relation to cancer or precancerous conditions, submit an abstract for each reportable diagnosis and/or treatment of cancer to the OCCR within 180 days of date of first contact. This includes but is not limited to hospitals, ambulatory surgery centers, free standing clinics, oncology clinics, and radiation oncology clinics. The data required includes patient demographics, diagnostic information, disease characteristics, first course of treatment, and vital status. The basis for these requirements is found in Oklahoma Administrative Code at <https://rules.ok.gov/code?q> (type “Cancer Registry” in the search box).

## REPORTABILITY

Cases reportable to the OCCR include patients newly diagnosed with cancer, clinically or pathologically; patients receiving first course cancer treatment; patients that present from an outside facility with a clinical diagnosis and are seeking tissue confirmation by biopsy; patients that have cancer previously diagnosed and treated elsewhere and present for diagnosis and/or treatment of recurrent or persistent disease; or patients who expire with active cancer at the reporting facility. Class of Case defines the facility’s role in the patient’s cancer diagnosis and treatment.

For a complete explanation, see [Class of Case](#) in Section 5.

Class of Case	Description
00	Newly diagnose a patient with a reportable disease
10-14	Diagnose and treat reportable diseases
20-22	Treatment only for a newly diagnosed reportable disease
30	Clinical diagnosis (imaging or physician statement) elsewhere and the patient presents to the reporting facility for a confirmatory biopsy (histologic confirmation). <b>DO NOT</b> report cases presenting for other types of diagnostic workup, including consult only, treatment plan only, and additional imaging.
32	Diagnose and/or treat recurrence or persistence of a reportable disease previously diagnosed and treated elsewhere. <i>Class of case 32 also includes patients who expire at a facility with active cancer.</i>
34, 36	Not required by the CoC but reportable to OCCR.

## REPORTABLE DISEASES

Diseases reportable to the OCCR include:

1. Malignancies with an ICD-O-3 (ICD-O-3.2 beginning with diagnosis year 2021) behavior code of 2 (in situ) or 3 (invasive) are reportable for all sites (for exceptions see Non-Reportable Diseases below).
2. Vulvar intraepithelial neoplasia (VIN III) C51.\_, vaginal intraepithelial neoplasia (VAIN III) C52.9, anal intraepithelial neoplasia (AIN III) C21.\_ are reportable to the NPCR and therefore reportable to the OCCR by all facilities. The class of case is either 34 or 36 depending on the facility’s role in caring for the patient.

3. Non-malignant primary intracranial and central nervous system tumors, diagnosed on or after 1/1/2004 with an ICD-O-3 behavior code of 0 or 1 are reportable for the following sites:
  - Meninges (C70.0, C70.1, C70.9)
  - Brain (C71.0- C71.9)
  - Spinal cord (C72.0)
  - Cauda equina (C72.1)
  - Olfactory nerve (72.2)
  - Optic nerve (C72.3)
  - Acoustic nerve (C72.4)
  - Cranial nerve NOS (C72.5)
  - Overlapping lesion of brain and CNS (C72.8)
  - Nervous system NOS (C72.9)
  - Pituitary gland (C75.1)
  - Craniopharyngeal duct (C75.2)
  - Pineal gland (C75.3)
4. As of diagnosis year 2021, GIST is reportable by default with behavior code /3 **unless stated to be benign**. If stated to be benign, the behavior code is /0 and not reportable. Prior to 2021 Gastrointestinal Stromal Tumor (GIST) (8936) was reportable if noted to have multiple foci, metastasis, positive lymph nodes, or stated to be malignant. Assign behavior code /3.
5. As of diagnosis year 2021, nearly all thymomas are reportable with behavior code /3 **unless stated to be benign**. Exceptions are microscopic thymoma or thymoma benign (8580/0), micronodular thymoma with lymphoid stroma (8580/1), and ectopic hamartomatous thymoma (8587/0) which remain non-reportable. Prior to 2021, thymomas are reportable if noted to have multiple foci, metastasis, positive lymph nodes, or stated by a physician to be malignant.
6. Beginning 1/1/2023, all cases diagnosed with pilocytic astrocytoma/juvenile pilocytic astrocytoma and related terminology are to be reported with behavior /1. They will no longer be collected with malignant behavior (/3). ICD-O code 9421/3 will be valid for the diagnosis of high-grade astrocytoma with piloid features or HGAP only. Coding instructions are included in the remarks section for 9421/1 and 9421/3 in the 2023 ICD-O Update Tables 1 and 2.
  - From 1976 to 2000, WHO assigned code 9421/3 to pilocytic astrocytoma of the brain. Beginning with the release of ICD-O-3 in 2001, WHO changed the behavior for this neoplasm from /3 to /1 making it non-reportable. 9421/3 was removed from ICD-O-3, however, the standard setting organizations in North America opted to continue collecting these tumors as 9421/3 in CNS sites. The practice did not change once benign/borderline CNS tumors became reportable in 2004. The exception being pilocytic astrocytoma/optic glioma of the optic nerve which are coded 9421/1 effective 2018 and forward.
  - The 5th Ed Central Nervous System Tumors reinstated code 9421/3 for a newly identified neoplasm: High-grade astrocytoma with piloid features (HGAP).

- Mature teratoma of the testis in adults is malignant (assign 9080/3) but continues to be non-reportable in prepubescent children (9080/0). Report only if pubescence is explicitly stated in the medical record. Do not report if there is no mention of pubescence in the medical record.
7. Cystic pancreatic endocrine neoplasm (CPEN), 8150/3.
  8. Beginning 2021, solid pseudopapillary neoplasm of pancreas, 8452/3 (synonymous with solid pseudopapillary carcinoma, C25.\_).
  9. Beginning 2021, early or evolving melanoma in situ, or any other early or evolving melanoma, is reportable.
  10. Beginning 2022, low-grade appendiceal mucinous neoplasm (LAMN) is reportable. LAMN now has a behavior of /2 and /3 making it reportable. LAMNs are slow-growing neoplasms that have the potential for peritoneal spread and can result in patient death. LAMNs demonstrate an interesting biology in that they do not have hematogenous dissemination risk, but risk for appendiceal perforation, which can result in peritoneal dissemination, repeated recurrences after surgery and even death.
    - 8480/2 Low-grade appendiceal mucinous neoplasm
    - 8480/2 High-grade appendiceal mucinous neoplasm
    - 8480/3 Appendiceal mucinous neoplasm with extra-appendiceal spread
  11. Beginning 01/01/2023
    - Lymphangiomyomatosis behavior has changed from /1 to /3 and is reportable.
    - Mesothelioma In situ (C38.4) is reportable.
  12. Beginning 01/01/2016
    - Lobular neoplasia grade III (LN III)/lobular intraepithelial neoplasia grade III (LIN III) breast C500-C509 is reportable.
    - Pancreatic intraepithelial neoplasia (PanIN III) is reportable.
    - Penile intraepithelial neoplasia III (PeIN III) is reportable.

## NON-REPORTABLE DISEASES

Malignancies **not** reportable to OCCR include:

1. Malignant primary skin cancers (C44.\_) with histology codes 8000-8005, 8010-8046, 8050-8084, 8090-8110.  
Example: squamous cell carcinoma (8070/3) and basal cell carcinoma (8090/3) of skin are not reportable.
2. Carcinoma in situ of the cervix (CIS), cervical intraepithelial neoplasia grade III (CIN III), and squamous intraepithelial neoplasia (SIN III) of cervix and skin.  
There are two histology codes for HPV-related adenocarcinoma in situ of the cervix. These are not reportable.
  - 8483/2 Adenocarcinoma in situ, HPV-associated (C530-C531, C538-C539)
  - 8484/2 Adenocarcinoma in situ, HPV-independent, NOS (C530-C531, C538-C539)
3. Prostatic intraepithelial neoplasia (PIN III) after 01/01/2001.

4. Serous borderline tumor micropapillary variant (C56.9) histology code 8460/2 beginning with diagnosis year 2018. Histology code 8460/2 is still reportable for non-invasive low grade serous carcinoma (C56.9).
5. Benign/borderline central nervous system tumors diagnosed prior to 2004.
6. Malignant tumors diagnosed prior to 1997 (OCCR reference date).
7. In situ (behavior code /2) lymphomas are not reportable.
8. Non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP), for primary site thyroid, code 8343/2. Reportable 2017-2020 only.
9. High grade dysplasia of the colon is not reportable even though it has been designated in situ (/2) in the WHO classification.

### DIAGNOSIS – PATHOLOGICAL VS CLINICAL

A pathological diagnosis is made by examining body tissues (histology) or fluids (cytology) under a microscope to identify the presence of malignant cells. A clinical diagnosis is made by a physician after a physical exam, reviewing signs and symptoms, lab reports and/or imaging tests. Most of the time a clinical diagnosis will be followed by a pathological diagnosis. Both methods of diagnosis are reportable with one exception. If a clinical diagnosis is made and is then proven to be benign by pathology, it becomes non-reportable.

### AMBIGUOUS TERMINOLOGY FOR DETERMINING REPORTABILITY

There are times when a definitive statement of malignancy cannot be found. A thorough review of a patient’s medical record may result in the finding of ambiguous terms. The ambiguous terms listed below are considered reportable when they are used in conjunction with the words malignant, cancer, carcinoma, sarcoma, etc.

Ambiguous Terms that Constitute a Reportable Diagnosis	
Apparent(ly)	Most likely (must have both words)
Appears	Presumed
Comparable with	Probable
Compatible with	Suspect(ed)
Consistent with	Suspicious (for)
Favors	Typical of
Malignant appearing	
Additional Terms that Constitute a Reportable Diagnosis for Nonmalignant Primary Intracranial and Central Nervous System Tumors Only*	
Neoplasm	Tumor
*Beginning with diagnosis year 2004 and only for C70.0-C72.9 and C75.1-C75.3	



**Note 1:** Do not substitute synonyms such as ‘supposed’ for ‘presumed,’ or ‘equal’ for ‘comparable.’ Do not substitute ‘likely’ for ‘most likely.’ Use only the exact words on the list or their conjugate forms, for example, “favored” is allowed as a substitute for ‘favor.’

**Note 2:** If a **cytology report** uses only an ambiguous term for the diagnosis, do not interpret it as a diagnosis of cancer. Do not report ambiguous cytology *unless* a physician makes a statement of malignancy, the patient receives cancer-directed therapy or tissue diagnosis confirms ambiguous cytology. Under these circumstances, cytology may be used as the date of diagnosis.

**Note 3:** The ambiguous terms list is applicable to hematopoietic and lymphoid neoplasms for determining **reportability only**. The use of ambiguous terms for assigning and reporting histology is covered in the Hematopoietic and Lymphoid Neoplasms Coding Manual.

[https://seer.cancer.gov/tools/heme/Hematopoietic Instructions and Rules.pdf](https://seer.cancer.gov/tools/heme/Hematopoietic%20Instructions%20and%20Rules.pdf)

Ambiguous Terms that <b>DO NOT</b> Constitute a Reportable Diagnosis	
Cannot be ruled out	Questionable
Equivocal	Rule out
Possible	Suggests
Potentially malignant	Worrisome

### EXAMPLES USING AMBIGUOUS TERMS

**Do report** – Mammogram report states breast mass is **suspicious** for malignancy. Suspicious for malignancy is reportable ambiguous terminology. Please note, BI-RADS terms are not considered diagnostic on their own. For example, BI-RADS 5, highly suggestive of malignancy, does not constitute a diagnosis.

**Do report** – Discharge summary final diagnosis states **probable** primary lung malignancy. Probable primary lung malignancy is reportable ambiguous terminology.

**Do not report** – An outpatient CT scan of the chest documents a right lower lobe lung nodule, **possible** malignancy. The patient has no other encounters with your facility. Possible is not a reportable ambiguous term.

**Do not report** – **Cytology** from bronchial washings, final diagnosis: **Suspicious** for malignancy. Suspicious is an ambiguous reportable term, but cytology is the exception (see Note 2).

### DIFFERENTIAL DIAGNOSIS

A **differential** diagnosis is made when a physician does not have enough information to assign a **definitive** diagnosis. Only report cases with a differential diagnosis if all possible disease processes mentioned are reportable.

**Do report** – CT exam of the chest shows a nodule in the left lower lung. The radiologist report has a differential diagnosis of **suspicious** for lung cancer vs **metastatic** lung lesion. Both are reportable terms.

**Do report** – Pathology report of brain tissue states **CNS lymphoma** vs **CNS metastasis** from unknown primary. Both are reportable conditions.

**Do not report** – MRI of the left thigh says deep tissue mass consistent with **atypical lipoma** or **liposarcoma**. The patient does not return to your facility. Atypical lipoma is not a reportable condition.

**Do not report** – Bone survey states patient has a solitary lesion in the right humerus compatible with a **bone island** or **solitary plasmacytoma**. “Compatible” is a reportable ambiguous term, but a bone island is not a reportable condition.

## CASEFINDING

Casefinding is a system for identifying every patient (inpatient or outpatient) who is diagnosed and/or treated with a reportable condition. The reporter for each facility is responsible for identifying all reportable conditions. Methods of casefinding include review of disease index, pathology reports, radiology reports and treatment records (surgery, chemotherapy, radiation, etc.).

### Medical Record Disease Index

The disease index is a comprehensive listing of all patients—inpatient or outpatient, who are discharged with an ICD-10-CM cancer diagnosis code. The disease index should be obtained after medical records are completed and coded and must be based on year of admission. The report should include the following information: patient first and last names, medical record number, date of birth, social security number, discharge date, all primary and secondary ICD-10-CM codes, and the type of encounter. Since many cancer patients have multiple encounters at a facility, the report should be sorted by medical record number. This will ensure all visits for each patient are grouped together. The facility reporter is responsible for reviewing each patient on the disease index to identify reportable cases.

The following list is to be used by appropriate staff to create the disease index. It includes the required reportable neoplasms and ICD-10-CM codes. An Excel spreadsheet and a PDF file with the current codes can be downloaded at: <https://seer.cancer.gov/tools/casefinding/>. If IT staff is available at your facility, enlist their help in creating the disease index report.

### How to use the Case Finding Code List for Reportable Tumors

In the first column, first row “C00.- - C43.-” means all codes that begin at C00.- and end at C43.- are included as reportable. For example, C00.9 is not specifically stated but it falls in that range as does C43.9. On the second row we find “C44.0, C44.9.” There are no dashes, therefore these are the only two codes that apply. They are not ranges.

<b>COMPREHENSIVE ICD-10-CM Casefinding Code List for Reportable Tumors (EFFECTIVE DATES: 10/1/2023-9/30/2024) Please refer to your standard setter(s) for specific reporting requirements before using the Casefinding List</b>	
<b>ICD-10-CM Code</b>	<b>Explanation of Code</b>
C00.- - C43.-, C4A.-, C45.- - C48.-, C49.- -C96.-	Malignant neoplasms (excluding category C44 and C49.A), stated or presumed to be primary (of specified site) and certain specified histologies
C44.00, C44.09	Unspecified/other malignant neoplasm of skin of lip
C44.10-, C44.19-	Unspecified/other malignant neoplasm of skin of eyelid
C44.13-	Sebaceous cell carcinoma of skin of eyelid, including canthus
C44.20-, C44.29-	Unspecified/other malignant neoplasm skin of ear and external auricular canal
C44.30-, C44.39-	Unspecified/other malignant neoplasm of skin of other/unspecified parts of face
C44.40, C44.49	Unspecified/other malignant neoplasm of skin of scalp & neck
C44.50-, C44.59-	Unspecified/other malignant neoplasm of skin of trunk
C44.60-, C44.69-	Unspecified/other malignant neoplasm of skin of upper limb, incl. shoulder
C44.70-, C44.79-	Unspecified/other malignant neoplasm of skin of lower limb, including hip
C44.80, C44.89	Unspecified/other malignant neoplasm of skin of overlapping sites of skin
C44.90, C44.99	Unspecified/other malignant neoplasm of skin of unspecified sites of skin
C49.A-	Gastrointestinal Stromal Tumors Note: All GIST tumors are now reportable starting in 2021 (per ICD-O-3.2), including GIST, NOS
D00.- - D05.-, D07.--D09	In-situ neoplasms <i>Note 1: Excludes carcinoma in situ of the cervix (D06._)</i> <i>Note 2: Excludes prostatic intraepithelial neoplasia (PIN III-8148/2) of the prostate. Other prostate in situ histologies are reportable.</i> <i>Note 3: For D04 (carcinoma in situ of the skin), excludes basal and squamous cell in situ lesions.</i>
D18.02	Hemangioma of intracranial structures and any site
D32.-	Benign neoplasm of meninges (cerebral, spinal and unspecified)
D33.-	Benign neoplasm of brain and other parts of central nervous system
D35.2 - D35.4	Benign neoplasm of pituitary gland, craniopharyngeal duct and pineal gland
D42.-, D43.-	Neoplasm of uncertain or unknown behavior of meninges, brain, CNS
D44.3 - D44.5	Neoplasm of uncertain or unknown behavior of pituitary gland, craniopharyngeal duct and pineal gland
D45	Polycythemia vera (9950/3) ICD-10-CM Coding instruction note: Excludes familial polycythemia (C75.0), secondary polycythemia (D75.1)
D46.-	Myelodysplastic syndromes (9980, 9982, 9983, 9985, 9986, 9989, 9991, 9992)
D47.02	Systemic mastocytosis
D47.1	Chronic myeloproliferative disease (9963/3, 9975/3) ICD-10-CM Coding instruction note: Excludes the following: Atypical chronic myeloid leukemia BCR/ABL-negative (C92.2_) Chronic myeloid leukemia BCR/ABL-positive (C92.1_) Myelofibrosis & Secondary myelofibrosis (D75.81) Myelophthisic anemia & Myelophthisis (D61.82)
D47.3	Essential (hemorrhagic) thrombocythemia (9962/3) Includes: Essential thrombocytosis, idiopathic hemorrhagic thrombocythemia

D47.4	Osteomyelofibrosis (9961/3) Includes: Chronic idiopathic myelofibrosis Myelofibrosis (idiopathic) (with myeloid metaplasia) Myelosclerosis (megakaryocytic) with myeloid metaplasia Secondary myelofibrosis in myeloproliferative disease
D47.9	Neoplasm of uncertain behavior of lymphoid, hematopoietic and related tissue, unspecified (9970/1, 9931/3)
D47.Z-	Neoplasm of uncertain behavior of lymphoid, hematopoietic and related tissue, unspecified (9960/3, 9970/1, 9971/3, 9931/3) <b>Note:</b> Effective 1/1/2021, PTLN (9971/3) is no longer reportable (9971/1)
D49.6, D49.7	Neoplasm of unspecified behavior of brain, endocrine glands and other CNS
D72.11-	Hypereosonophilic syndrome [HES] (9964/3)
K31.A22	Gastric intestinal metaplasia with high grade dysplasia
N85.02	Endometrial intraepithelial neoplasia [EIN]
R85.614	Cytologic evidence of malignancy on smear of anus
R87.614	Cytologic evidence of malignancy on smear of cervix
R87.624	Cytologic evidence of malignancy on smear of vagina
R90.0	Intracranial space-occupying lesion found on diagnostic imaging of central nervous system

**Note: Beginning with cases diagnosed 1/1/2023, pilocytic astrocytoma are coded 9421/1. Cases diagnosed prior to 1/1/2023 are coded 9421/3.**

### Pathology Reports

All pathology reports, both positive and negative, must be reviewed by the facility reporter to ensure that all reportable cases are identified. Included in the pathology review are histology reports, cytology reports, bone marrow reports, hematology reports and autopsy reports.

### Treatment Logs

Either electronic or physical logs of patients receiving treatment (radiation therapy, systemic therapy, surgery, interventional radiology, and interventional gastroenterology) should be reviewed to ensure that all reportable cases are identified. Reviewing treatment logs is required for free standing treatment facilities and ambulatory surgery centers.

## MULTIPLE PRIMARIES AND HISTOLOGIES

Rules have been devised to aid cancer reporters in identifying whether a recurrence of a previously reported cancer is considered a new primary and must be reported as such, or whether a newly diagnosed cancer is in fact, multiple primaries based on location and histology, with the need to report more than one primary. The current guidelines for this process are the Solid Tumor Rules.

**SOLID TUMOR RULES**

The SEER Solid Tumor Rules were initially released in 2018 and are similar to the 2007 Multiple Primary and Histology Coding Rules. Follow the guidelines as described in the General Instructions and in the Site-Specific Modules of the Solid Tumor Rules when determining multiple primaries for the listed sites.

Site-specific modules include:

- Head & Neck
- Colon (includes colon, rectosigmoid, and rectum)
- Lung
- Cutaneous Melanoma (beginning 2021)
- Breast
- Kidney
- Urinary Sites (includes bladder, renal pelvis, ureter, etc.)
- Malignant CNS and Peripheral Nerves
- Non-Malignant CNS Tumors
- Other Sites

Access the current [Solid Tumor Rules](#) at the SEER website also linked in [section 1](#) page 18 of this manual.

**HEMATOPOIETIC AND LYMPHOID NEOPLASMS**

Follow the guidelines as described in the [Hematopoietic and Lymphoid Neoplasm Coding Manual](#) and [Database](#) when determining multiple primaries and histology. Also found in [section 1](#) page 18 of this manual.

## OCCR CODING AND STAGING REQUIREMENTS BY MANUAL & DIAGNOSIS YEAR

STAGING		
Manual	Effective Years	Use for OCCR diagnosis years
<a href="#">Summary Staging Guide</a>	1977-2000	1997-2000
<a href="#">SEER Summary Stage 2000</a>	2001-2003, 2016-2017	2001-2003, 2016-2017
<a href="#">SEER Summary Stage 2018</a>	2018-	2018-
<a href="#">AJCC Cancer Staging Manual 7<sup>th</sup> Ed. and Errata</a>	2010-2017	2016-2017
<a href="#">Collaborative Stage Data Collection System</a>	2004-2017	2004-2017
DATA COLLECTION		
<a href="#">Registry Operations and Data Standards (ROADS)</a>	1996-2002	1997-2002
<a href="#">Facility Oncology Registry Data Standards (FORDS)</a>	2003-2017	2003-2017
<a href="#">Standards for Oncology Registry Entry (STORE)</a>	2018-	2018-
<a href="#">SEER Program Code Manual</a>	1988-2004	1997-2004
<a href="#">Historical SEER Program Coding and Staging Manuals</a>	2004-2022	2004-2022
<a href="#">SEER Program Coding and Staging Manual</a>	2023 & 2024	2023 & 2024
GRADE		
<a href="#">Grade Coding Instructions 2014</a>	2014-2017	2014-2017
<a href="#">Grade Coding instructions and Tables</a>	2018-	2018-
PRIMARY SITE AND HISTOLOGY		
International Classification of Diseases for Oncology (ICD-O)	1976-2000	1997-2000
<a href="#">ICD-O Third Edition, First revision</a>	2001-2017 2018+ (primary site only)	2001-2017 2018+ (primary site only)
<a href="#">ICD O 3 Coding Updates</a> Histology Only	(3.1) 2018-2020 (3.2) 2021-	(3.1) 2018-2020 (3.2) 2021-
<a href="#">ICD-O-3 Hematopoietic Primaries Table</a>	2001-2009	2001-2009
<a href="#">MPH Coding Rules – Hematopoietic &amp; Lymphoid Neoplasms (online database and manual)</a>	2010-	2010
<a href="#">Multiple Primaries and Histology Coding Rules (MPH)</a>	2007-2017	2007-2017
<a href="#">Solid Tumor Rules</a>	2018-	2018-
TREATMENT		
<a href="#">SEER Self Instructional Manuals for Cancer Registrars, Book 8: Antineoplastic Agents, third edition</a>	1993-2004	1997-2004
<a href="#">SEER*RX Interactive Antineoplastic Database</a>	2005-	2005-
<a href="#">CTR Guide to Coding Radiation Therapy Treatment in the STORE</a>	2019-	2019-
MISCELLANEOUS		
<a href="#">PSA Lab Value (Prostate CS SSF 1) Coding Guidelines</a>	2004-2017	2004-2017

# **SECTION 4**

  

# **REPORTING REQUIREMENTS**

**TIMELINESS**

All hospitals, clinics, laboratories, pathologists, physicians or dentists, or all facilities providing diagnostic or treatment services in relation to cancer diseases or precancerous conditions, shall report all cancer within 180 days of initial diagnosis, or admission for treatment, or admission for disease recurrence/persistence.

Although treatment is generally started within the first four months after diagnosis, the initial course of treatment can cover a long period of time (i.e., prostate patient treated with hormone therapy before brachytherapy or surgery). That is why the planned first course of treatment can be used to complete treatment information. Do not exclude cases from submission due to incomplete treatment. Document the incomplete treatment with treatment plan information.

**SUBMISSION SCHEDULE**

Patients Admitted for Diagnosis, Treatment or Recurrence/Persistence:	Should be Submitted in the Following Month:
January	July
February	August
March	September
April	October
May	November
June	December
July	January
August	February
September	March
October	April
November	May
December	June



# **SECTION 5**

# **PATIENT INFORMATION**

## Reporting Facility Number

NAACCR Item #	Length	Source of Standard
540	10	CoC

### Description

Number that identifies the facility reporting the case.

### Justification

Used for monitoring data submissions and accuracy of the data.

### Coding Instructions

The Oklahoma Central Cancer Registry assigns a unique 3-digit number to every cancer reporter in the State of Oklahoma. This is entered as a 10-digit code with leading zeros. The reporting facility number is either automatically entered by the cancer registry software or it is assigned when files are uploaded to the central registry.

## Type of Reporting Source

NAACCR Item #	Length	Source of Standard	Manual
500	1	SEER	SEER Program Coding and Staging Manual

### Description

Identifies the source documents used to abstract the majority of information in the tumor being reported. This may not be the source document that identified the case but rather the source document(s) that provided the most complete information.

### Justification

This data item records the source of the documents used to abstract the case.

### Coding Instructions

Enter the code for the source of the facility and/or documents used to abstract the case.

CODE	LABEL	SOURCE DOCUMENTS	PRIORITY
1	Hospital inpatient; Managed health plans with comprehensive, unified medical records	Hospital inpatient offices/facilities with a comprehensive, unified record <ul style="list-style-type: none"> <li>• HMO physician office or group</li> <li>• HMO–affiliated freestanding laboratory, surgery, radiation or oncology clinic</li> </ul> Includes outpatient services of HMOs and large multispecialty physician group practices with unified records	1
2	Radiation Treatment Centers or Medical Oncology Centers (hospital affiliated or independent)	Facilities with a stand–alone medical record <ul style="list-style-type: none"> <li>• Radiation treatment centers</li> <li>• Medical oncology centers (hospital affiliated or independent)</li> </ul> There were no source documents from code 1.	2

3	Laboratory Only (hospital affiliated or independent)	Laboratory with a stand-alone medical record There were no source documents from codes 1, 2, 8, or 4.	5
4	Physician's Office/Private Medical Practitioner (LMD)	Physician's office that is NOT an HMO or large multispecialty physician group practice There were no source documents from codes 1, 2, or 8.	4
5	Nursing/Convalescent Home/Hospice	Nursing or convalescent home or a hospice. There were no source documents from codes 1, 2, 8, 4, or 3.	6
6	Autopsy Only	The cancer was first diagnosed on autopsy. There were no source documents from codes 1, 2, 8, 4, 3, or 5.	7
7	Death Certificate Only	Death certificate Death certificate is the only source of information; follow-back activities did not identify source documents from codes 1, 2, 8, 4, 3, 5 or 6. If another source document is subsequently identified, the Type of Reporting Source code must be changed to the appropriate code in the range of 1, 2, 8, 4, 3, 5, or 6.	8
8	Other hospital outpatient units/surgery centers	Other hospital outpatient units/surgery centers Includes, but not limited to, outpatient surgery and nuclear medicine services. There were no source documents from codes 1 or 2.	3

*Note:* When multiple source documents are used to abstract a case, use the following priority order to assign a code for Type of Reporting Source: Codes: 1, 2, 8, 4, 3, 5, 6, 7.

### Definitions

**Comprehensive, unified medical record:** A hospital or managed health care system that maintains a single record for each patient. That record includes all encounters in affiliated locations.

**Stand-alone medical record:** An independent facility; a facility that is not a part of a hospital or managed care system. An independent medical record containing only information from encounters with that specific facility.

**Managed health plan:** Any facility where all of the diagnostic and treatment information is maintained in one-unit record (all records for the patient from all departments, clinics, offices, etc. in a single file with the same medical record number). The abstractor is able to use the unit record when abstracting the case.

*Examples:* HMOs or other health plan such as Kaiser, Veterans Administration, or military facilities.

**Physician office:** A physician's office performs examinations and tests. Physician offices may perform limited surgical procedures.

*Note:* The category "physician's office" also includes facilities that are called surgery centers when surgical procedures under general anesthesia cannot be performed in these facilities.

**Surgery center:** Surgery centers are equipped and staffed to perform surgical procedures under general

Anesthesia. The patient usually does not stay overnight.

*Note:* If the facility cannot perform surgical procedures under general anesthesia, code as physician's office.

### **Priority Order for Assigning Type of Reporting Source**

Code the source that provided the best information used to abstract the case.

- Example A: A patient is admitted to your hospital and subsequently diagnosed with breast cancer. Code the reporting source to 1 (Facility Inpatient/Outpatient or Clinic). All documents in the medical record are used to abstract case.
- Example B: A patient is admitted to your facility and expires. It is unknown at the time of death if the patient has cancer. An autopsy is performed at your facility and kidney cancer is found. Code the reporting source to 6 (autopsy only). The autopsy report is the only document used for cancer information.
- Example C: The patient had a biopsy in a physician's office. The only patient record available is the pathology report from a freestanding laboratory. Code the reporting source to 3 [Laboratory Only (hospital-affiliated or independent)]. Reporting source should reflect the lab where this case was identified. The MD office added nothing to the case, not even a confirmation of malignancy.

## **Date of First Contact**

NAACCR Item #	Length	Source of Standard	Manual
580	8	CoC	Standards for Oncology Registry Entry (STORE)

### **Description**

The date of the facility's first contact with the patient (inpatient or outpatient) for diagnosis or treatment of cancer. If the patient admits for reasons other than cancer, the date of first contact is the date that cancer was first suspected during the admission. If the patient has been diagnosed and/or treated for cancer elsewhere and has active cancer, the date of first contact is the date of admission to your facility with active cancer.

### **Justification**

Used to determine compliance with reporting cases to the Oklahoma Central Cancer Registry within the required 180 days from the date of first contact. It can also be used to determine the time from first contact to date abstracted or date of treatment.

### **Coding Instructions**

- Date format is YYYYMMDD however, most cancer registry software allows the registrar to input the date as MMDDYYYY and will automatically convert the date into the correct format when sent to the state central registry.
- A date must be entered in this field.
- Autopsy only cases, use the date of death.

Example A: On March 28, 2019, a patient is admitted to the hospital with complaints of abdominal pain and 20-pound weight loss over the last month. A CT of the abdomen and pelvis is performed on March 29, 2019, showing a mass in the colon and a liver lesion that is suspicious for metastatic malignancy. Enter the date of first contact as 03/29/2019.

Example B: A patient presents to your facility on January 13, 2018, for radiation oncology consultation after being diagnosed with cancer elsewhere three weeks prior. Staging scans are ordered and are performed on January 17, 2018. Simulation takes place on January 23, 2018. Radiation therapy begins on January 29, 2018. Enter the date of first contact as 01/29/2018.

## Accession Number

NAACCR Item #	Length	Source of Standard	Manual
550	9	CoC	Standards for Oncology Registry Entry (STORE)

### Description

A unique number assigned by the reporting facility. It consists of the year in which the patient was first seen at the reporting facility and the sequential order in which the patient was abstracted.

### Justification

Protects the patient's identity and allows cases to be identified on a local, state, and national level. The central registry refers to this number when following back to reporting facilities.

### Coding Instructions

1. The first four digits consist of the year the patient was first seen at the facility for diagnosis or treatment of cancer reportable to the central cancer registry. The following five digits are assigned in consecutive order in which the case is entered into the registry. Each year accession numbers start over at 00001.
2. **Do not** assign a new accession number for patients who are already in the registry and have been reported to OCCR. Sequence numbers are used to differentiate between multiple primaries for the same patient. All primaries for the same patient in the reporting facility's registry must have the same accession number.

Example: A patient is diagnosed at your facility in 2014 with colon cancer. The accession number was assigned as 201400249. The patient has a second reportable cancer diagnosed in 2018, Lung primary. The accession number is assigned as 201800249. The sequence number is used to differentiate between the two primary cancers.

*Note: Some registry software automates entry of the accession number. It is important to note that Web Plus abstraction does not automate this entry and you must maintain a separate list that is easily searchable to avoid assigning the same patient multiple accession numbers. A spreadsheet is recommended. You may create your own or contact OCCR for a template.*

## Medical Record Number

NAACCR Item #	Length	Source of Standard	NAACCR Data Dictionary
2300	11	CoC	NAACCR Data Dictionary Version 23

### Description

Number used to identify the patient in the reporting facility's medical record system. This should be the number assigned by the hospital's HIM department only and not department-specific numbers.

### Justification

Patients are identified within a reporting facility using the medical record number. The central registry refers to this number when following back to reporting facilities.

### Coding Instructions

Enter the eleven-digit number used to identify the patient within the medical record on the first admission with a reportable cancer. Medical record number containing less than 11 digits are acceptable.

## Class of Case

NAACCR Item #	Length	Source of Standard	Manual
610	2	CoC	Standards for Oncology Registry Entry (STORE)

### Description

Class of case reflects the facility's relationship to the patient and its role in the diagnosis and/or treatment of the cancer.

### Justification

Separates the reporting facility's cancer cases into analytic and nonanalytic categories. OCCR requires facilities to report both analytic and some nonanalytic cases regardless of approval status with the ACoS. Class of Case codes required to be reported are 00, 10, 11, 12, 13, 14, 20, 21, 22, 32, and 38. Class of Case 34 and 36 are also required for specific histologies.

- Analytic cases** (codes 00–22) Cancer diagnosed at the reporting facility or in a staff physician's office and/or received any of the first course treatment at the reporting facility.  
*Note: A facility network clinic or outpatient center belonging to the facility is part of the facility.*
- Non-analytic cases** (codes 30–49 and 99) Cancer diagnosed and received all of the first course of treatment at another facility, or cases which were diagnosed and/or received all or part of the first course of treatment at the reporting facility prior to the registry's reference date (reference date applies to ACoS facilities, facilities striving for ACoS certification, or facilities that follow ACoS standards and do not seek certification).

### Coding Instructions

- Code the Class of Case that most accurately describes the patient's relationship to the facility.
- Code 00 applies only when it is known the patient went elsewhere for treatment. If that information is not available, code Class of Case 10.
- A staff physician (codes 10–12, 41) is a physician who is employed by the reporting facility, under contract with it, or a physician who has routine practice privileges there. Treatment provided in a

staff physician’s office is provided “elsewhere.” That is because care given in a physician’s office is not within the hospital’s realm of responsibility.

4. If the hospital purchases a physician practice, it will be necessary to determine whether the practice is now legally considered part of the hospital (their activity is coded as the hospital’s activity) or not. If the practice is not legally part of the hospital, it will be necessary to determine whether the physicians involved have routine admitting privileges or not, as with any other physician.

**Class of Case**

<b>Analytic Cases</b>		<b>R=Required N=Not Required</b>
<b><i>Initial diagnosis at the reporting facility or in a staff physician’s office</i></b>		<b>R</b>
00	Initial diagnosis at the reporting facility AND all treatment or a decision not to treat was done elsewhere. <i>Note: 00 only applies when it is known that the patient went elsewhere for treatment. If you do not know this information, you should code Class of Case 10.</i>	<b>R</b>
10	Initial diagnosis at the reporting facility or in an office of a physician with admitting privileges AND part or all of first course treatment or a decision not to treat was at the reporting facility, NOS.	<b>R</b>
11	Initial diagnosis in an office of a physician with admitting privileges AND part of first course treatment was done at the reporting facility.	<b>R</b>
12	Initial diagnosis in an office of a physician with admitting privileges AND all first course treatment or a decision not to treat was done at the reporting facility.	<b>R</b>
13	Initial diagnosis at the reporting facility AND part of first course treatment was done at the reporting facility; part of first course treatment was done elsewhere.	<b>R</b>
14	Initial diagnosis at the reporting facility AND all first course treatment or a decision not to treat was done at the reporting facility.	<b>R</b>
<b><i>Initial diagnosis elsewhere</i></b>		<b>R</b>
20	Initial diagnosis elsewhere AND all or part of first course treatment was done at the reporting facility, NOS.	<b>R</b>
21	Initial diagnosis elsewhere AND part of first course treatment was done at the reporting facility; part of first course treatment was done elsewhere.	<b>R</b>
22	Initial diagnosis elsewhere AND all first course treatment or a decision not to treat was done at the reporting facility.	<b>R</b>
<b>Non-analytic Cases</b>		
<b><i>Patient appears in person at reporting facility</i></b>		
30*	Initial diagnosis and all first course treatment elsewhere AND reporting facility performed a <b>confirmation biopsy</b> after being diagnosed on imaging elsewhere. <b>*Note:</b> only reportable for confirmation biopsy of initial diagnosis. You must know the patient was clinically diagnosed elsewhere on imaging or physician statement and document such in text. <b>DO NOT</b> report consult only, treatment plan only, staging workup only after initial diagnosis elsewhere).	<b>R</b>
31	Initial diagnosis and all first course treatment elsewhere AND reporting facility provided in-transit care; or hospital provided care that facilitated treatment elsewhere (for example, stent placement).	<b>N</b>
32	Diagnosis AND all first course treatment provided elsewhere AND patient presents at reporting facility for diagnosis or treatment of disease recurrence or persistence (active disease).	<b>R</b>

	<i>Note: 32 includes patients that expire at the reporting facility with a reportable active disease that does not meet the criteria for an analytic Class of Case.</i>	
33	Diagnosis AND all first course treatment provided elsewhere AND patient presents at reporting facility with disease history only (disease not active).	<b>N</b>
34*	Type of case not required by CoC to be accessioned (for example, a benign colon tumor) AND initial diagnosis AND part or all of first course treatment by reporting facility. <b>*Reportable only for the following histology and primary sites: squamous intraepithelial neoplasia, grade III (8077/2) to include AIN III (C21.1), VIN III (C51. *) VAIN III (C52. *)</b>	<b>R</b>
35	Case diagnosed before facility's Reference Date AND initial diagnosis AND all or part of first course treatment by reporting facility.	<b>N</b>
36*	Type of case not required by CoC to be accessioned (for example, a benign colon tumor) AND initial diagnosis elsewhere AND all or part of first course treatment by reporting facility. <b>*Reportable only for the following histology and primary sites: squamous intraepithelial neoplasia, grade III (8077/2) to include AIN III (C21.1), VIN III (C51. *) VAIN III (C52. *)</b>	<b>R</b>
37	Case diagnosed before facility's Reference Date AND initial diagnosis elsewhere AND all or part of first course treatment by facility	<b>N</b>
38	Initial diagnosis established by autopsy at the reporting facility, cancer not suspected prior to death. <b>Note: 38 should only be used if the reporting facility performs autopsies</b>	<b>R</b>
<b>Patient does not appear in person at reporting facility</b>		
40	Diagnosis AND all first course treatment given at the same staff physician's office.	<b>N</b>
41	Diagnosis and all first course treatment given in two or more different offices of physicians with admitting privileges.	<b>N</b>
42	Non-staff physician or non-CoC accredited clinic or other facility, not part of reporting facility, accessioned by reporting facility for diagnosis and/or treatment by that entity (for example, hospital abstracts cases from an independent radiation facility).	<b>N</b>
43	Pathology or other lab specimens only.	<b>N</b>
49	Death certificate only (central registry only)	<b>N</b>
99	Nonanalytic case of unknown relationship to facility (not for use by CoC accredited cancer programs for analytic cases).	<b>N</b>

## Last Name

NAACCR Item #	Length	Source of Standard	Manual
2230	40	SEER	SEER Program Coding & Staging Manual

### Description

Identifies the last name of the patient.

### Justification

Used by the central registry and reporting facility as a patient identifier.

### Coding Instructions

1. Enter the last name in UPPER CASE letters.
2. Blank spaces, hyphens and apostrophes are allowed. Other punctuations are **not** allowed.
3. Truncate the name if longer than 40 characters.



4. If the last name is unknown, do **not** leave the field blank. Enter the last name as UNKNOWN. Every effort should be made to locate a last name in the medical record. UNKNOWN should only be used as a last resort. *Note: document in Text Remarks that last name is unknown.*
5. This field may be updated if the last name changes.

## First Name

NAACCR Item #	Length	Source of Standard	Manual
2240	40	SEER	SEER Program Coding & Staging Manual

### Description

Identifies the first name of the patient.

### Justification

Used by the central registry and reporting facility as a patient identifier.

### Coding Instructions

1. Enter the last name in UPPER CASE letters.
2. Blank spaces, hyphens and apostrophes are allowed. Other punctuation is **not** allowed.
3. Truncate the name if longer than 40 characters.
4. If the first name is unknown, do **not** leave the field blank. Enter the first name as UNKNOWN. Every effort should be made to locate a first name in the medical record. UNKNOWN should only be used as a last resort. *Note: document in Text Remarks that first name is unknown.*
5. This field may be updated if the last name changes.

## Middle Name

NAACCR Item #	Length	Source of Standard	Manual
2250	40	SEER	SEER Program Coding & Staging Manual

### Description

Identifies the middle name or middle initial of the patient.

### Justification

Used by the central registry and reporting facility to differentiate between patients with the same first and last names.

### Coding Instructions

1. Enter the full middle name. Enter the middle initial if the full middle name is not available.
2. Blank spaces, hyphens and apostrophes are allowed. Other punctuation is **not** allowed.
3. Truncate the name if longer than 40 characters.
4. If the middle name is unknown, or the patient has no middle name, **leave the field blank**. Do **not** enter UNK for unknown, NA for not applicable or NMN for no middle name.

## Name-Birth Surname

NAACCR Item #	Length	Source of Standard	Manual
2232	40	NAACCR	SEER Program Coding & Staging Manual

### Description

Last name (surname) of patient at birth, regardless of gender or marital status.

### Justification

Used by the central registry and reporting facility to link a single patient's cancers when a name change has occurred. It is also useful in identifying Spanish/Hispanic origin.

### Coding Instructions

1. Enter the maiden name of female patients who are or have been married if the information is available. Do **not** enter both first name and maiden name.
2. Blank spaces, hyphens, apostrophes, and other punctuation is allowed.
3. If the maiden name is unknown or the patient has no maiden name, **leave the field blank**.

## Alias Name

NAACCR Item #	Length	Source of Standard	NAACCR Data Dictionary
2280	40	NAACCR	NAACCR Data Dictionary

### Description

Records an alternate name or "AKA" (also known as) used by the patient, if known. Note that maiden name is entered in Name--Maiden [2390].

### Justification

A patient may use different names or nicknames. These names are used for matching multiple records for the same patient.

### Coding Instructions

1. If the patient has no alias name, **leave the field blank**.
2. Enter only the part of the patient's name that is used as an alias: First, Last or Last First.
3. If the patient uses an alias for both first and last names, enter alias last name followed by a space, then the alias first name.
4. Blank spaces, hyphens, apostrophes, and other punctuation is allowed.
5. No other special characters are allowed.

### Example

1. Robert Smith uses the name Bob Smith. Enter Bob in NAME--ALIAS.
2. Francis Brown uses the name Francis Smith. Enter Smith in NAME--ALIAS.
3. Stanley Lieber uses the name Stan Lee. Enter Lee Stan in NAME--ALIAS.

## Street Address at Diagnosis

NAACCR Item #	Length	Source of Standard	Manual
2330	60	SEER	SEER Program Coding & Staging Manual

### Description

Identifies the patient's address (number and street) at the time of diagnosis.

### Justification

Allows for the analysis of cancer clusters, environmental studies, or health services research and is useful for epidemiology purposes. A patient's physical address takes precedence over a post office box. If a patient has multiple primary tumors the address may be different if diagnosed at different times. Do not update this field if the patient moves after diagnosis.

### Coding Instructions

- Record the number and street address, or the rural mailing address of the patient's usual residence, when the cancer was diagnosed. If the address contains more than 60 characters, omit the least important element, such as the apartment number or space number.
- Do not omit elements needed to locate the address in a census tract, such as house number, street, direction or quadrant and street type (street, drive, lane, road, etc.).
- Periods, slashes, hyphens, and pound signs may be used in this field.
- Only use the post office box or the rural mailing address when the physical address is not available. Post office box addresses do not provide accurate geographical information for analyzing cancer incidence. Every effort should be made to obtain complete valid address information.
- Only use standard address abbreviations listed in the *U.S. Postal Service National Zip Code and Post Office Directory*, published by the U.S. Postal Service (USPS). A complete list of abbreviations can be found in Appendix C of USPS Pub 28.

### Street Address Abbreviations

Abbreviation	Description	Abbreviation	Description	Abbreviation	Description
APT	Apartment	FL	Floor	S	South
AVE	Avenue	B	North	SE	Southeast
BLDG	Building	NE	Northeast	SQ	Square
BLVD	Boulevard	NW	Northwest	ST	Street
CIR	Circle	PLZ	Plaza	STE	Suite
CT	Court	PK	Park	SW	Southwest
DEPT	Department	PKWY	Parkway	UNIT	Unit
DR	Drive	RD	Road	W	West
E	East	RM	Room		

- If the patient's address is not available in the medical record, enter **NO ADDRESS** or **UNKNOWN**. Do not leave blank. *Every effort should be made to obtain a valid address.* Record city as **Unknown**, states as **ZZ**, zip code as **99999** and county (FIPS) code as **999**.
- Address at diagnosis should **never** be changed.

**Please refer to the SEER Program Coding & Staging Manual pg. 51 for instructions on:**

- Changing the **current** address
- Legal status and citizenship
- Ambiguous residences: more than one residence (summer and winter homes), no usual residence (transients, homeless), persons away at school, persons in institutions, persons in the Armed Forces and on Maritime Ships
- Coding Country and State

### Address at Diagnosis – Supplemental

NAACCR Item #	Length	Source of Standard	Manual
2335	60	SEER	SEER Program Coding & Staging Manual

#### **Description**

Provides the ability to store additional address information such as the name of a place or facility (for example a nursing home, apartment complex, jail, or PO Box residential or other mailing address at the time of diagnosis).

#### **Justification**

A registry may receive the name of a facility instead of a proper street address containing the street number, name, direction, and other elements necessary to locate an address on a street file for the purpose of geocoding.

#### **Coding Instructions**

1. Record the place or facility (for example, a nursing home or name of an apartment complex) of the patient's usual residence when the tumor was diagnosed.
2. Do not use this data item to record the number and street address of the patient.

### City at Diagnosis

NAACCR Item #	Length	Source of Standard	Manual
70	50	CoC	SEER Program Coding & Staging Manual

#### **Description**

Identifies the name of the city or town in which the patient resides at the time of diagnosis.

#### **Justification**

Allows for the analysis of cancer clusters, environmental studies, or health services research and is useful for epidemiology purposes.

#### **Coding Instructions**

1. Record the patient's city or town at diagnosis.
2. If the city or town is unknown, record **UNKNOWN**, do not leave blank.
3. Do not use punctuation, special characters, or numbers.

## State at Diagnosis

NAACCR Item #	Length	Source of Standard	Manual
80	2	CoC	Standards for Oncology Registry Entry (STORE)

### Description

Identifies the patient's state of residence at the time of diagnosis and treatment.

### Justification

It allows for analysis of geographic and environmental studies and inclusion in state and national cancer publications/studies.

### Coding Instructions

1. Record the patient's state at diagnosis using the appropriate two-letter abbreviation. Refer to the code table in the STORE Manual pages 60-61 or the SEER Program Coding and Staging Manual Appendix B: Country and State Codes <https://seer.cancer.gov/tools/codingmanuals/index.html>
2. If the state is unknown, record **ZZ** for **UNKNOWN**, do not leave blank.
3. Do not use punctuation, special characters, or numbers.

## Postal Code at Diagnosis

NAACCR Item #	Length	Source of Standard	Manual
100	9	CoC	Standards for Oncology Registry Entry (STORE)

### Description

Identifies the postal code of the patient address at the time of diagnosis.

### Justification

Allows for the analysis of cancer clusters, environmental studies, or health services research.

### Coding Instructions

1. Enter the 5-digit zip code at time of diagnosis. Enter the 4-digit extended zip code if known. **Do not enter a hyphen** between the first five digits and the last four digits if entering a 9-digit zip code. Blanks are allowed for the extended 4-digits if it is unknown.
2. Unknown zip codes may be queried using [the USPS Look Up a Zip Code™](https://www.usps.com/zip-lookup) or <https://www.getzips.com/zip.htm>

## County at Diagnosis

NAACCR Item #	Length	Source of Standard	Manual
90	3	CoC	Standards for Oncology Registry Entry (STORE)

### Description

Identifies the county of residence at the time of diagnosis.

**Justification**

It allows for the analysis of cancer clusters, geographic or environmental studies and health services research.

**Coding Instructions**

1. Record the appropriate 3–digit code for county of residence.
2. Use codes issued by the Federal Information Processing Standards (FIPS) publication, Counties and Equivalent Entities of the United States, Its Possessions, and Associated areas. [More information can be found in the NAACCR Data Standards and Data Dictionary under FIPS Codes for Counties and Equivalent Entities.](#)

**Country at Diagnosis**

NAACCR Item #	Length	Source of Standard	Manual
102	3	CoC	Standards for Oncology Registry Entry (STORE)

**Description**

Identifies the country of residence at the time of diagnosis.

**Justification**

May be used for epidemiological purposes.

**Coding Instructions**

1. Record the appropriate 3–digit code for country of residence.
2. Refer to the SEER Program and Coding Manual: Appendix B <https://seer.cancer.gov/tools/codingmanuals/index.html>

**Social Security Number**

NAACCR Item #	Length	Source of Standard	Manual
2320	9	CoC	SEER Program Coding & Staging Manual

**Description**

Identifies the patient by social security number

**Justification**

The OCCR uses this data item for internal processes such as linking for resolution of duplicate persons and consolidation.

**Coding Instructions**

1. Record the social security if known. **Please double check for accuracy.**
2. If the social security number is unknown, record all 9's –999999999.
3. If only the last four digits are known, record the first five digits as 8's\*– 888881234 if the facility is state report only. *CoC accredited facilities should continue to use all 9's and document the last four digits in Text-Remarks.*

4. Every effort should be made to locate a social security number in the medical record.
5. The Medicare Beneficiary Identifier is not the patient’s social security number.
6. No hyphens or slashes are allowed.

*\*Note: Applies only to state report only facilities. The OCCR submitted a question to SEER regarding the use of 8’s in the SSN when only the last four digits are known. SEER has approved for state report only use at this time.*

**Invalid SSN**

Numbers with the below criteria are invalid and are not assigned by the social security administration. If the medical record has a number matching this criterion, please enter the number as unknown.

- First three digits = 000
- First three digits = 666
- Fourth and fifth digits = 00
- Last four digits = 0000
- First digit = 9 (except when first digit of 999999999)

**Date of Birth**

NAACCR Item #	Length	Source of Standard	Manual
240	8	SEER/CoC	Standards for Oncology Registry Entry (STORE) SEER Program Coding & Staging Manual

**Description**

Identifies the date of birth of the patient.

**Justification**

The OCCR uses this data item for matching records and is also used to calculate the age at diagnosis. It is useful when analyzing tumors according to age cohort.

**Coding Instructions**

1. Age at diagnosis must be entered.
2. The NAACCR format for this data item is YYYYMMDD, however some registry software allow you to code MMDDYYYY and will automatically convert the format for you when the abstract is selected for data submission.
3. If only the patient’s age is known, calculate the year of birth from the age and year of diagnosis. Record as YYYY, leaving the MM and DD blank.
4. Every effort should be made to locate a date of birth in the medical record.

## Birthplace – State

NAACCR Item #	Length	Source of Standard	Manual
252	2	NAACCR	Standards for Oncology Registry Entry (STORE) SEER Program Coding & Staging Manual

### Description

USPS abbreviation for the state, commonwealth, U.S. possession; or Canada Post abbreviation for the Canadian province/territory in which the patient was born.

### Justification

Birthplace is used to ascertain ethnicity, identify special populations at risk for certain types of cancers, and for epidemiological analyses.

### Coding Instructions

1. When available, record the patient's state of birth. Record unknown as ZZ.
2. A complete list of country and state codes can be found in the [SEER Program Coding and Staging Manual](#) Appendix B.

## Birthplace – Country

NAACCR Item #	Length	Source of Standard	Manual
254	3	NAACCR	Standards for Oncology Registry Entry (STORE) SEER Program Coding & Staging Manual

### Description

Code for the country in which the patient was born.

### Justification

Place of Birth is helpful for patient matching and can be used when reviewing race and ethnicity. It is important for algorithms for inputting race and ethnicity. It allows for more specific definition of the population being reported. Birthplace has been associated with variation in genetic, socioeconomic, cultural, and nutritional characteristics that affect patterns of disease.

### Coding Instructions

1. When available, record the patient's country of birth. Record unknown as ZZU.
2. A complete list of country and state codes can be found in the [SEER Program Coding and Staging Manual](#) Appendix B.

## Race 1–5

NAACCR Item #	Length	Source of Standard	Manual
160 - 164	2	SEER/CoC	Standards for Oncology Registry Entry (STORE) SEER Program Coding & Staging Manual

### Description

Identifies the primary race of the person.



### **Justification**

Racial origin captures information used in research and cancer control activities comparing stage at diagnosis and/or treatment by race. The full coding system should be used to allow for an accurate national comparison. The five race fields allow for coding of multiple races consistent with the Census 2000.

### **Coding Instructions**

1. Code all 5 race data items.
2. Race is analyzed with *Spanish/Hispanic Origin*. Both items must be recorded. If the patient has multiple tumors, all records must have the same race code.
3. Use the following priority order for coding race:
  - a. The patient's self-declared identification
  - b. Documentation in the medical record
  - c. Death certificate
4. If the patient is White or Caucasian with no other documented race, code Race 1 as white and race 2–5 as 88, regardless of the place of birth.
5. If there is a statement that the patient is Hispanic or Latino(a) and no further information is available, code Race 1 as white and race 2–5 as 88, regardless of the place of birth.

**Note:** Persons of Spanish or Hispanic origin may be of any race, although persons of Mexican, Central American, South American, Puerto Rican, or Cuban origin are usually White. Do NOT code a patient stated to be Hispanic or Latino as 98 (Other Race) in Race 1 and 88 in Race 2 – Race 5.
6. If the patient is multiracial, code all races using Race 2–5 and remaining race items as 88.
7. If the patient is multiracial and one race is white, code the other race(s) first with white in the net race data item.
8. If the person is multiracial and one of the races is Hawaiian, code Hawaiian as Race 1, followed by the other race(s).
9. A known race code must not be duplicated.
10. If Race 1 is 99, then Race 2–5 must be 99.
11. Code **07** takes priority over all other codes.
12. Codes **02–32, 96–98** take priority over code **01**.
13. Code only the specific race when both a specific race code and a non-specific race code apply.
  - a. Codes 04–17 take priority over code 96
  - b. Codes 16–17 take priority over code 15
  - c. Codes 20–32 take priority over code 97
  - d. Codes 02–32 and 96–97 take priority over code 98
  - e. Code 98 takes priority over code 99
14. Assign code **02** (Black) when the stated race is African American, Black, or Negro.
15. Assign code **03** for any person stated to be:
  - a. Native American (Western Hemisphere) OR
  - b. Indian, whether from North, Central, South, or Latin America
16. Assign a specific code when a specific Asian race is stated. Do not use code 96 when a specific race is known.

17. Code the race based on birthplace information when the race is recorded as Oriental, Mongolian, or Asian and the place of birth is recorded as China, Japan, the Philippines, or another Asian nation.

**Example 1:** Race is recorded as Asian, and the place of birth is recorded as Japan. Code race as 05 (Japanese) because it is more specific than 96.

**Example 2:** The person describes himself as an Asian–American born in Laos. Code race as 11 (Laotian) because it is more specific than 96.

18. Do not use codes 96, 97 or 98 for “multi–racial”.

- Codes 08–13 became effective with diagnoses on or after January 1, 1988.
- Code 14 became effective with diagnoses on or after January 1, 1994.
- In 2010, code 09 was converted to the new code 15, and codes 16 and 17 were added.
- Codes 20–97 became effective with diagnoses on or after January 1, 1991. SEER participants in San Francisco, San Jose–Monterey, and Los Angeles are permitted to use codes 14 and 20–97 for cases diagnosed after January 1, 1987.
- If Race Coding System–Current [170] is less than six (6) for cases diagnosed prior to January 1, 2000, then Race 2 through Race 5 must be blank.
- If a patient diagnosed prior to January 1, 2000, develops a subsequent primary after that date, then Race Coding System–Current must be seven (7), and data items Race 2 through Race 5 that do not have specific race recorded must be coded 88.

Refer to Appendix D in SEER Race and Nationality Descriptions from the 2000 Census and Bureau of Vital Statistics when race is unknown or not stated in the medical record and birthplace is recorded. In some cases, race may be inferred from nationality. Use Appendix D to identify nationalities from which race codes may be inferred. <https://seer.cancer.gov/tools/codingmanuals/>

## Spanish/Hispanic Origin

NAACCR Item #	Length	Source of Standard	Manual
190	1	SEER/CoC	Standards for Oncology Registry Entry (STORE) SEER Program Coding & Staging Manual

### Description

This data item is used to identify patients with Spanish/Hispanic surname or of Spanish origin.

### Justification

This code is used by hospital and central registries to identify whether or not the person should be classified as “Hispanic” for purposes of calculating cancer rates. Hispanic populations have different patterns of occurrence of cancer from other populations that may be included in the 01 (White) category of *Race 1* through *Race 5*.

### Coding Instructions

1. Coding Spanish Surname or Origin is not dependent on race. A person of Spanish descent may be white, black, or any other race.

2. Use all information to determine the Spanish/Hispanic Origin including:
  - a. The ethnicity stated in the medical record
    - i. Self-reported information takes priority over other sources of information
  - b. Hispanic origin stated on the death certificate
  - c. Birthplace
  - d. Information about life history and/or language spoken found in the abstracting process
  - e. A last name or maiden name found on a list of Hispanic/Spanish names
3. Assign code 6 when there is more than one ethnicity/origin (multiple codes), such as Mexican (code 1) and Dominican Republic (code 8). There is no hierarchy among the codes 1–5 or 8.
4. Assign code 7 when the only evidence of the patient’s Hispanic origin is a surname or maiden name and there is no evidence that the patient is not Hispanic. Code 7 is ordinarily for central registry use only.
5. Portuguese, Brazilians, and Filipinos are not presumed to be Spanish or non-Spanish. Assign code 7 when the patient is Portuguese, Brazilian, or Filipino and their name appears on a Hispanic surname list. Assign code 0 when the patient is Portuguese, Brazilian, or Filipino and their name does NOT appear on a Hispanic surname list.
6. Assign code 9 for death certificate only (DCO) cases when Spanish/Hispanic origin is unknown.

## Sex

NAACCR Item #	Length	Source of Standard	Manual
220	1	SEER/CoC	Standards for Oncology Registry Entry (STORE) SEER Program Coding & Staging Manual

### Description

Code for the sex of the patient.

### Definitions

- **Intersex:** A person born with ambiguous reproductive or sexual anatomy: chromosomal genotype and sexual phenotype other than XY–male and XX–female. An example is 45,X/46,XY mosaicism, also known as X0/XY mosaicism.
- **Transsexual:** A person who was assigned one gender at birth based on physical characteristics but who self-identifies psychologically and emotionally as the other gender.

### Coding Instructions

1. Assign code 3 for:
  - a. Intersexed (persons with sex chromosome abnormalities)
  - b. Hermaphrodite Note: Hermaphrodite is an outdated term.
2. Codes 5 and 6 may be used for cases diagnosed prior to 2015.
3. Codes 5 and 6 have priority over codes 1 and 2.
4. Assign code 5 for transsexuals who are natally male or transsexuals with primary site of C600–C639.
5. Assign code 6 for transsexuals who are natally female or transsexuals with primary site of C510–C589.

6. Assign code 4 for transsexuals with unknown natal sex and primary site is not C510–C589 or C600–C639.
7. When gender is not known:
  - a. Assign code 1 when the primary site is C600–C639.
  - b. Assign code 2 when the primary site is C510–C589.
  - c. Assign code 9 for primary sites not included above.

## Text Usual Occupation

NAACCR Item #	Length	Source of Standard	National Program of Cancer Registries
310	100	NPCR	<a href="https://www.cdc.gov/niosh/docs/2011-173/pdfs/2011-173.pdf">https://www.cdc.gov/niosh/docs/2011-173/pdfs/2011-173.pdf</a>

### Description

Text area for information about the patient’s usual occupation, also known as usual type of job or work.

### Justification

Used to identify new work–related health hazards; serves as an additional measure of socioeconomic status; identifies occupational groups in which cancer screening or prevention activities may be beneficial.

### Coding Instructions

1. Record as available in the medical record. Be descriptive, specific, and complete.
2. Record the patient’s usual occupation (i.e., the kind of work performed during most of the patient’s working life before diagnosis of this tumor).
3. Do not record “retired.” If usual occupation is not available or is unknown, record the patient’s current or most recent occupation, or any available occupation. If no occupation is documented in the medical record or there is no indication of the occupation, record as **UNKNOWN**. *Do not* record NA, N/A, or Unavailable.
4. This data item may be updated if information providing a more accurate industry becomes available at a later date.

Please refer to *A Registrar’s Guide to Coding Industry and Occupation*

<https://www.cdc.gov/niosh/docs/2011-173/pdfs/2011-173.pdf>

### Examples

Inadequate	Adequate
Teacher	High School Teacher
Laborer	Residential bricklayer
Worked in a warehouse	Worked in a shipping department
Self–employed	Self–employed landscaper

## Text Usual Industry

NAACCR Item #	Length	Source of Standard	NAACCR Data Dictionary
320	100	NPCR	<a href="https://www.cdc.gov/niosh/docs/2011-173/pdfs/2011-173.pdf">https://www.cdc.gov/niosh/docs/2011-173/pdfs/2011-173.pdf</a>

### Description

Text area for information about the patient's usual industry, also known as usual kind of business/industry.

### Justification

Used to identify new work-related health hazards; serves as an additional measure of socioeconomic status; identifies industrial groups or worksite-related groups in which cancer screening or prevention activities may be beneficial.

### Coding Instructions

1. Record as available in the medical record. Be descriptive, specific, and complete.
2. Record the primary type of activity carried on by the business/industry at the location where the patient was **employed for the greatest number of years** (*longest held*) before diagnosis of the cancer. Be sure to distinguish among "manufacturing," "wholesale," "retail," and "service" components of an industry that performs more than one of these components.
3. This data item may be updated if information providing a more accurate industry becomes available at a later date.
4. If no information is available regarding the industry in which the reported occupation was carried out, record as **UNKNOWN**. **Do not** record NA, N/A, Unavailable or Retired.
5. If the patient was not a student or homemaker and had never worked, record "never worked" as the usual industry.

### Examples

Inadequate	Adequate
Automobile industry	Automobile manufacturing
Manufacturing	Automobile manufacturing
ABC, Inc	ABC, Inc., Los Angeles, CA

Please refer to *A Registrar's Guide to Coding Industry and Occupation*

<https://www.cdc.gov/niosh/docs/2011-173/pdfs/2011-173.pdf>

## Tobacco Use Smoking Status

NAACCR Item #	Length	Source of Standard	Manual
344	1000	NPCR	SEER Program Coding & Staging Manual

### Description

Record the patient's past or current use of tobacco (cigarette, cigar and/or pipe). Tobacco smoking history can be obtained from sections such as the Nursing Interview Guide, Flow Chart, Vital Stats or

Nursing Assessment section, or other available source from the patient's hospital medical record or physician office record.

### **Justification**

Cigarette smoking is the leading preventable cause of death in the US and a major risk factor for cancer. In addition to describing tobacco use patterns and trends in patients diagnosed with cancer, the collection of cigarette smoking history can enable researchers to better understand the association of cigarette smoking to cancer outcomes. Cigarette use data at diagnosis may help health professionals better understand how tobacco use impacts cancer prognosis, including how smoking is related to effectiveness of treatment and survival. In addition, this information is important to target and assess tobacco control efforts to cancer survivors and their families.

### **Coding Instructions**

1. Record the past or current use of tobacco.
  - a. Tobacco use includes cigarette, cigar, and/or pipe.
2. Do not record the patient's past or current use of e-cigarette vaping devices.
3. Assign code 2 when the medical record indicates patient has smoked tobacco in the past but does not smoke now
  - a. If there is evidence in the medical record that the patient quit recently (within 30 days prior to diagnosis), assign code 1: current smoker. The 30 days prior information, if available, is intended to differentiate patients who may have quit recently due to symptoms that lead to a cancer diagnosis.
4. Assign **code 9** when the medical record only indicates **"No"**

Code	Description
0	Never smoker
1	Current smoker
2	Former smoker
3	Smoker, current status unknown
9	Unknown if ever smoked

### **Text–Remarks**

NAACCR Item #	Length	Source of Standard	NAACCR Data Dictionary
260	1000	NPCR	<a href="http://datadictionary.naaccr.org/default.aspx?c=10&amp;Version=22">http://datadictionary.naaccr.org/default.aspx?c=10&amp;Version=22</a>

### **Description**

Text area for information that is given only in coded form elsewhere or for which the abstract provides no other place. Overflow data can also be placed here. Problematic coding issues can also be discussed in this section.

### **Justification**

- NAAACR approved abbreviations should be used (see the NAACCR Data Dictionary [Abbreviations and Acronyms](#))
- Do not repeat information from other text fields.
- For text documentation that is continued from one text field to another, use asterisks or other symbols to indicate the connection with preceding text.
- Do not include irrelevant information.

## Sequence Number

NAACCR Item #	Length	Source of Standard	Manual
560	2	CoC	Standards for Oncology Registry Entry (STORE)

### Description

Used to indicate the order in which multiple reportable neoplasms (malignant and non-malignant) for a single person over their lifetime without regard to when or where the cancer was diagnosed. Sequence Number 00 indicates that the person has only one malignant neoplasm in his lifetime. Sequence Number 01 indicates the first of two or more malignant neoplasms, while 02 indicates the second of two or more malignant neoplasms, and so on. Because the time period of Sequence Number is a person's lifetime, reportable neoplasms not included in the hospital registry are also allotted a sequence number. For example, a registry may contain a single record for a patient with a sequence number of 02 because the first reportable neoplasm occurred before the hospital registry's reference date. Similarly, Sequence Number 60 indicates the patient has only one non-malignant neoplasm, and Sequence Number 61 represents the first of multiple non-malignant neoplasms.

### Justification

Used to distinguish among cases with the same accession number and to select patients for certain studies according to single or multiple tumors.

### Coding Instructions

1. Codes 00-59 and 99 indicate neoplasms of malignant (in situ or invasive) behavior (Behavior equals 2 or 3). Codes 60-88 indicate neoplasms of non-malignant behavior (Behavior equals 0 or 1).
2. Code 00 if the patient has a single reportable primary. If the patient develops a subsequent invasive or in situ reportable tumor, change the code for the first tumor from 00 to 01, and number subsequent tumors sequentially.
3. Code 60 only if the patient has a single non-malignant reportable primary. If the patient develops a subsequent non-malignant reportable primary, change the code for the first tumor from 60 to 61, and assign codes to subsequent non-malignant reportable primaries sequentially.
4. Any tumor in the patient's past which is reportable or reportable-by-agreement at the time the current tumor is diagnosed must be taken into account when sequencing subsequently accessioned tumors. However, do not reassign sequence numbers if one of those tumors becomes non-reportable later.

- Sequence numbers should be reassigned if the facility learns later of an unaccessioned tumor that affects the sequence

#### Timing Rule

If two or more invasive or in situ reportable primaries are diagnosed at the same time, assign the lowest sequence number to the diagnosis with the worst prognosis. If no difference in prognosis is evident, the decision is arbitrary.

### Primary Payer at Diagnosis

NAACCR Item #	Length	Source of Standard	Manual
630	2	CoC	Standards for Oncology Registry Entry (STORE)

#### Description

Primary payer/insurance carrier at the time of initial diagnosis and/or treatment at the reporting facility.

#### Justification

This item is used in financial analysis and as an indicator for quality and outcome analyses.

#### Coding Instructions

- Record the type of insurance documented on the patient admission page.
- When multiple insurances are listed for the admission, code the first insurance.
- Code the insurance listed on the admission page that is closest to the date of diagnosis. Do not update the insurance if it changes.
- Codes 21 and 65–68 should be used for patients diagnosed on or after January 1, 2006.

### Medicare Beneficiary Identifier

NAACCR Item #	Length	Source of Standard	Manual
2315	11	NAACCR	NAACCR Data Dictionary

#### Description

Congress passed the Medicare Access and CHIP Reauthorization ACT to remove Social Security Number (SSN) from Medicare ID card and replace the existing Medicare Health Insurance Claim Numbers with a Medicare Beneficiary Identifier (MBI). The MBI will be a randomly generated identifier that will not include a SSN or any personal identifiable information.

#### Justification

The MBI is a step to minimize the risk of identity theft for Medicare beneficiaries and reduce opportunities for fraud. In early 2018, CMB plans to issue new Medicare cards with an MBI. A Health Insurance Claim Number will still be assigned to each Medicare beneficiary and will still be used for internal data exchanges between CMS and the states, but the new MBI must be used in all interactions with the beneficiary, the provider community and all external partners. The collection of the MBI should not change how registries currently collect SSN.



***Coding Instructions***

Note: The Medicare Beneficiary Identifier (MBI) is randomly generated and has 11 characters, consisting of numbers and letters, entered without dashes. The MBI format: <https://www.cms.gov/Medicare/New-Medicare-Card/Understanding-the-MBI-with-Format.pdf>

# **SECTION 6**

# **CANCER INFORMATION**

## Prior to beginning the abstract

It is helpful to read the general instructions at the beginning of each of the following references:

NAACCR Data Standards and Data Dictionary  
 STORE Manual  
 ICD-O Manual  
 Site Specific Data Items Manual  
 Grade Manual  
 Solid Tumor Rules

This will help you understand what needs to be considered before you start the first abstract and to refresh the information in question later in abstracting.

Many of these sources have a way to refer questions to them to help clarify the requirement. STORE and SEER have a list of questions and answers that have already been referred to them that can be used to help you. These resources are called the [CAnswer forum](#) and [SEER Inquiry \(SINQ\)](#). You must have an account to view and post questions on the CAnswer forum. Registration is free. Helpful websites are listed in [Section 1](#).

## Date of Initial Diagnosis

NAACCR Item #	Length	Source of Standard	Manual
390	8	SEER/CoC	Standards for Oncology Registry Entry (STORE) SEER Program Coding & Staging Manual

### Description

Date of initial diagnosis of the reportable tumor by a recognized medical practitioner, whether clinically or microscopically confirmed. Initial diagnosis may take place at the reporting facility or elsewhere.

### Justification

The timing for staging and treatment of cancer begins with the date of initial diagnosis for cancer.

### Coding Instructions

- Date format:
 

YYYYMMDD	complete date is known
YYYYMM	Year and month are known/estimated day is unknown
YYYY	Year is known/estimated; month and day cannot be estimated or are unknown
Blank	Year, month and day cannot be estimated or are unknown
- Cases with an unknown year of diagnosis cannot be transmitted to NPCR and NAACCR by the central registry. It is very important to do everything possible to determine the year of diagnosis.
- The initial diagnosis can be from a clinical diagnosis using ambiguous reportable terminology. Use this date as the initial date of diagnosis. If later confirmed by a pathology specimen, do not update the initial date of diagnosis. The date remains the date reportable diagnostic terms were used. Refer to the list of ambiguous terms under Reportable Diseases and Casefinding.

4. Date of diagnosis based on pathology report is the date the specimen was taken and not the date the pathology report was read, created, or finalized.
5. If in retrospect, a recognized medical practitioner states the patient had cancer at an earlier date, record the date of diagnosis as the earlier date. If documentation later shows an earlier date of diagnosis, record the date from the documentation. *It is important that the text documentation supports the date of initial diagnosis that is recorded in the abstract.*
6. For autopsy and death certificate only cases, the date of initial diagnosis will be the date of death.
7. If the patient receives treatment prior to a definitive diagnosis, use the date that treatment was started as the date of initial diagnosis.
8. Positive **tumor markers** alone are **not** diagnostic of cancer. Use the date of clinical, histologic, or positive cytologic confirmation as the date of diagnosis.
9. Use the date of suspicious cytology when the diagnosis is proven by subsequent biopsy, excision, or other means.

Example: Cytology suspicious for malignancy 01/12/2022. Diagnosis of carcinoma per biopsy on 02/06/2022. Record 01/12/2022 as the date of diagnosis.

**Note 1:** “Ambiguous” cytology means that the diagnosis is preceded by an ambiguous term such as apparently, appears, compatible with, etc.

**Note 2:** Do not use ambiguous cytology **alone** for case ascertainment.

## Estimating Dates

If an exact date is not available, use all the information available to calculate the month and year of diagnosis. After applying these rules, you should rarely have a blank date. *Blank dates are strongly discouraged as these cases are not counted in Oklahoma’s annual cancer incidence.*

Documentation	Date code/description
Spring	April (04)
Summer or Middle of the Year	July (07)
Fall or Autumn	October (10)
Winter	Determine if this means the beginning or end of the year. Use December (12) or January (01) as determined.
Early in the Year	January (01)
Late in the Year	December (12)
Recently	Use the year and month of admission and leave the day blank. If the patient was admitted during the first week of a month, use the previous month.
Several Months Ago	If the patient was not previously treated or if first course treatment started elsewhere and was continued at the reporting facility, assume the case was first diagnosed three months before admission with day unknown (blank).
A Couple of Years	Code two years earlier
A Few Years	Code three years earlier

**Example:** A patient was admitted to your facility on June 15, 2018. The History and Physical states the patient has lung carcinoma diagnosed about two months ago. Record the date of diagnosis as 04/ /2018.

**Example:** A patient was admitted to your facility on October 30, 2019. The History and Physical states the patient has bone metastasis from prostate cancer diagnosed in the spring. Record the date of diagnosis as 04/ /2019.

**Example:** On February 05, 2018, a mammogram reveals a mass in the lower inner quadrant of the patient's left breast. The radiologist's impression states compatible with carcinoma. On February 15, 2018, the patient has an excisional breast biopsy that confirms infiltrating ductal carcinoma. Record the date of diagnosis as 02/05/2018.

### Morphology ICD-O-3: Type and Behavior

NAACCR Item #	Length	Source of Standard	Manual
522, 523	4, 1	SEER/CoC	Standards for Oncology Registry Entry (STORE) SEER Program Coding & Staging Manual

#### **Description**

Histologic Type ICD–O–3 describes the microscopic composition of cells and/or tissue for a specific primary. Behavior Code describes the malignant potential of the tumor, ranging from /0 benign to /3 malignant (invasive).

#### **Justification**

Histology is a basis for staging and the determination of treatment options. It also affects the prognosis and course of the disease. It assists in identifying multiple primaries.

#### **Standard References for Histology Codes in Priority Order**

Solid Tumor Rules

<https://seer.cancer.gov/tools/solidtumor/>

2022 ICD-O-3.2

<https://www.naaccr.org/icdo3/>

Hematopoietic and Lymphoid Neoplasm Coding Manual

[https://seer.cancer.gov/tools/heme/Hematopoietic\\_Instructions\\_and\\_Rules.pdf](https://seer.cancer.gov/tools/heme/Hematopoietic_Instructions_and_Rules.pdf)

Hematopoietic and Lymphoid Neoplasm Database

<https://seer.cancer.gov/seertools/hemelymph/>

**Note:** A definitive solid tumor histology can be coded only after the determination of single vs. multiple primaries has been made. Refer to Solid Tumor Rules to determine the number of primaries for solid tumors.

#### **Coding Instructions**

*Solid Tumor Manual*

Use the Solid Tumor Manual to determine the number of primaries first, then the definitive histology

<https://seer.cancer.gov/tools/solidtumor/>

1. Apply the general instructions for coding histologic type in the Solid Tumor Rules
2. Apply the site-specific histology coding rules in the Solid Tumor Rules

Primary site groupings currently available for 2018 STR: Colon, Head and Neck, Kidney, Lung, Malignant CNS and Peripheral Nerves, Non-Malignant CNS, Urinary Sites and Cutaneous Melanoma

**Note:** Do not use these rules to determine case reportability, tumor grade or behavior.

*ICD-O-3 Changes Effective January 1, 2024*

<https://www.naaccr.org/icdo3/>

The 2024 ICD-O-3.2 Update Guidelines includes comprehensive tables listing changes to ICD-O-3.2 including new ICD-O codes, terminology and reportability changes effective for cases diagnosed 1/1/2024 forward. The 2023 update represents changes identified in recently published 5th Ed WHO Classification of Tumors books. Included in these guidelines are instructions for using the tables together with ICD-O-3.2.

*Note: Do not use the printed or PDF version of the ICD-O manual to determine histology for cases diagnosed 01/01/2018 and forward. If the Solid Tumor Rules instruct to use the ICD-O-3.2, use the Excel spreadsheet and coding tables.*

*Use the Coding Instructions for Hematopoietic and Lymphoid Neoplasms (9530/3-9992/3):*

1. Search the database to determine reportability <https://seer.cancer.gov/seertools/hemelymph/>
2. Use the database to code primary site, histology, grade
3. Use the *Hematopoietic and Lymphoid Neoplasms* coding manual and not the online database to determine the number of primaries. Only use the Multiple Primaries Calculator in the online database when the manual instructs you to use it.

[https://seer.cancer.gov/tools/heme/Hematopoietic Instructions and Rules.pdf](https://seer.cancer.gov/tools/heme/Hematopoietic%20Instructions%20and%20Rules.pdf)

### Behavior Coding Instructions

Code	Description
0	Benign (for use with intracranial and CNS site only beginning with 2004)
1	Uncertain whether benign or malignant, borderline malignancy, low malignant potential, and uncertain malignant potential
2	Carcinoma in situ; intraepithelial; noninfiltrating; noninvasive
3	Malignant, primary and/or metastatic site; Invasive

## Primary Site

NAACCR Item #	Length	Source of Standard	Manual
400	4	SEER/CoC	Standards for Oncology Registry Entry (STORE) SEER Program Coding & Staging Manual

### Description

Identifies the primary site of the cancer. This is the site in which the cancer originated or began. A *metastatic* site indicated that the primary (originating) cancer has spread from the original site to other areas in the body.

### Justification

Identifies the primary site of the cancer

### Coding Instructions

Code for the primary site of the tumor being reported using either ICD-O-2 or ICD-O-3. NAACCR adopted ICD-O-2 as the standard coding system for tumors diagnosed beginning January 1, 1992. In addition, NAACCR recommended that tumors diagnosed prior to 1992 be converted to ICD-O-2. The topography (primary site) codes did not change between ICD-O-2 and ICD-O-3.

Coding Guidelines for Topography for solid tumors are provided beginning on page 19 of the ICD-O-3.

1. Follow the instructions in the Solid Tumor Rules then move to ICD-O to assign primary site codes for solid tumors
2. Follow instructions in the Hematopoietic and Lymphoid Neoplasm database and coding manual for assigning primary site codes for lymphomas, leukemias and other hematopoietic neoplasms.
3. **Do not** code a metastatic site as the primary site. Use all available information to code primary site.
4. Be specific down to the subsite code when applicable.
5. Overlapping lesion: When a primary cancer occupies contiguous overlapping subsites within an organ and the exact point of origin cannot be determined, use .8 to code the subsite  
*Note:* Beginning with cases diagnosed 1/1/2018 and later for skin cancers overlapping sites in the head and neck ONLY: Assign the primary site code for the site where the epicenter is; **do not** use code 44.8.
6. When the primary cancer is multifocal throughout an organ or when there is no information identifying the subsite from which the primary cancer arose, use code .9 to indicate the site is not otherwise specified (NOS).
7. Multiple cancers that arise in different subsites of the same anatomic site are reported as a single primary and point of origin cannot be determined, use code .9 as the last digit of the primary site.
8. When the primary site is documented as unknown primary use code C80.9
9. Kaposi's Sarcoma is coded to the site in which it originates. Code to skin NOS (C44.9) if the disease arises simultaneously in the skin and another site, AND the primary site is not identified.
10. Some histology/behavior terms in ICD-O-3 have a related site code in parenthesis, e.g., hepatoma (C22.0).
  - a. Code the site as documented in the medical record and ignore the suggested ICD-O-3 code when a different primary site is specified in the medical record.

- b. Code the suggested ICD-O-3 site code when there is no information available indicating a different primary site.
- 11. When the medical record does not contain enough information to assign a primary site
  - a. Consult a physician advisor to assign the site code
  - b. Code Unknown Primary Site (C809) if there is not enough information to assign an NOS or Ill-Defined site category.
  - c. Assign the NOS code for the body system when there are two or more possible primary sites documented and all are within the same system.  
*Example:* Two possible sites are documented in the GI system such as colon and small intestine: code to the GI tract, NOS (C269). Document the possible primary sites in the appropriate text field.
- 12. A subareolar/retroareolar carcinoma is coded to the central portion of the breast (C50.1) which indicates that the cancer arose in the breast tissue beneath the nipple, not the nipple itself.

**Occult Cervical Lymph Node**

Beginning with cases diagnosed 1/1/2018 and later, for a head and neck primary lymph node involvement with no head and neck tumor found or specified by a physician (e.g., Occult Head and Neck Lymph Node), the primary site will be coded:

- C76.0 if the neck node has not been tested or is negative for both HPV and EBV. The AJCC Chapter 6 Cervical Lymph Nodes and Unknown Primary Tumor of the Head and Neck will be used.
- C10.9 if the neck node is p16 positive indicating human papilloma virus (HPV). The AJCC Chapter 10 HPV Mediated (p16+) Oropharyngeal Cancer will be used.
- C11.9 if the neck node is EBVR positive, or both EBVR and p16 positive, indicating Epstein - Barr virus (EBV). The AJCC Chapter 9 Nasopharynx will be used.

**P16 and EBV Status**

		EBV		
		Positive	Negative	Unknown
HPV (p16)	Positive	C11.9 Nasopharynx	C10.9 Oropharynx	C10.9 Oropharynx
	Negative	C11.9 Nasopharynx	C76.0 Ill-defined Site of the Head and Neck	C76.0 Ill-defined Site of the Head and Neck
	Unknown	C11.9 Nasopharynx	C76.0 Ill-defined Site of the Head and Neck	C76.0 Ill-defined Site of the Head and Neck



## Grade Clinical

NAACCR Item #	Length	Source of Standard	Manual
3843	1	NAACCR	Grade Manual <a href="https://apps.naaccr.org/ssdi/list/">https://apps.naaccr.org/ssdi/list/</a> Standards for Oncology Registry Entry (STORE)

### Description

Grade Clinical is new beginning 2018. This data item records the grade of a solid primary tumor before any treatment (surgical resection or initiation of any treatment including neoadjuvant). For cases diagnosed 2018 and later, this data -- item along with Grade Pathological and Grade Post Therapy -- replaces the data item Grade [NAACCR Item #440] as well as site specific factors for cancer sites with alternative grading systems (e.g., breast [Bloom-Richardson], prostate [Gleason]).

### Justification

Grade is a measure of the aggressiveness of the tumor. Grade and cell type are important prognostic indicators for many cancers. For some sites, grade is required to assign the clinical stage group.

### Coding Instructions

1. Refer to the most recent version of the SSDI-Grade manual for general and specific primary site grouping instructions. <https://apps.naaccr.org/ssdi/list/>
2. For those cases that are eligible for AJCC staging, the recommended grading system is specified in the AJCC Chapter.

*Note: the OCCR only requires AJCC staging for cases diagnosed in 2016 or 2017.*

3. The AJCC Chapter-specific grading systems (codes 1-5) take priority over the generic grade definitions (codes A-E, L, H, 9).
4. For those cases that are not eligible for AJCC staging, if the recommended grading system is not documented, the generic grade definitions would apply.
5. Code grade for hematopoietic and lymphoid neoplasms using the current hematopoietic and lymphoid neoplasm manual.
6. **NAACCR data item #440 Grade is no longer applicable for cases diagnosed 2018 and forward.** Grade is still required for cases diagnosed prior to 2018.

## Grade Pathological

NAACCR Item #	Length	Source of Standard	Manual
3844	1	NAACCR	Grade Manual <a href="https://apps.naaccr.org/ssdi/list/">https://apps.naaccr.org/ssdi/list/</a> Standards for Oncology Registry Entry (STORE)

### Description

Grade Pathological is new beginning in 2018. This data item records the grade of a solid primary tumor that has been resected and for which no neoadjuvant therapy was administered.

### Justification

Grade is a measure of the aggressiveness of the tumor. Grade and cell type are important prognostic indicators for many cancers. For some sites, grade is required to assign the clinical stage group.

**Coding Instructions**

1. Refer to the most recent version of the SSDI-Grade manual for general and specific primary site grouping instructions. <https://apps.naaccr.org/ssdi/list/>
2. Record the highest grade documented from any microscopic specimen of the primary site whether from the clinical workup or the surgical resection.
3. Unless the grade instruction manual states to code as 8, this data item should be coded to 9 when the patient receives neoadjuvant treatment followed by resection of the primary site.
4. For those cases that are eligible AJCC staging, the recommended grading system is specified in the AJCC Chapter.
5. The AJCC Chapter-specific grading systems (codes 1-5) take priority over the generic grade definitions (codes A-E, L, H, 9).
6. For those cases that are not eligible for AJCC staging, if the recommended grading system is not documented, the generic grade definitions would apply.
7. Code grade for hematopoietic and lymphoid neoplasms using the current hematopoietic and lymphoid neoplasm manual.
8. **NAACCR data item #440 Grade is no longer applicable for cases diagnosed 2018 and forward.** Grade is still required for cases diagnosed prior to 2018.

**Grade Post Therapy Clin (yc)**

NAACCR Item #	Length	Source of Standard	Manual
1068	1	NAACCR	Grade Manual <a href="https://apps.naaccr.org/ssdi/list/">https://apps.naaccr.org/ssdi/list/</a> Standards for Oncology Registry Entry (STORE)

**Description**

Grade Post Therapy Clin (yc) is new for 2021. This data item records the grade of a solid primary tumor that has been biopsied following neoadjuvant therapy.

**Justification**

Grade is a measure of the aggressiveness of the tumor. Grade and cell type are important prognostic indicators for many cancers. For some sites, grade is required to assign the clinical stage group.

**Coding Instructions**

1. This item should be left blank unless the patient received neoadjuvant treatment followed by tissue biopsy of the primary site.
2. When the patient has received neoadjuvant treatment followed by tissue biopsy of the primary site, Grade Clinical, Grade Pathological and Grade Post Therapy Clin (yc) will all be recorded.

## Grade Post Therapy Path (yp)

NAACCR Item #	Length	Source of Standard	Manual
3845	1	NAACCR	Grade Manual <a href="https://apps.naacr.org/ssdi/list/">https://apps.naacr.org/ssdi/list/</a> Standards for Oncology Registry Entry (STORE)

### Description

Grade Post Therapy Path (yp) is revised for 2021. This data item records the grade of a solid primary tumor that has been resected following neoadjuvant therapy.

### Justification

Grade is a measure of the aggressiveness of the tumor. Grade and cell type are important prognostic indicators for many cancers. For some sites, grade is required to assign the clinical stage group.

### Coding Instructions

1. This item should be left blank unless the patient received neoadjuvant treatment followed by resection of the primary site.
2. When the patient has received neoadjuvant treatment followed by resection of the primary site, Grade Clinical, Grade Pathological and Grade Post Therapy Path (yp) will all be recorded.

## Laterality

NAACCR Item #	Length	Source of Standard	Manual
410	1	SEER/CoC	Standards for Oncology Registry Entry (STORE) SEER Program Coding & Staging Manual

### Description

Laterality describes the side of a paired organ or side of the body on which the reportable tumor originated.

### Justification

Laterality supplements staging and extent of disease information and defines the number of primaries involved.

### Coding Instructions

1. Assign code 0 when primary site is unknown (C809) or Ill-defined (C760-C768)
2. Use the pair organ table in the STORE manual to determine which primary sites should be coded with laterality 1-9.
3. Use code 9 when the tumor originated in a paired site, but laterality is not known AND there is no statement that only one side of the paired organ is involved.
4. Metastatic sites are not coded with laterality. Code laterality to the primary site where the tumor originated if known.
5. Primary sites within situ behavior: If laterality is not known code to 3 (only one side involved, right or left origin of primary not indicated). Laterality for in situ behavior cannot be 9 or 4.

**Paired Organs List**

ICD-0-3 CODES	PRIMARY SITE
C07.9	Parotid gland
C08.0	Submandibular gland
C08.1	Sublingual gland
C09.0	Tonsillar fossa
C09.1	Tonsillar pillar
C09.8	Overlapping lesion of tonsil
C09.9	Tonsil, NOS
C30.0	Nasal cavity (excluding nasal cartilage and nasal septum code)
C30.1.	Middle ear (tympanic cavity)
C31.0	Maxillary sinus (antrum)
C31.2	Frontal sinus
C34.0	Main bronchus (excluding carina)
C34.1-C34.9	Lung
C38.4	Pleura
C40.0	Long bones of upper limb and scapula
C40.1	Short bones of upper limb
C40.2	Long bones of lower limb
C40.3	Short bones of lower limb
C41.3	Rib and clavicle (excluding sternum)
C41.4	Pelvic bones (excluding sacrum, coccyx, and symphysis pubis)
C44.1	Skin of eyelid
C44.2	Skin of external ear
C44.3	Skin of other and unspecified parts of face (midline code "9")
C44.4	Skin of Scalp and Neck
C44.5	Skin of trunk
C44.6	Skin of upper limb and shoulder
C44.7	Skin of lower limb and hip
C47.1	Peripheral nerves and autonomic nervous system of upper limb and shoulder
C47.2	Peripheral nerves and autonomic nervous system of lower limb and hip
C49.1	Connective subcutaneous, and other soft tissues of upper limb and shoulder
C49.2	Connective, subcutaneous, and other soft tissues of lower limb and hip
C50.0-C50.9	Breast
C56.9	Ovary
C57.0	Fallopian tube
C62.0-C62.9	Testis
C63.0	Epididymis
C63.1	Spermatic cord
C64.9	Kidney, NOS
C65.9	Renal pelvis
C66.9	Ureter

C69.0-C69.9	Eye and lacrimal gland
C70.0	Cerebral meninges, NOS (excluding diagnoses prior to 2004)
C71.0	Cerebrum (excluding diagnoses prior to 2004)
C71.1	Frontal lobe (excluding diagnoses prior to 2004)
C71.2	Temporal lobe (excluding diagnoses prior to 2004)
C71.3	Parietal lobe (excluding diagnoses prior to 2004)
C71.4	Occipital lobe (excluding diagnoses prior to 2004)
C72.2	Olfactory nerve (excluding diagnoses prior to 2004)
C72.3	Optic nerve (excluding diagnoses prior to 2004)
C72.4	Acoustic nerve (excluding diagnoses prior to 2004)
C72.5	Cranial nerve, NOS (excluding diagnoses prior to 2004)
C74.0-C74.9	Adrenal gland (cortex, medulla)
C75.4	Carotid body

## Lymphovascular Invasion

NAACCR Item #	Length	Source of Standard	Manual
1182	1	AJCC	Standards for Oncology Registry Entry (STORE) SEER Program Coding & Staging Manual

### Description

Indicates the presence or absence of tumor cells in lymphatic channels (not lymph nodes) or blood vessels within the primary tumor as noted microscopically by the pathologist.

### Justification

Lymphovascular invasion is an indicator of prognosis.

### Coding Instructions

- Code from the pathology report(s).** If not available, code the absence or presence of lymphovascular invasion as described in the medical record.
  - The primary sources of information about lymphovascular invasion are the pathology check lists (synoptic reports) developed by the College of American Pathologists. If the case does not have a checklist or synoptic report, code from other sections of the pathology report or a physician's statement, in that order.
  - Do not code perineural invasion in this field.
  - Information to code this field can be taken from any specimen from the primary tumor (biopsy or resection).
  - If lymphovascular invasion is identified in any primary tumor specimen, code as present/identified.
  - Assign Code 8 Not applicable for benign/borderline brain and CNS tumors.
- Use **code 0** when the pathology report indicates there is no lymphovascular invasion. Assign code 0 for in situ cases.
- Use **code 1** when the pathology report or a physician's statement indicates that lymphovascular invasion (or one of its synonyms) is present in the specimen.

*Synonyms for lymphovascular invasion:* Angiolymphatic invasion, Blood vessel invasion, Lymph Vascular emboli, Lymphatic invasion, Lymph-vascular invasion, and Vascular invasion.

4. Use **code 8** for Lymphoma and Hematopoietic diseases.
5. Use **code 9** where there is no microscopic examination of primary tissue specimen, primary specimen is cytology only or fine needle aspiration, the biopsy is a very small tissue sample, it is not possible to determine whether lymphovascular invasion is present, the pathologist indicates the specimen is insufficient to determine lymphovascular invasion.
6. Revised CAP Protocols and AJCC 8th Edition chapters will indicate which chapters will use the new codes (2, 3, and 4) and which will only use the existing codes (0, 1, 8, 9), as there are some disease sites where distinguishing between L and V is not medically appropriate.

**NOTE:** Refer to the STORE manual for the complete list of detailed instructions, table, and lists.

## Diagnostic Confirmation

NAACCR Item #	Length	Source of Standard	Manual
490	1	SEER/CoC	Standards for Oncology Registry Entry (STORE) SEER Program Coding & Staging Manual

### Description

This data item records the best method used to confirm the presence of the cancer being reported. The best method could occur at any time throughout the entire course of the disease. It is not limited to the confirmation at the time of initial diagnosis.

### Justification

This item is an indicator of the precision of diagnosis. The percentage of solid tumors that are clinically diagnosed only is an indication of whether casefinding includes sources beyond pathology reports. Complete casefinding must include both clinically and pathologically confirmed cases.

### Coding Instructions

#### Solid Tumors

1. The codes are in priority order; code 1 has the highest priority. Always code the procedure with the lower numeric value when presence of cancer is confirmed with multiple diagnostic methods.
2. Change to a lower code, if at ANY TIME during the course of disease the patient has a diagnostic confirmation with a higher priority.
3. Assign **code 1** when the microscopic diagnosis is based on:
  - a. Tissue specimens from fine needle aspirate, biopsy, surgery, autopsy, or D&C
  - b. Bone marrow specimens (aspirate and biopsy).
4. Assign **code 2** when the microscopic diagnosis is based on:
  - a. Examination of cells (rather than tissue) including but not limited to: sputum smears, bronchial brushings, bronchial washings, prostatic secretions, breast secretions, gastric fluid, spinal fluid, peritoneal fluid, pleural fluid, urinary sediment, cervical smears, or vaginal smears.

- b. Paraffin block specimens from concentrated spinal, pleural, or peritoneal fluid
- 5. Assign **code 4** when there is information that the diagnosis of cancer was microscopically confirmed, but the type of confirmation is unknown
- 6. Assign **code 5** when the diagnosis of cancer is based on laboratory tests or tumor marker studies that are clinically diagnostic for that specific cancer
  - Note:* For tests and tumor markers that may be used to help diagnose cancer, see:
    - <http://www.cancer.gov/cancertopics/factsheet/detection>
    - <http://www.cancer.gov/cancertopics/factsheet/detection/tumor-markers>
- 7. Assign **code 6** when the diagnosis is based only on:
  - a. The surgeon's operative report from a surgical exploration or endoscopy such as colonoscopy, mediastinoscopy, or peritoneoscopy and no tissue was examined
  - b. Gross autopsy findings (no tissue or cytologic confirmation)
- 8. Assign code 7 when the only confirmation of malignancy was diagnostic imaging such as computerized axial tomography (CT scans), magnetic resonance imaging (MRI scans), or ultrasounds/sonography
- 9. Assign code 8 when the case was diagnosed by any clinical method not mentioned in preceding codes. The diagnostic confirmation is coded 8 when the only confirmation of disease is a physician's clinical diagnosis.
- 10. Assign **code 9** when it is unknown if the diagnosis was confirmed microscopically or for death certificate only case

*Hematopoietic and Lymphoid Neoplasms (9590/3 – 9992/3):* See the Hematopoietic and Lymphoid Neoplasm Coding Manual and Database for coding instructions.

## Primary Site Text

NAACCR Item #	Length	Source of Standard	NAACCR Data Dictionary
2580	100	NPCR	NAACCR Data Dictionary

### **Description**

This narrative text section is used to document the primary site and laterality of the tumor being reported.

### **Justification**

Text documentation is an essential component of a complete electronic report and is heavily utilized for quality control and special studies. Text is needed to justify coded values and to document supplemental information not transmitted within coded values. High-quality text documentation facilitates consolidation of information from multiple reporting sources at the central registry.

The text field must contain a description that has been entered by the reporter independently from the code(s). If software generates text automatically from codes, the text cannot be utilized to check coded values. Information documenting the disease process should be entered manually from the medical record and should not be generated electronically from coded values.

### **Coding Instructions**

1. Text documentation is **REQUIRED AND MUST BE PROVIDED BY ALL REPORTING FACILITIES**.
2. State the specific location of the primary site, including subsite.
3. Include available information on tumor laterality.

## Histology Text

NAACCR Item #	Length	Source of Standard	NAACCR Data Dictionary
2590	100	NPCR	NAACCR Data Dictionary

### Description

This narrative text section is used to document information regarding the histologic type, behavior, and grade (differentiation) of the tumor being reported.

### Justification

Text documentation is an essential component of a complete electronic report and is heavily utilized for quality control and special studies. Text is needed to justify coded values and to document supplemental information not transmitted within coded values. High-quality text documentation facilitates consolidation of information from multiple reporting sources at the central registry.

The text field must contain a description that has been entered by the reporter independently from the code(s). If software generates text automatically from codes, the text cannot be utilized to check coded values. Information documenting the disease process should be entered manually from the medical record and should not be generated electronically from coded values.

### Coding Instructions

1. Text documentation is **REQUIRED AND MUST BE PROVIDED BY ALL REPORTING FACILITIES**.
2. Include information on histologic type and behavior.
3. Include information on differentiation from scoring systems such as Gleason's Score, Bloom-Richardson Grade, etc.

## Pathology Text

NAACCR Item #	Length	Source of Standard	NAACCR Data Dictionary
2570	4000	NPCR	NAACCR Data Dictionary

### Description

This narrative text section is used to provide information from pathology and cytology reports that are pertinent to the diagnosis and extent of disease. Use this field to substantiate the histology, behavior, grade, lymph node(s), tumor size, surgical margin status, extent of disease (e.g., direct extension and/or metastatic disease) as well as the date, place, slide number and specimen examined.

### Justification

Text documentation is an essential component of a complete electronic report and is heavily utilized for quality control and special studies. Text is needed to justify coded values and to document supplemental



information not transmitted within coded values. High-quality text documentation facilitates consolidation of information from multiple reporting sources at the central registry.

The text field must contain a description that has been entered by the reporter independently from the code(s). If software generates text automatically from codes, the text cannot be utilized to check coded values. Information documenting the disease process should be entered manually from the medical record and should not be generated electronically from coded values.

### **Coding Instructions**

1. Text documentation is **REQUIRED AND MUST BE PROVIDED BY ALL REPORTING FACILITIES**.
2. Record all pathology (tissue, cytology, etc.) reports that pertain to the diagnosis or staging of the tumor.
3. See additional clarifications in the OCCR Texting Table in Appendix G.
4. No codes are to be entered into this field. This field is for narrative text only.
5. Tumor size is to be recorded in this field; if multiple tumor dimension are provided on the pathology report, record all dimensions (if appropriate).
6. In the order listed, record the date, place, type of imaging technique and findings:

1	Date(s) of procedure.
2	Place where tissue specimen was obtained.
3	Pathology report number
4	Origin of the specimen being examined (e.g., biopsy, surgical specimen, etc.)
5	Final histologic diagnosis (include microscopic information if a more specific histology and/or grade is described, following the guidelines in the histology/behavior/grade section of this manual.
6	Lymph node status.
7	Description of tumor size.
8	Surgical (residual) margin status as it relates to the residual tumor status.
9	Description of tumor invasion from gross, microscopic and final diagnosis (e.g., through the basement membrane; invasion of the wall without extension through the wall; invasion into adjacent structures/tissues/organs). Record both positive and negative findings.
10	Record additional comments from the pathologist, including differential diagnoses considered and ruled out or favored.

### **Physical Exam Text**

NAACCR Item #	Length	Source of Standard	NAACCR Data Dictionary
2520	4000	NPCR	NAACCR Data Dictionary

#### **Description**

This data item is used to describe in narrative format the date of first contact with your facility, place, type of visit (inpatient or outpatient), presenting symptoms at diagnosis, physical examination (tumor location, size, extension and lymph nodes), impression, treatment plan, and any other pertinent information that further substantiates codes.

#### **Justification**

Text documentation is an essential component of a complete electronic report and is heavily utilized for quality control and special studies. Text is needed to justify coded values and to document supplemental information not transmitted within coded values. High-quality text documentation facilitates consolidation of information from multiple reporting sources at the central registry.

The text field must contain a description that has been entered by the reporter independently from the code(s). If software generates text automatically from codes, the text cannot be utilized to check coded values. Information documenting the disease process should be entered manually from the medical record and should not be generated electronically from coded values.

### **Coding Instructions**

1. Record the dates of inpatient admit/discharge, place, type of visit, presenting symptoms at diagnosis, result of physical exam, impression and treatment plan (if known).
2. For lymphomas, any mention of lymph nodes, such as “enlarged”, “visible swelling”, or “palpable” is considered involvement and should be recorded.
3. For prostate cancers, record the results of the digital rectal exam. Any mention of “induration” or “palpable nodule” should be reported.
4. See Appendix D for acceptable abbreviations.

### **X-ray/Scan Text**

NAACCR Item #	Length	Source of Standard	NAACCR Data Dictionary
2530	4000	NPCR	NAACCR Data Dictionary

### **Description**

This data item is used to describe in narrative format date, type of procedure, and all positive and negative findings that substantiate the staging that is recorded. These reports may describe findings related to malignant involvement. Procedures such as bowel studies (GI series, barium enema), bladder and kidney studies (IVP), or radioisotope scan (brain, bone, liver scans) should be recorded if they provide additional information about the extent of disease, positive or negative.

### **Justification**

Text documentation is an essential component of a complete electronic report and is heavily utilized for quality control and special studies. Text is needed to justify coded values and to document supplemental information not transmitted within coded values. High-quality text documentation facilitates consolidation of information from multiple reporting sources at the central registry.

The text field must contain a description that has been entered by the reporter independently from the code(s). If software generates text automatically from codes, the text cannot be utilized to check coded values. Information documenting the disease process should be entered manually from the medical record and should not be generated electronically from coded values.

### **Coding Instructions**

1. Text documentation is **REQUIRED AND MUST BE PROVIDED BY ALL REPORTING FACILITIES.**

- 2.
3. Record all X-rays, scans, and/or other imaging reports that pertain to the diagnosis and extent of disease of the tumor.
4. See additional clarifications in the OCCR Texting Table in Appendix G.
5. In the order listed, record the date, place, type of imaging technique and findings:

1	Date(s), type(s) of X-ray/scan(s), and imaging area.
2	Place where imaging was performed.
3	Final diagnosis
4	Description of tumor invasion. Lymph node status and tumor size if mentioned. Record both positive and negative findings.
5	Record any additional comments from the physician, including differential diagnoses considered and any ruled out or favored.

### Lab Tests Text

NAACCR Item #	Length	Source of Standard	NAACCR Data Dictionary
2550	4000	NPCR	NAACCR Data Dictionary

#### Description

This data item is used to describe in narrative format date, type and value of a lab test that specifically applies to the type of cancer or primary site being abstracted and it is a part of a definitive clinical picture for the disease. Indicate whether positive, negative, elevated, normal, etc. Below are some examples:

Breast	Estrogen/progesterone receptor assay; HER2 studies
Colorectal	Carcinoembryonic Antigen (CEA)
Prostate	Prostatic specific antigen (PSA)
Multiple myeloma	Monoclonal immunoglobulin in urine or serum protein electrophoresis
Testis	Human chorionic gonadotrophin (HcG)
Liver	Alphafetoprotein (AFP)
Thyroid (Medullary carcinoma)	Elevated calcitonin

#### Justification

Text documentation is an essential component of a complete electronic report and is heavily utilized for quality control and special studies. Text is needed to justify coded values and to document supplemental information not transmitted within coded values. High-quality text documentation facilitates consolidation of information from multiple reporting sources at the central registry.

The text field must contain a description that has been entered by the reporter independently from the code(s). If software generates text automatically from codes, the text cannot be utilized to check coded values. Information documenting the disease process should be entered manually from the medical record and should not be generated electronically from coded values.

**Coding Instructions**

1. Text documentation is **REQUIRED AND MUST BE PROVIDED BY ALL REPORTING FACILITIES**.
2. Record the date, type of lab test, and findings. Narrative documentation to support the required lab site specific data items must be provided. If a registrar elects to code other optional lab values, please provide narrative documentation in this free text field.
3. See additional clarifications in the OCCR Texting Table in Appendix G.
4. In the order listed, record the date, place, type of lab tests and findings:

1	Date(s), type(s) of lab test/tissue specimen(s).
2	Place where lab test/tissue specimen(s) was performed.
3	Final diagnosis
4	Information can include tumor markers, serum and urine electrophoresis, special studies, etc. Record both positive and negative findings.

**Scopes Text**

NAACCR Item #	Length	Source of Standard	NAACCR Data Dictionary
2540	4000	NPCR	NAACCR Data Dictionary

**Description**

This data item is used to describe in narrative format date, type of endoscopic procedure, and all positive and negative findings for staging and treatment.

**Justification**

Text documentation is an essential component of a complete electronic report and is heavily utilized for quality control and special studies. Text is needed to justify coded values and to document supplemental information not transmitted within coded values. High-quality text documentation facilitates consolidation of information from multiple reporting sources at the central registry.

The text field must contain a description that has been entered by the reporter independently from the code(s). If software generates text automatically from codes, the text cannot be utilized to check coded values. Information documenting the disease process should be entered manually from the medical record and should not be generated electronically from coded values.

**Coding Instructions**

1. Text documentation is **REQUIRED AND MUST BE PROVIDED BY ALL REPORTING FACILITIES**.
2. Record all endoscopic exams that pertain to the diagnosis, extent of disease, and treatment of the tumor.
3. See additional clarifications in the OCCR Texting Table in Appendix G.
4. In the order listed, record the date, place, type of endoscopic exam and findings:

1	Date(s) and type(s) of endoscopic exam.
2	Place where endoscopic exam was performed.

---

3	Tumor location and tumor size
4	Description of tumor invasion. Lymph node status and tumor size if mentioned. Record both positive and negative findings.

# **SECTION 7**

# **STAGING**

## SEER Summary Stage 2018

NAACCR Item #	Length	Source of Standard	Manual
764	1	SEER	<a href="#">SS2018 Manual</a> or <a href="#">SEER*RSA</a> + SS2018 Gen Instructions

### Description

This item stores the directly assigned Summary Stage 2018. Effective for cases diagnosed 1/1/2018 and forward.

### Justification

The SEER program has collected staging information on cases since its inception in 1973. Summary Stage groups cases into broad categories of in situ, local, regional, and distant. Summary Stage can be used to evaluate disease spread at diagnosis, treatment patterns and outcomes over time.

### Coding Instructions

- Any information found that is clinical or pathological can be used in staging the cancer if it is within **four months of diagnosis** in the absence of disease progression or upon completion of **surgery(ies)** in first course of treatment, whichever is longer.
- When there is doubt about assigning the appropriate stage, assign the lesser stage. Do not over stage.
- When multiple tumors are reported as a single primary, assign the greatest Summary Stage from any tumor.
- Information for Summary Stage from a surgical resection **after neoadjuvant treatment may be used**, but ONLY if the extent of disease is greater than the pre-treatment clinical findings.
- Autopsy reports are used just as are pathology reports, applying the same rules for inclusion and exclusion.
- TNM information may be used to assign Summary Stage if it is the only information available.
- Document the assessment of the Summary Stage as well as the choice of the Summary Stage assignment in the STAGE text field on the abstract.
- Text for PE, X-ray/Scan text, Scopes, Lab Test, Operative and Path should contain the pertinent information which led to the assigned Summary Stage.

### Ambiguous Terminology for Summary Stage 2018

Use the following lists to interpret the intent of the clinician ONLY when further documentation is not available and/or there is no specific statement of involvement in the medical record. The physician's definitions/descriptions and choice of therapy have priority over these lists because individual clinicians may use these terms differently. Refer to the Summary Stage 2018 manual General Coding Instructions <https://seer.cancer.gov/tools/ssm/>.

Use the following lists as a guide **when no other information is available**.

#### Involved

Adherent  
Apparent(ly)  
Appears to  
Comparable with

Incipient invasion  
Induration  
Infringe/infringing  
Into\*

Compatible with	Intrude
Contiguous/continuous with	Most likely
Encroaching upon*	Onto*
Extension to, into, onto, out onto	Overstep
Features of	Presumed
Fixation to another structure other than primary**	Probable
Fixed to another structure**	Protruding into (unless encapsulated)
Impending perforation of	Suspected
Impinging upon	Suspicious
Impose/imposing on	To*
	Up to

**Not Involved**

Abuts	Extension to without invasion/involvement of
Approaching	Kiss/kissing
Approximates	Matted (except for lymph nodes)
Attached	Possible
Cannot be excluded/ruled out	Questionable
Efface/effacing/effacement	Reaching
Encased/encasing	Rule out
Encompass(ed)	Suggests
Entrapped	Very close to
Equivocal	Worrisome

\* interpret as involvement whether the description is clinical or operative/pathological

\*\* interpret as involvement of other organ or tissue

Code	Description
0	In situ
1	Localized Only
2	Regional by Direct Extension Only
3	Regional to Lymph Nodes Only
4	Regional by BOTH direct extension AND regional lymph nodes
7	Distant site(s)/nodes involved or systemic for some hematopoietic cancers
8	Benign, borderline *
9	Unknown if extension or metastasis (unstaged, unknown, or unspecified) Death certificate only case

\*Applicable for the following Summary Stage 2018 Chapters: Brain, CNS Other, Intracranial Gland

**Note:** Code 5 Regional, NOS can no longer be coded beginning with SS2018. It is still applicable for SS2000.



## Text Staging

NAACCR Item #	Length	Source of Standard	NAACCR Data Dictionary
2600	4000	NPCR	NAACCR Data Dictionary

### Description

This data item is used to provide narrative text to substantiate codes assigned for the stage of disease at diagnosis. This field may also be used for additional text for staging information not entered in the DX Procedures Text data item.

### Justification

Text documentation is an essential component of a complete electronic report and is heavily utilized for quality control and special studies. Text is needed to justify coded values and to document supplemental information not transmitted within coded values. High-quality text documentation facilitates consolidation of information from multiple reporting sources at the central registry.

The text field must contain a description that has been entered by the reporter independently from the code(s). If software generates text automatically from codes, the text cannot be utilized to check coded values. Information documenting the disease process should be entered manually from the medical record and should not be generated electronically from coded values.

### Coding Instructions

Text documentation is **REQUIRED AND MUST BE PROVIDED BY ALL REPORTING FACILITIES.**

No codes are to be written in this field. This field is for narrative documentation only. Write a brief description of the extent of disease. Describe the organs, tissues, and lymph nodes involved with cancer. If the tumor is localized, a statement such as “cancer confined to prostate capsule” or “confined to prostate, nodal and metastatic workup is negative” is sufficient. A regional cancer might be described as “hepatocellular carcinoma of the liver with extension to the gallbladder”. A distant cancer might be described as “left breast cancer with metastasis to the lung, bone and mediastinal lymph nodes.”

See additional clarifications in the OCCR Texting Table in [Appendix G](#).

See [Appendix D](#) for acceptable abbreviations.

## Site-Specific Data Items (SSDI)

NAACCR Item #	Length	Source of Standard	Manual
		NAACCR	<a href="https://apps.naaccr.org/ssdi/list/">https://apps.naaccr.org/ssdi/list/</a>

### Description

Site specific data items apply to specific primary sites, histologies and years of diagnosis. In some cases, a Schema discriminator is required to be coded to further describe the site and /or histology. A list of schema discriminators 1 and 2 can be found in the SSDI manual.

### Coding Instructions

You will need to use the [SSDI manual](#) or [SEER\\*RSA](#) for the general rules and specific coding instructions for each primary site grouping.

*\*NOTE: SEER\*RSA does not provide general instructions. It is important that you review and are familiar with the general instructions. Site-specific instructions take priority over the general instructions.*

**OCCR Required SSDIs**

	NAACCR Item #	Item Name	Primary Site(s)	Histologies
Brain	3816	Brain Molecular Markers	C700, C710-C719	8000-8700, 8720-8790, 8802, 8810, 8815, 8850, 8890, 8900, 9064, 9070-9071, 9080, 9084-9085, 9100-9105, 9120, 9133, 9140, 9180, 9220, 9362, 9364, 9380-9540, 9680, 9699, 9702-9715, 9751-9759; Behavior 3
			C700, C710-C719	8000-9993; Behavior 0,1
Melanoma Skin	3817	Breslow Tumor Thickness	C000-C002, C006, C440-C449, C500, C510-C512, C518-C519, C600-C602, C608-C609, C632	8720-8790
	3932	LDH Lab Value		
Breast	3827	Estrogen Receptor Summary	C500-C506, C508-C509	8000-8700, 8982-8983
			C501-C506, C508-C509	8720-8790
	3915	Progesterone Receptor Summary	C500-C506, C508-C509	8000-8700, 8982-8983
			C501-C506, C508-C509	8720-8790
3855	HER2 Overall Summary	C500-C506, C508-C509	8000-8700, 8982-8983	
		C501-C506, C508-C509	8720-8790	
Liver	3835	Fibrosis Score	C220	8000-8700, 8720-8790
Prostate	3838	Gleason Patterns Clinical	C619	8000-8700, 8720-8790
	3840	Gleason Score Clinical		
	3839	Gleason Patterns Pathological		
	3841	Gleason Score Pathological		
	3842	Gleason Tertiary Pattern		
	3920	PSA Lab Value		
Colon & Rectum	3890	Microsatellite Instability (MSI)	C180, C182-C189, C199, C209	8000-8149, 8154, 8160-8231, 8243-8248, 8250-8682, 8690-8700, 8720-8790
Cervix (2021+)	3956	p16	C530-C531, C538-C539	8000-8700, 8720-8790, 8980, 9110 Year of Diagnosis: 2021-9998, 9999
Anus (2023+)			C210-C212, C218	8000-8700, 8720-8790
Vulva (2024+)			C510-C512, C518-C519	8000-8040, 8042-8180, 8191-8246, 8248-8700, 9020, 9071

Esophagus & EG J (Squamous)	3829	Esophagus and EGJ Tumor Epicenter  New for OCCR 2022+	C150-C155, C158-159 C160	8050-8054, 8020, 8070, 8074, 8077, 8083, 8560
Appendix	3960	Histologic Subtype New for 2023+	C181	8480

## STAGE PROGNOSTIC FACTORS

### Tumor Size Summary

NAACCR Item #	Length	Source of Standard	Manual
756	3	NPCR/CoC	Standards for Oncology Registry Entry (STORE)

#### Description

Records the most accurate measurement of a solid primary tumor.

#### Justification

The size of the tumor is one indication of the extent of disease. It is used by both clinicians and researchers. Tumor size that is independent of stage is also useful for quality assurance efforts.

#### Coding Instructions

All measurements should be in millimeters (mm).

#### Record the size in the specified order:

1. Size measured on the surgical resection specimen, when surgery is administered as the first definitive treatment, i.e., no pre-surgical treatment administered.
  - a. If there is a discrepancy among tumor size measurements in the various sections of the pathology report, code the size from the synoptic report (also known as CAP protocol or pathology report checklist). If only a text report is available, use: final diagnosis, microscopic, or gross examination, in that order.

*Example:* Chest x-ray shows 3.5 cm mass; the pathology report from the surgery states that the same mass is malignant and measures 2.8 cm. Record tumor size as 028 (28 mm).

*Example:* Pathology report states lung carcinoma is 2.1 cm x 3.2 cm x 1.4 cm. Record tumor size as 032 (32 mm).

2. If neoadjuvant therapy followed by surgery, do not record the size of the pathologic specimen. Code the largest size of tumor prior to neoadjuvant treatment; if unknown code size 999.

*Example:* Patient has a 2.2 cm mass in the oropharynx; fine needle aspiration of mass confirms squamous cell carcinoma. Patient receives a course of neoadjuvant combination chemotherapy. Pathologic size after total resection is 2.8 cm. Record tumor size as 022 (22mm).

3. If no surgical resection, then the largest measurement of the tumor from physical exam, imaging, or other diagnostic procedures prior to any other form of treatment (See coding rules below).
4. If 1, 2, and 3 do not apply, the largest size from all information available within four months of the date of diagnosis, in the absence of disease progression.

### Coding Rules

1. Tumor size is the **diameter** of the tumor, **not the depth or thickness** of the tumor.
2. Recording less than/greater than Tumor Size:
  - a. If tumor size is reported as less than x mm, or less than x cm, the reported tumor size should be 1 mm less; for example, if size is < 1 cm code as 009, < 2 cm is coded as 019, < 3 cm is coded as 029, < 4 cm is coded as 039, < 5 cm is coded as 049. If stated as less than 1 mm, use code 001.
  - b. If tumor size is reported as more than x mm or more than x cm, code size as 1 mm more; for example, if size is >10 mm, size should be coded as 011. Often these are given in cm such as > 1 cm, which is coded as 011, > 2 cm is coded as 021, > 3 cm is coded as 031, > 4 cm is coded as 041, > 5 cm is coded as 051. If described as anything greater than 989 mm (98.9 cm) code as 989.
  - c. If tumor size is reported to be between two sizes, record tumor size as the midpoint between the two: i.e., add the two sizes together and then divide by two (“between 2 and 3 cm” is coded as 025).
3. **Rounding:** Round the tumor size only if it is described in fractions of millimeters. If the largest dimension of a tumor is less than 1 millimeter (between 0.1 and 0.9 mm), record size as 001 (do not round down to 000). If tumor size is greater than 1-millimeter, round tenths of millimeters in the 1-4 range down to the nearest whole millimeter, and round tenths of millimeters in the 5-9 range up to the nearest whole millimeter. Do not round tumor size expressed in centimeters to the nearest whole centimeter (rather, move the decimal point one space to the right, converting the measurement to millimeters). For breast cancer, please follow the AJCC 8th Edition, Breast Chapter.

*Examples:*

Breast cancer described as 6.5 millimeters in size. Round up Tumor Size as 007.

Cancer in polyp described as 2.3 millimeters in size. Round down Tumor Size as 002.

Focus of cancer described as 1.4 mm in size. Round down as 001.

5.2 mm breast cancer. Round down to 5 mm and code as 005.

4. **Priority of imaging/radiographic techniques:** Information on size from imaging/radiographic techniques can be used to code size when there is no more specific size information from a pathology or operative report, but it should be taken as low priority over a physical exam.
5. **Tumor size discrepancies among imaging and radiographic reports:** If there is a difference in reported tumor size among imaging and radiographic techniques, unless the physician specifies which imaging is most accurate, record the largest size in the record, regardless of which imaging technique reports it.
6. **Always code the size of the primary tumor, not the size of the polyp, ulcer, cyst, or distant metastasis.** However, if the tumor is described as a “cystic mass,” and only the size of the entire mass is given, code the size of the entire mass, since the cysts are part of the tumor itself.
7. Record the size of the invasive component, if given.
  - a. If both an in situ and an invasive component are present and the invasive component is measured, record the size of the invasive component even if it is smaller.

*Example:* Tumor is mixed in situ and invasive adenocarcinoma, total 3.7 cm in size, of which 1.4 cm is invasive. Record tumor size as 014 (14 mm).
  - b. If the size of the invasive component is not given, record the size of the entire tumor from the surgical report, pathology report, radiology report or clinical examination.

*Example:* A breast tumor with infiltrating duct carcinoma with extensive in situ component; total size 2.3 cm. Record tumor size as 023 (23 mm).

*Example:* Duct carcinoma in situ measuring 1.9 cm with an area of invasive ductal carcinoma. Record tumor size as 019 (19 mm).
8. Record the largest dimension or diameter of tumor, whether it is from an excisional biopsy specimen or the complete resection of the primary tumor. Example: Tumor is described as 2.4 x 5.1 x 1.8 cm in size. Record tumor size as 051 (51 mm).
9. Record the size as stated for purely in situ lesions.
10. **Disregard microscopic residual or positive surgical margins when coding tumor size.** Microscopic residual tumor does not affect overall tumor size. The status of primary tumor margins may be recorded in a separate data item.
11. **Do not add the size of pieces or chips together to create a whole;** they may not be from the same location, or they may represent only a very small portion of a large tumor. However, if the pathologist states an aggregate or composite size (determined by fitting the tumor pieces together and measuring the total size), record that size. If the only measurement describes pieces or chips, record tumor size as 999.
12. **Multifocal/multicentric tumors:** If the tumor is multi-focal or if multiple tumors are reported as a single primary, code the size of the largest invasive tumor or if all of the tumors are in situ, code the size of the largest in situ tumor.
13. **Tumor size code 999 is used when size is unknown or not applicable.** Sites/morphologies where tumor size is not applicable are listed here.

Hematopoietic, Reticuloendothelial, and Myeloproliferative neoplasms: histology codes 9590-9992  
Kaposi Sarcoma

Melanoma Choroid  
 Melanoma Ciliary Body  
 Melanoma Iris

**14. Document the information to support coded tumor size in the appropriate text data item of the abstract.**

Code	Label
000	No Mass/Tumor Found
001	1 mm or described as less than 1 mm
002-988	Exact size in millimeters (2 mm to 988 mm)
989	989 millimeters or larger
990	Microscopic focus or foci and no size of focus is given
998	<p>SITE-SPECIFIC CODES</p> <p>Alternate descriptions of tumor size for specific sites:</p> <p>Familial/multiple polyposis:</p> <ul style="list-style-type: none"> <li>- Rectosigmoid and rectum (C19.9, C20.9)</li> <li>- Colon (C18.0, C18.2-C18.9)</li> </ul> <p>If no size is documented:</p> <p>Circumferential:</p> <ul style="list-style-type: none"> <li>- Esophagus (C15.0-C15.5, C15.8-C15.9)</li> </ul> <p>Diffuse; widespread: 3/4s or more; linitis plastica:</p> <ul style="list-style-type: none"> <li>- Stomach and Esophagus GE Junction (C16.0-C16.6, C16.8-C16.9)</li> </ul> <p>Diffuse, entire lung or NOS:</p> <ul style="list-style-type: none"> <li>- Lung and main stem bronchus (C34.0-C34.3, C34.8-C34.9)</li> </ul> <p>Diffuse:</p> <ul style="list-style-type: none"> <li>- Breast (C50.0-C50.6, C50.8-C50.9)</li> </ul>
999	<p>Unknown; size not stated</p> <p>Not documented in patient record</p> <p>Size of tumor cannot be assessed</p> <p>Not Applicable</p>

# **SECTION 8**

## **SOLID TUMOR RULES**

## History of the Multiple Primary and Histology Coding Rules and Solid Tumor Rules

In 2007, the Multiple Primary and Histology (MPH) Coding Rules reference manual was released to ensure consistent coding of cancer primaries and histology. The rules were based on the World Health Organization (WHO) International Classification of Diseases for Oncology (ICD-O) series of books (commonly referred to as “blue book” or “purple book”). The MPH manual was the first to be broken down into site specific categories. A task force sponsored by the National Cancer Institute (NCI) Surveillance Epidemiology and End Results (SEER) Program included members from many organizations with interest in cancer data collection such as SEER reporting regions, American College of Surgeons (ACoS), Centers for Disease Control and Prevention (CDC), National Program of Cancer Registries (NPCR), etc. As cancer data collection evolved and became more complex, the need for updated instructions resulted in the development of the Solid Tumor Rules. Along with a module for General Instructions, eight site specific modules were released in 2018: Head and Neck, Colon (which includes rectal cancers), Lung, Breast, Kidney, Urinary sites, Non-malignant CNS (central nervous system), and Malignant CNS and Peripheral Nerves. A ninth module was added for 2021: Cutaneous (skin) Melanoma. Melanoma can arise in sites other than skin such as ocular melanoma. This module does not apply to those primaries. A tenth module has been added for 2023: Other Sites. All primary sites that do not have a specific Solid Tumor Rule module are governed by the Other Sites Solid Tumor Rules. Rectosigmoid and rectum are included in Colon Solid Tumor Rules. Peripheral nerves are included in the Malignant CNS Solid Tumor Rules. The Hematopoietic and Lymphoid Neoplasm Database and Coding Manual are used for lymphoma, leukemia, and other blood-related cancer.

## Using the Solid Tumor Rules

It is vitally important to read the General Instructions module before using a site-specific module. The following tips will aid you in using the Solid Tumor Rules:

1. Always open the Solid Tumor Rules on the SEER website (<https://seer.cancer.gov/tools/solidtumor/>) each time they are accessed. This ensures you have to most up-to-date information available. When accessing the Solid Tumor Rules, be sure to open in Adobe Acrobat Reader for full functionality. There are hyperlinks throughout the documents for navigation and they function best with Adobe Acrobat Reader.
2. Each module is truly site specific. Rules from one module **cannot** be used for another site.
3. It may be necessary to go through the rules more than one time (see number 4B).
4. Hierarchy order of rules:
  - A. **Single tumor, single histology:**
    - i. General Instructions Module
    - ii. Equivalent Terms and Definitions
    - iii. Multiple Primary Rules
    - iv. Histology Rules
  - B. For **multiple tumors**, multiplicity must be determined by using Histology Rules **first** to establish working histologies for each tumor, followed by the Multiple Primary Rules to verify whether single or multiple primaries.
    - i. If multiple tumors are determined to be a single primary:
      1. General Instructions Module
      2. Equivalent Terms and Definitions



3. Multiple Primary Rules
4. Histology Rules
- ii. If determined to be multiple primaries, apply rules for each separate primary:
  5. General Instructions Module
  6. Equivalent Terms and Definitions
  7. Multiple Primary Rules
  8. Histology Rules
5. Perhaps the most important rule of all, whether for Solid Tumor Rules or MPH Rules, follow the rules in order and when you come to the rule that applies to your situation:

**STOP!**

Do not look any further, or mistakes will be made.

# **SECTION 9**

# **ABSTRACTING TREATMENT DATA**

## Text Requirements

Text documentation to support cancer diagnosis, stage and treatment codes **must be provided by all facilities**. *The main purpose of text fields in the abstract is to justify coded values and to document supplemental information not transmitted within coded values.*

Text documentation is an essential component of an abstract and is heavily utilized in quality control, to validate data at time of NPCR audits and special studies. It is also used to assure that the data meets the standards of ACoS, NAACCR, NCDB, SEER and NPCR. Adequate text is a data quality indicator and a major part of Quality and Completeness Studies.

The OCCR relies solely on the text documentation provided from reporting facilities to ensure coding in the abstract is correct. High quality text facilitates consolidation of information from multiple reporting sources at the central registry, as well as in reabstraction audits.

Please see [Appendix G](#) for details on text documentation requirements, as well as examples.

## First Course of Treatment

Cancer-directed therapy or definitive treatment is treatment that is recommended by the physician that will affect control, change, remove or destroy the cancer-involved tissue of the primary site or of a metastatic site. It is administered before the disease progresses or recurrence occurs. The **first course of treatment** is any cancer-directed treatment recorded in the treatment plan and administered before disease progression or recurrence. If there is no treatment plan, established protocol or management guidelines and a consultation with a physician advisor is not possible, use the principle: "Initial treatment must begin within four months of the date of initial diagnosis." This includes any first course treatment administered at the reporting facility or elsewhere, all treatment **planned** or administered by physician(s). Treatment can include multiple types and may last for a year or more. Any treatment meeting this guideline evaluation **must** be coded in the appropriate treatment data field and documented in the *Treatment Text* field(s).

"Active surveillance" is a form of planned treatment for some patients. It is coded in *RX--Summ--Treatment Status* [1285].

"No therapy" is a treatment option that occurs if the patient refuses treatment, the family or guardian refuses treatment, the patient dies before treatment starts, or the physician recommends no treatment be given. If the patient refuses all treatment, code "patient refused" (code 7 or 87) for all treatment modalities.

Maintenance treatment given as part of the first course of planned care is first course treatment.

**NOTE:** Leukemia treatment includes all therapies planned and delivered by the physician(s) during the first diagnosis of leukemia. This includes all treatment that is remission-inducing or remission-maintaining. It may include multiple methods and can last more

than a year. After relapse of the first remission, the treatment administered is not considered first course of treatment.

**NOTE:** If there is a change in systemic therapy because of a failure of the original delivered treatment or a reaction to the treatment by the patient, the new treatment therapy is considered to be first course of treatment if the replacement agents belong to the same group as the original agent, there is no change in the regimen. However, if the replacement agent is of a different group than the original agent, the new regimen represents the start of subsequent therapy. Please refer to SEER\*RX <https://seer.cancer.gov/tools/seerrx/>.

**NOTE:** Prostate cancer patients are often treated with “watchful waiting.” This is considered first course of treatment. If a PSA is done later and additional treatment is started, this is considered subsequent treatment and not part of first course of treatment. Prostate patients are also treated with hormone therapy followed by brachytherapy as part of first course of treatment and may take up to a year to complete the treatment.

### Neoadjuvant Treatment

Sometimes radiation therapy or chemotherapy is given before surgery is performed to shrink the size of the tumor or reduce the cancer spread. This neoadjuvant treatment (pre-treatment before surgery) is coded as part of first course of treatment.

### Diagnostic Procedure

NAACCR Item #	Length	Source of Standard	Manual
1350	2	SEER/CoC	Standards for Oncology Registry Entry (STORE) SEER Program Coding & Staging Manual

#### Description

Identifies the positive surgical procedure(s) performed to diagnose and/or stage disease.

#### Justification

This data item is used to track the use of surgical procedure resources that are not considered treatment.

#### Coding Instructions

Codes	Description
00	No surgical diagnostic or staging procedure was performed.
01	A biopsy (incisional, needle, or aspiration) was done to a site other than the primary site. No exploratory procedure was done.
02	A biopsy (incisional, needle, or aspiration) was done to the primary site; or biopsy or removal of a lymph node to diagnose or stage lymphoma.
03	A surgical exploration only. The patient was not biopsied or treated.
04	A surgical procedure with a bypass was performed, but no biopsy was done.

05	An exploratory procedure was performed, and a biopsy of either the primary site or another site was done.
06	A bypass procedure was performed, and a biopsy of either the primary site or another site was done.
07	A procedure was done, but the type of procedure is unknown.
09	No information of whether a diagnostic or staging procedure was performed.

1. Record the type of procedure performed as part of the initial diagnosis and workup, whether this is done at your institution or another facility.
2. Only record positive procedures. For benign and borderline reportable tumors, report the biopsies positive for those conditions. For malignant tumors, report procedures if they were positive for malignancy.
3. If both an incisional biopsy of the primary site and an incisional biopsy of a metastatic site are done, use code 02 (incisional biopsy of primary site).
4. If a lymph node is biopsied or removed to diagnose or stage lymphoma, and that node is NOT the only node involved with lymphoma, use code 02. If there is a single lymph node involve with lymphoma, use the data item *RX – Surg 2023* [1291] to code these procedures.
5. Do not code surgical procedures which aspirate, biopsy, or remove regional lymph nodes in an effort to diagnose and/or stage disease in this data item. Use the data item *Scope of Regional Lymph Node Surgery* [1292] to code these procedures. Do not record the date of surgical procedures which aspirate, biopsy, or remove regional lymph nodes in the data item *Date of Surgical Diagnostic and Staging Procedure* [1280]. See instructions for *Scope of Regional Lymph Node Surgery* [1292].
6. Code brushings, washings, cell aspiration, and hematologic findings (peripheral blood smears) as positive cytologic diagnostic confirmation in the data item *Diagnostic Confirmation* [490]. These are not considered surgical procedures and should not be coded in this item.
7. Do not code excisional biopsies with clear or microscopic margins in this data item. Use the data item *RX Summ – Surg 2023* [1291] to code these procedures.
8. If a needle biopsy precedes an excisional biopsy or more extensive surgery, and upon the excisional biopsy or more extensive surgery the surgical margins are clear (i.e., no tumor remains), DO NOT consider the needle biopsy to be an excisional biopsy. The needle biopsy should be recorded as such in the *Surgical Diagnostic and Staging Procedure* [1350] data item and the excisional biopsy or more extensive surgery in the *RX Summ – Surg 2023* [1291].
9. Do not code palliative surgical procedures in this data item. Use the data item *Palliative Procedure* [3270] to code these procedures.

### Date of Diagnostic Procedure

NAACCR Item #	Length	Source of Standard	Manual
1280	8	SEER/CoC	Standards for Oncology Registry Entry (STORE) SEER Program Coding & Staging Manual

#### Description

Records the date on which the surgical diagnostic and/or staging procedure was performed.

**Justification**

This data item is used to track the use of surgical procedure resources that are not considered treatment.

**Coding Instructions**

1. Record the date on which surgical diagnostic and/or staging procedure described in Surgical Diagnostic and Staging Procedure [1350] was performed at this or any facility.
2. Blank is allowed.
3. Beginning in 2010, the way dates are transmitted has changed. In order that registry data can be interoperable with other data sources, dates are transmitted in a format widely accepted outside of the registry setting. However, this modification does not necessarily mean that the way dates are entered in any particular registry software product has changed. Software providers can provide the best information about data entry in their own systems. The traditional format for Date of Surgical Diagnostic and Staging Procedure is MMDDCCYY, with 99 identifying unknown month or day, and 99999999 representing an entirely unknown date. The interoperable form of Date of Surgical Diagnostic and Staging Procedure transmits in CCYYMMDD form, where blank spaces are used for unknown trailing portions of the date or where a date is not applicable.

**DX Procedures Text**

NAACCR Item #	Length	Source of Standard	NAACCR Data Dictionary
2560	4000	NPCR	NAACCR Data Dictionary

**Description**

Text area for manual documentation of all surgical procedures that provide information for staging.

**Justification**

Text documentation is an essential component of a complete electronic report and is heavily utilized for quality control and special studies. Text is needed to justify coded values and to document supplemental information not transmitted within coded values. High-quality text documentation facilitates consolidation of information from multiple reporting sources at the central registry.

The text field must contain a description that has been entered by the reporter independently from the code(s). If software generates text automatically from codes, the text cannot be utilized to check coded values. Information documenting the disease process should be entered manually from the medical record and should not be generated electronically from coded values.

**Coding Instructions**

1. Text documentation is **REQUIRED AND MUST BE PROVIDED BY ALL REPORTING FACILITIES**.
2. All surgical procedures from which diagnosis and/or staging information was obtained should be documented, regardless of where it was performed, should be documented in date order.
3. Enter text for all diagnostic procedures that provide descriptions of biopsies, surgical resections, number of lymph nodes removed, size of tumor removed, documentation of residual tumor, evidence of invasion of surrounding areas, and/or reason primary site surgery could not be completed.

4. If no surgery was performed or if it is unknown if the recommended or intended surgery was performed, this should be documented.

### Date 1<sup>st</sup> Course RX CoC

NAACCR Item #	Length	Source of Standard	Manual
1270	8	SEER/CoC	Standards for Oncology Registry Entry (STORE) SEER Program Coding & Staging Manual

#### Description

Date on which treatment (surgery, radiation, systemic, other therapy, active surveillance, or decision for no treatment) began at any hospital or non-hospital setting to include treatment centers, physician offices, ambulatory surgery centers, etc.

#### Justification

Used to measure the delay between diagnosis and the onset of treatment. A secondary use for this date is as a starting point for survival statistics (rather than using the diagnosis date). This date cannot be calculated from the respective first course treatment modality dates if no treatment was given. Therefore, providing the date on which active surveillance is chosen, a physician decides not to treat a patient, or a patient's family or guardian declines treatment is important.

#### Coding Instructions

1. Record the earliest of the following dates:
  - Date of First Surgical Procedure [1200]
  - Date Radiation started [1210]
  - Date Systemic therapy started [3230]
    - RX Date Chemotherapy [1220]
    - RX Date-Hormone Therapy [1230]
    - RX Date Immunotherapy [1240]
  - Date Other Treatment started [1250]
  - RX Summary—Scope of Reg Ln Surgery [1292]
  - RX Summ—Surg Other Reg/Dist [1294]
  - RX Summ—Transplant/Endocrine [3250]
2. Excisional biopsy: code as date therapy initiated when it is the first treatment
3. Active Surveillance or Watchful Waiting (*RX Summ--Treatment Status* [1285] = 2), record the date the decision was made.
4. No Treatment (*RX Summ--Treatment Status* [1285] = 0), in which a physician decides not to treat a patient or a patient's family, or guardian declines all treatment, the date of first course of treatment is the date this decision was made.
5. Leave data item blank if the cancer was diagnosed at autopsy and not suspected prior to that.
6. The Date 1st Crs Rx Flag [1271] is used to explain why Date of First Course of Treatment is not a known date. When an incisional biopsy is performed and further surgery reveals residual or only microscopic residual, code date of incisional biopsy as the excisional biopsy date.
7. Date Format:
  - MMDDYYYY when the complete date is known.

- MMYYYY when the year and month are known but the day is unknown.
  - YYYY when the year is known but the month and day are unknown.
  - Treatment dates for a fetus prior to birth are to be assigned the actual date of the event.
8. Unproven Therapy: code date initiated as date therapy initiated.
  9. Unknown Date: code the date of admission to the hospital for inpatient or outpatient. treatment when the exact date of the first treatment is unknown.
  10. Leave Blank:
    - When no treatment is given during the first course.
    - When treatment status is coded 2, Active Surveillance (watchful waiting).
    - When it is unknown whether the patient had treatment.
    - Death Certificate only cases when the date is unknown and cannot be estimated.
    - Autopsy only cases.

See Section 6: Cancer Information, [Estimating Dates](#) for instruction on estimating dates.

### RX Summary – Scope of Reg LN Surgery

NAACCR Item #	Length	Source of Standard	Manual
1292	2	SEER/CoC	Standards for Oncology Registry Entry (STORE) SEER Program Coding & Staging Manual

#### Description

Describes the removal, biopsy, or aspiration of **regional** lymph node(s) at the time of surgery of the primary site or during a separate surgical event at all facilities.

#### Justification

Can be used to compare and evaluate the extent of surgical treatment.

#### Coding Instructions

1. Use the **operative report** as the primary source document to determine whether the operative procedure was a sentinel lymph node biopsy (SLNBx), a more extensive dissection of regional lymph nodes, or a combination of both SLNBx and regional lymph node dissection. The operative report will designate the surgeon's planned procedure as well as a description of the procedure that was actually performed. The pathology report may be used to complement the information appearing in the operative report, but the **operative report takes precedence** when attempting to distinguish between SLNBx and regional lymph node dissection or a combination of these two procedures. Do not use the number of lymph nodes removed and pathologically examined as the sole means of distinguishing between a SLNBx and a regional lymph node dissection.
2. Code **regional** lymph node procedures in this data item. Record distant lymph node removal in Surgical Procedure of Other Site.
  - a. Include lymph nodes that are regional in the current AJCC Staging Manual 8<sup>th</sup> ed., 3<sup>rd</sup> printing.
3. Record all surgical procedures that remove, biopsy, or aspirate regional lymph node(s) even if there were no surgical procedures of the primary site performed. The regional lymph node



surgical procedure(s) may be done to **diagnose** cancer, **stage** the disease, or as a part of the initial **treatment**.

*Example:* Patient has a sentinel node biopsy of a single lymph node. Assign code 2 (Sentinel lymph node biopsy [only]).

4. Add the number of all lymph nodes removed during each surgical procedure performed as part of the first course of treatment. The Scope of Regional Lymph Nodes field is **cumulative**.
  - a. Do not add regional nodes that were aspirated, and that node is in the resection field. Do not add the aspirated node to the total number.
  - b. When a regional node is aspirated and it is NOT in the resection field, count as an additional node and add it to the total number.

Code	Description	Definition	General Instructions
0	None	No regional lymph node surgery. No lymph nodes found in the pathologic specimen. Diagnosed at autopsy.	
1	Biopsy or aspiration of regional lymph nodes, NOS	Biopsy or aspiration of regional lymph nodes(s) regardless of the extent of involvement.	Review the operative report to confirm the type of biopsy performed (excisional or aspiration). It should not include dye or tracer for SLNBx (code 2)
2	Sentinel lymph node biopsy only	Biopsy of the first few lymph node(s) into which a tumor drains.	The operative report states that a SLNBx was performed or describes using dye, tracer, or combination to identify a lymph node(s) for removal. <i>Note:</i> When a SLNBx is performed, additional non-SLNs can be taken during the same operative procedure. Code this a SLNBx (code 2). If the operative report confirms that a regional lymph node dissection followed the SLNBx, code these as 6.
3	Number of regional lymph nodes removed unknown, not stated; regional lymph nodes removed, NOS	Sampling or dissection of regional lymph node(s) and the number removed is not stated or is unknown. The operative report should not identify this as SLNBx.	Check the operative report to ensure this procedure is not a SLNBx only (code 2), or a SLNBx with a regional lymph node dissection (code 6 or 7)
4	1 to 3 regional lymph nodes removed	Sampling or dissection of lymph node(s) with between one and three lymph nodes in the specimen and is not a SLNBx.	Code 4 should be used infrequently. Review the operative report to ensure the procedure was not a SLNBx only.
5	4 or more regional lymph nodes removed	Sampling or dissection of lymph node(s) with four or more lymph nodes in the specimen and is not a SLNBx.	Code 5: If a relatively small number of nodes was examined pathologically, review the operative report to confirm the procedure was not a SLNBx only (code 2). If a relatively large number of nodes was examined pathologically, review the operative report to confirm that there was not a SLNBx in addition to a more extensive regional lymph node

			<p>dissection during the same, or separate, procedure (code 6 or 7).</p> <p>Infrequently, a SLNBx is attempted, and the patient fails to map (i.e., no sentinel lymph nodes are identified by the dye and/or radio label injection). When mapping fails, surgeons usually perform a more extensive dissection of regional lymph nodes. Code these cases as 2 if no further dissection of regional lymph nodes was undertaken, or 6 when regional lymph nodes were dissected during the same operative event.</p>
6	Sentinel node biopsy and code 3, 4, or 5 at same time or timing not noted	SLNBx performed in the same surgical procedure with either code 3, 4 or 5 or timing is not known.	<p>Generally, SLNBx followed by a regional lymph node completion will yield a relatively large number of nodes. However, it is possible for these procedures to harvest only a few nodes. If relatively few nodes are pathologically examined, review the operative report to confirm whether the procedure was limited to a SLNBx only.</p> <p>Infrequently, a SLNBx is attempted, and the patient <b>fails to map</b> (i.e., no sentinel lymph nodes are identified by the dye and/or radio label injection). When mapping fails, the surgeon usually performs a more extensive dissection of regional lymph nodes. <b>Code these cases as 6.</b></p>
7	Sentinel node biopsy and code 3, 4, or 5 at different times	SLNBx performed followed by Code 3, 4 or 5 performed at different times.	<p>Generally, SLNBx followed by regional lymph node completion will yield a relatively large number of nodes. However, it is possible for these procedures to harvest only a few nodes.</p> <p>If relatively few nodes are pathologically examined, review the operative report to confirm whether the procedure was limited to a SLNBx only.</p>
9	Unknown or not applicable	It is unknown whether regional lymph node surgery was performed Death Certificate Only Lymphomas with a lymph node primary Unknown or Ill-defined primary Hematopoietic, reticuloendothelial, immunoproliferative, or myeloproliferative disease.	<p>The status of regional lymph node surgery should be known for surgically treated cases (i.e., cases coded 19-90 in the data item Surgery of Primary Site [NAACCR Item #1290]). Review surgically treated cases coded as 9 in Scope of Regional Lymph Node Surgery to confirm the code.</p> <p>See additional instructions below.</p>

5. Assign code **9** for:
- Intracranial and central nervous system primaries (C70.0–C70.9, C71.0–C71.9, C72.0–C72.9, C75.1–C75.3).
  - Lymphomas (M-9590-9726, 9728-9732, 9734-9740, 9750-9762, 9811-9831, 9940, 9948 and 9971) with a lymph node primary site (C77.0–C77.9).
  - Unknown or ill-defined primary site (C76.0–C76.8, C80.9).
  - Hematopoietic, reticuloendothelial, immunoproliferative, or myeloproliferative disease (C42.0, C42.1, C42.3, C42.4 or M-9727, 9733, 9741-9742, 9764-9809, 9832, 9840-9931, 9945-9946, 9950-9967, and 9975-9992).

## Regional Nodes Positive

NAACCR Item #	Length	Source of Standard	Manual
820	2	SEER/CoC	Standards for Oncology Registry Entry (STORE) SEER Program Coding & Staging Manual

### Description

Records the exact number of regional nodes examined by the pathologist and found to contain metastases. Beginning with tumors diagnosed on or after January 1, 2004, this item is a component of the Collaborative Stage system (CS). This item was discontinued from CS in 2016 however, it continues to be required.

### Justification

This data item is necessary for pathologic staging, and it serves as a quality measure for pathology reports and the extent of the surgical evaluation and treatment of the patient.

### Coding Instructions

Codes	Description
00	All nodes examined are negative
01-89	1-89 nodes are positive (code exact number of nodes positive)
90	90 or more nodes are positive
95	Positive aspiration of lymph node(s) was performed
97	Positive nodes are documented, but the number is unspecified
98	No nodes were examined
99	It is unknown whether nodes are positive; not applicable; not stated in patient record

When definition of regional nodes differs between the AJCC Cancer Staging Manual and the SEER Program Coding and Staging Manual, use the AJCC definition.

- Code only **regional lymph nodes** in this data item. Include lymph nodes that are regional in the current AJCC staging manual. Do not code distant lymph node information in this data item.
- Based on **pathologic information only**. Record regardless of whether the patient received neoadjuvant (preoperative) treatment.
- True **in situ cases** cannot have positive lymph nodes, so the only allowable codes are 00 (negative) or 98 (not examined). Codes 01-97 and 99 are not allowed.

4. **Nodes positive is cumulative.** Record the total number of regional lymph nodes removed and found to be positive by pathologic examination.
  - a. The number of regional nodes positive is cumulative from all procedures that remove lymph nodes through the completion of surgeries in the first course of treatment.
  - b. Do **not** count a positive aspiration or core biopsy of a lymph node in the same lymph node chain removed at surgery as an additional node in Regional Nodes Positive when there are positive nodes in the resection. In other words, if there are positive regional lymph nodes in a lymph node dissection, do not count the core needle biopsy or the fine needle aspiration if it is in the same chain. See also Use of Code 95 below.
  - c. Include the node in the count of Regional Nodes Positive when the positive aspiration or core biopsy is from a node in a different node region.
  - d. A Lymph node that is core-biopsied or aspirated can be assumed to be part of the lymph node chain surgically removed. Do not include it in the count of Regional Nodes Positive.
  - e. **Priority of lymph node counts.** Use information in the following priority when there is a discrepancy regarding the number of positive lymph nodes use the information in the following priority order: final diagnosis, synoptic report (also known as the CAP protocol or pathology report checklist), microscopic, gross.
5. **Positive nodes in multiple primaries in same organ:**
  - a. Determine the histology of the metastases in the nodes and code the nodes as positive for the primary with that histology when there are multiple primary cancers with different histologic types in the same organ and the pathology report just states the number of nodes positive.
  - b. Code the nodes as positive for all primaries when no further information is available
6. **Isolated Tumor Cells (ITCs) in lymph nodes:**

All primary sites **except** cutaneous melanoma and Merkel cell carcinoma of skin

  - a. Count only lymph nodes that contain micrometastases or larger (metastases greater than 0.2 millimeters in size).
  - b. Assume the metastases are larger than 0.2 mm and count the lymph node(s) as positive when the path report indicates that nodes are positive, but the size of metastasis is not stated.
  - c. Do not include in the count of lymph nodes positive any nodes that are identified as containing ITCs.
  - d. Cutaneous melanoma and Merkel cell carcinoma: count nodes with ITCs as positive lymph nodes.
7. Use **code 95** when the only procedure for regional lymph nodes is a needle aspiration (cytology) or core biopsy (tissue). There are no surgically resected lymph nodes or surgically resected lymph nodes are negative.
8. Use **code 97** for any combination of positive aspirated, biopsied, sampled, or dissected lymph nodes when the number of involved nodes cannot be determined on the basis of cytology or histology. Code 97 includes positive lymph nodes diagnosed by either cytology or histology.
9. Use **code 98** when the assessment of lymph nodes is clinical only, no lymph nodes are removed and examined, a dissection of a lymph node drainage area is found to contain no lymph nodes at

the time of pathologic examination. When Regional Nodes Positive is coded 98, Regional Nodes Examined is usually coded 00.

10. Use **code 99** when it is unknown whether regional lymph nodes are positive or for:

- Placenta
- Brain and Cerebral Meninges
- Other Parts of Central Nervous System
- Intracranial Gland Hematopoietic, Reticuloendothelial, Immunoproliferative and Myeloproliferative Neoplasms
- Hodgkin and non-Hodgkin Lymphoma
- Myeloma and Plasma Cell Disorders
- Other and Ill-Defined Primary Sites
- Unknown Primary Site

### Regional Nodes Examined

NAACCR Item #	Length	Source of Standard	Manual
830	2	SEER/CoC	Standards for Oncology Registry Entry (STORE) SEER Program Coding & Staging Manual

#### Description

Records the total number of regional lymph nodes that were removed and examined by the pathologist. Beginning with tumors diagnosed on or after January 1, 2004, this item is a component of the Collaborative Stage system (CS). This item was discontinued from CS in 2016, however, it continues to be required.

#### Justification

This data item serves as a quality measure of the pathologic and surgical evaluation and treatment of the patient.

#### Coding Instructions

Codes	Description
00	No nodes were examined
01-89	1-89 nodes were examined (code the exact number of regional lymph nodes examined)
90	90 or more nodes were examined
95	No regional nodes were removed, but aspiration of regional nodes was performed
96	Regional lymph node removal was documented as a sampling, and the number of nodes is unknown/not stated
97	Regional lymph node removal was documented as a dissection, and the number of nodes is unknown/not stated
98	Regional lymph nodes were surgically removed, but the number of lymph nodes is unknown/not stated and not documented as a sampling or dissection; nodes were examined, but the number is unknown
99	It is unknown whether nodes were examined; not stated in patient record

When definition of regional nodes differs between the AJCC Cancer Staging Manual and the SEER Program Coding and Staging Manual, use the AJCC definition.

1. Code only **regional lymph nodes in this data item**. Include lymph nodes that are regional in the current AJCC staging manual. Do not code distant lymph node information in this data item.
2. Based on **pathologic information only**. Record regardless of whether the patient received neoadjuvant (preoperative) treatment.
3. Use **code 00** when the assessment of lymph nodes is clinical, no lymph nodes are removed or examined, or a dissection of a lymph node drainage area is found to contain no lymph nodes at the time of pathologic examination. When Regional Nodes Examined is coded 00, Regional Nodes Positive is coded 98.
4. **Nodes removed and examined is cumulative**. Record the total number of regional lymph nodes removed and examined by the pathologist.
  - a. The number of regional lymph nodes examined is cumulative from all procedures that removed lymph nodes through the completion of surgeries in the first course of treatment with the exception of aspiration or core biopsies coded to 95.
  - b. Do not count a positive aspiration or core biopsy of a lymph node in the same lymph node chain removed at surgery as an additional node in Regional Nodes Examined.
  - c. If the positive aspiration or core biopsy is from a node in a different node region, include the node in the count of Regional Nodes Examined.
  - d. If the location of the lymph node that is aspirated or core-biopsied is not known, assume it is part of the lymph node chain surgically removed, and do not include it in the count of Regional Nodes Examined.
  - e. When neither the type of lymph node removal procedure nor the number of lymph nodes examined is known, use code 98.
5. **Priority of lymph node counts**. If there is a discrepancy regarding the number of lymph nodes examined, use information in the following priority: final diagnosis, synoptic report (also known as CAP protocol or pathology report checklist), microscopic, gross.
6. Use **code 95** when the only procedure for regional lymph nodes is a needle aspiration (cytology) or core biopsy (tissue).
7. **Lymph node biopsy**. If a lymph node biopsy was performed, code the number of nodes removed, if known. If the number of nodes removed by biopsy is not known, use code 96.
8. **Code 96 Definition of "sampling."** A lymph node "sampling" is removal of a limited number of lymph nodes. Other terms for removal of a limited number of nodes include lymph node biopsy, berry picking, sentinel lymph node procedure, sentinel node biopsy, selective dissection. Use code 96 when a limited number of nodes are removed but the number is unknown.
9. **Code 97 Definition of "dissection."** A lymph node "dissection" is removal of most or all of the nodes in the lymph node chain(s) that drain the area around the primary tumor. Other terms include lymphadenectomy, radical node dissection, lymph node stripping. Use code 97 when more than a limited number of lymph nodes are removed, and the number is unknown.
10. **Multiple lymph node procedures**. If both a lymph node sampling and a lymph node dissection are performed and the total number of lymph nodes examined is unknown, use code 97.
11. Use **code 99** if it is unknown whether nodes were removed or examined or:

Placenta  
 Brain and Cerebral Meninges  
 Other Parts of Central Nervous System  
 Intracranial Gland Hematopoietic, Reticuloendothelial, Immunoproliferative and  
 Myeloproliferative Neoplasms  
 Hodgkin and non-Hodgkin Lymphoma  
 Myeloma and Plasma Cell Disorders  
 Other and Ill-Defined Primary Sites  
 Unknown Primary Site

### RX Date - Surgery

NAACCR Item #	Length	Source of Standard	Manual
1200	8	CoC	Standards for Oncology Registry Entry (STORE)

#### Description

Records the earliest date on which any first course surgical procedure was performed.

#### Justification

This item can be used to sequence multiple treatment modalities and to evaluate the time intervals between treatments.

#### Coding Instructions

- Record the date of the first surgical procedure of the types coded as *Surgical Procedure of Primary Site* [1290], *Scope of Regional Lymph Node Surgery* [1292] or *Surgical Procedure/Other Site* [1294] performed at this or any facility.
- If two or more cancer-directed surgeries are performed, enter the date for the first cancer-directed surgery.
- If the date is estimated, indicate so in the surgery text box by entering (est. date) after the date.  
*Example: 04/15/2020 (est. date) ABC Medical Center, Prostatectomy...*

#### Date Format:

- MMDDYYYY when the complete date is known.
- MMYYYY when the year and month are known but the day is unknown.
- YYYY when the year is known but the month and day are unknown.
- Treatment dates for a fetus prior to birth are to be assigned the actual date of the event.

### RX Summ--Surg Prim Site 03-2022

NAACCR Item #	Length	Source of Standard	Manual
1290	2	SEER/CoC	SEER Program Coding & Staging Manual Standards for Oncology Registry Entry (STORE)

#### Description

Describes a surgical procedure that removes and/or destroys tissue of the primary site and is performed as part of the initial diagnostic and staging work-up or first course of therapy. The most definitive surgical procedure performed at any facility should be coded in this data item. Applicable for cases diagnosed 2003-2022.

### **Justification**

Identifies the specific cancer-directed surgery of the primary site.

### **Coding Instructions**

Code	Label	Definition
00	None	No surgical procedure of primary site. Diagnosed at autopsy.
10-19	Site-specific codes; tumor destruction	Tumor destruction, no pathologic specimen produced.
20-80	Site-specific codes; resection	Surgery codes can be found in the <a href="#">STORE manual</a> Appendix A or the <a href="#">SEER Coding Manual</a> Appendix C
90	Surgery, NOS	A surgical procedure to the primary site was done, but no information on the type of surgical procedure is provided.
98	Site-specific codes; special	Special Code
99	Unknown	Patient record does not state whether a surgical procedure of the primary site was performed, and no information is available. Death certificate only.

Surgery codes can be found in the [STORE manual](#) Appendix A or the [SEER Coding Manual](#) Appendix C

- If registry software allows only one procedure to be collected, document the most invasive surgical procedure for the primary site.
- If registry software allows multiple procedures to be recorded, this item refers to the most invasive surgical procedure of the primary site.
- For codes 00 through 79, the codes are hierarchical. Codes listed last take precedence over preceding codes. Code 98 takes precedence over code 00. Use codes 80 and 90 only if more precise information about the surgery is not available.
- Excisional biopsies that remove the entire tumor and/or leave only microscopic margins are coded in this data item.
- If a needle biopsy is performed prior to an excisional biopsy or more extensive surgery, and the excisional biopsy or more extensive surgery reveals no residual cancer, the needle biopsy is NOT considered an excisional biopsy and should be coded in the data item *Surgical Diagnostic and Staging Procedure*.
- If regional tissue or organs are removed, only code in this data item if they are removed in continuity with the primary site, except where noted in STORE appendix B.
- If a portion of the primary site is surgically resected followed by an additional surgical resection to remove the remainder of the primary site, code the total final results. Do not rely on registry software to perform this task for you.
- If the procedure coded in this data item is also palliative (provided to prolong a patient's life by controlling symptoms, to alleviate pain, or to make the patient more comfortable) then **also** record this surgery in the *Palliative Care* data item.



## RX Summ--Surg Prim Site 2023

NAACCR Item #	Length	Source of Standard	Manual
1291	4	SEER/CoC	Standards for Oncology Registry Entry (STORE) SEER Program Coding & Staging Manual

### Description

Records the Surgery of Primary Site describes a surgical procedure that removes and/or destroys tissue of the primary site that is performed as part of the initial diagnostic and staging work-up or first course of therapy. Applicable for cases diagnosed 2023 and forward.

### Justification

This data item can be used to compare the efficacy of treatment options.

### Coding Instructions

1. Replaces Surgical Procedure of Primary Site [1290] for cases diagnosed 01/01/2023 and forward.
2. For diagnosis years 2003 – 2022, leave this data item blank and complete data item Surgical Procedure of Primary Site [NAACCR data item #1290]
3. See the 2023 STORE manual site-specific codes found in Appendix A.
4. For diagnosis year 2023 and forward, this data item must be completed.
5. If registry software allows only one procedure to be collected, document the most invasive surgical procedure for the primary site.
6. If registry software allows multiple procedures to be recorded, this item refers to the most invasive surgical procedure of the primary site.
7. Codes A000-A790 are hierarchical. Use codes A800 and A900 only if more precise information about the surgery is not available.
8. Code A980 for any case coded to primary site C420, C421, C423, C424, C760-C768,C809

Note: All 2023 site specific surgery codes begin with a letter A except for skin which start with a letter B to indicate a significant change in coding.

For melanoma skin surgical codes ONLY:

- The priority order for sources used to assign surgery codes:
  - Operative report, statement from a physician, description of the surgical procedure on a pathology report, results of the pathology report. Code based on the description of the procedure.
  - Do not code based on margin status documented in the pathology report.

## Rx Date - Most Definitive Surgical Resection of The Primary Site

NAACCR Item #	Length	Source of Standard	Manual
3170	8	CoC	Standards for Oncology Registry Entry (STORE)

### Description

Records the date of the most definitive surgical procedure of the primary site performed as part of the first course of treatment.

**Justification**

This item is used to measure the lag time between diagnosis and the most definitive surgery of the primary site. This may or may not be the date of **RX Date - Surgery**. The most definitive surgery is the most extensive resection of the primary site done during the first course of treatment.

**Coding Instructions**

Date of most definitive surgery should be entered even when no residual cancer is found in the surgical specimen.

**Reason for No Surgery of Primary Site**

NAACCR Item #	Length	Source of Standard	Manual
1340	2	SEER/CoC	SEER Program Coding & Staging Manual Standards for Oncology Registry Entry (STORE)

**Description**

Records the reason that no surgery was performed on the primary site.

**Justification**

This data item provides information related to the quality of care and describes why primary site surgery was not performed.

**Coding Instructions**

Code	Label
0	Surgery of the primary site was performed.
1	Surgery of the primary site was not performed because it was not part of the planned first course treatment. Diagnosed at autopsy.
2	Surgery of the primary site was not recommended/performed because it was contraindicated due to patient risk factors (comorbid conditions, advanced age, progression of tumor prior to planned surgery etc).
5	Surgery of the primary site was not performed because the patient died prior to planned or recommended surgery.
6	Surgery of the primary site was not performed; it was recommended by the patient's physician, but was not performed as part of the first course of therapy. No reason was noted in patient record.
7	Surgery of the primary site was not performed; it was recommended by the patient's physician, but this treatment was refused by the patient, the patient's family member, or the patient's guardian. The refusal was noted in patient record.
8	Surgery of the primary site was recommended, but it is unknown if it was performed. Further follow-up is recommended.
9	It is unknown whether surgery of the primary site was recommended or performed. Death certificate only.

- Assign **Code 0** when surgery of the primary site performed. Surgery codes 10-90.
- Assign **code 1-8** when surgery of the primary site is coded 00 or 98.
  - Assign **code 1** when:

- Surgery is not planned as first course treatment which is documented in a treatment plan in the medical record or a physician statement that it was not recommended.
- There is no information in the medical record about surgery and either:
  - It is known that surgery is not usually performed for this type and/or stage of cancer.
  - There is no reason to suspect that the patient would have had surgery of the primary site, e.g., the patient has advanced stage cancer.
- The treatment plan offered multiple treatment options including surgery and the patient selected treatment other than surgery of the primary site.
- The patient chose not to have any treatment. This includes refusal **before** any treatment recommendations are made.
- Watchful waiting or active surveillance is recommended by the physician.
- Assign **code 6** when it is *known* that surgery was recommended, *and* it is *known* that surgery was not performed *and* there is **no documentation** to explain why no surgery was performed.
- Assign **code 7** when the patient chooses not to have any treatment. This includes refusal **after** treatment recommendations are made and surgery is included in the recommended treatment.
  - Note:* A discussion with a physician that surgery *may* be an option is not a recommendation for surgery.  
A referral to a surgeon is *not* considered a recommendation for surgery.
- Assign **code 8** when surgery is known to be recommended but it is unknown if the patient had surgery.
- Assign code 9 when there is no documentation that surgery was recommended or performed. For death certificate only and autopsy only cases.

**RX Summ--Surg Other Regional/Distant**

NAACCR Item #	Length	Source of Standard	Manual
1294	2	SEER/CoC	SEER Program Coding & Staging Manual Standards for Oncology Registry Entry (STORE)

**Description**

Records the surgical removal of distant lymph nodes or other tissue(s) or organ(s) removed beyond the primary site performed at any facility as part of first course treatment.

**Justification**

Documents the extent of surgical treatment and is useful in evaluating the extent of metastatic involvement.

**Coding Instructions**

Code	Label	Definition
0	None	No surgical procedure of non-primary site was performed. Diagnosed at autopsy.
1	Non-primary surgical procedure performed	Non-primary surgical resection to other site(s), unknown if whether the site(s) is regional or distant.
3	Non-primary surgical procedure to other regional sites	Resection of regional site.
4	Non-primary surgical procedure to distant lymph node(s)	Resection of distant site.
5	Combination of codes	Any combination of surgical procedures 2, 3, or 4.
9	Unknown	It is unknown whether any surgical procedure of a non-primary site was performed. Death certificate only.

- Assign the highest numbered code that describes the surgical resection of distant lymph nodes or other tissue or organs beyond the primary site surgical code and received as first course treatment at any facility.
- Incidental removal of tissue or organs that are not involved with cancer is not coded in this data item.
- Surgical Procedure/Other Site is collected for each surgical event even if surgery of the primary site was not performed.
- Assign Code 1 if any surgery is performed to treat tumors of unknown or ill-defined primary sites (C76.0–76.8, C80.9) or for hematopoietic, reticuloendothelial, immunoproliferative, or myeloproliferative disease (C42.0, C42.1, C42.3, C42.4 or M-9727, 9733, 9741-9742, 9764-9809, 9832, 9840-9931, 9945-9946, 9950-9967, and 9975-9992). When the involved contralateral breast is removed for a single primary breast cancer.
- If the procedure coded in this item was palliative (provided to prolong a patient's life by controlling symptoms, to alleviate pain, or to make the patient more comfortable) then also record this surgery in the item Palliative Care.

**Text Surgery**

NAACCR Item #	Length	Source of Standard	NAACCR Data Dictionary
2610	1000	NPCR	<a href="#">NAACCR Data Dictionary</a>

**Description**

Text area for information describing all surgical procedures performed as part of treatment.

**Justification**

Text documentation is an essential component of a complete cancer abstract. It is heavily utilized for quality control, special studies and consolidation of information reported from multiple sources.

**Coding Instructions**

1. Text documentation is **REQUIRED AND MUST BE PROVIDED BY ALL REPORTING FACILITIES.**

2. All first course surgery, regardless of where it was performed, should be documented in date order.
3. If no surgery was performed or if it is unknown if the recommended or intended surgery was performed, this should be documented.

### Date Radiation Started

NAACCR Item #	Length	Source of Standard	Manual
1210	8	CoC	Standards for Oncology Registry Entry (STORE)

#### Description

Date on which first course radiation therapy for the diagnosis was started at any facility.

#### Justification

Identifies the Initial start date of first course radiation therapy.

#### Coding Instructions

1. Enter the date radiation therapy began.
2. Date format is DDMMYYYY when the full date is known, MMYYYY when only the month and year are known and YYYY when only the year is known.
3. If radiation therapy was performed but the date is not known, enter the year of diagnosis as the start date and leave the month and day blank. *Do not leave the date blank.*
4. If no radiation therapy was given or it is unknown if radiation therapy was given, leave the date blank.

### Radiation Treatment Modality Phase I

NAACCR Item #	Length	Source of Standard	Manual
1506	2	CoC	Standards for Oncology Registry Entry (STORE)

#### Description

Identifies the radiation modality administered during the first phase of radiation treatment delivered during the first course of treatment.

#### Justification

Radiation modality reflects whether a treatment was external beam, brachytherapy, a radioisotope as well as their major subtypes, or a combination of modalities. This data item should be used to indicate the radiation modality administered during the first phase of radiation.

#### Coding Instructions

1. Radiation treatment modality will typically be found in the radiation oncologist's summary letter for first course of treatment. The OCCR only requires Radiation Treatment Modality Phase I. We do not require phase II and phase III to be reported.
2. For purposes of this data item, photons, x-rays, and gamma-rays are equivalent.

3. Use code 13 - Radioisotopes, NOS for radioembolization procedures, e.g., intravascular Yttrium-90.
  - a. Do not confuse a radioiodine scan with treatment. Only treatment is recorded in this item.
4. This data item replaces RX--Regional RX Modality.

Code	Description
00	No radiation treatment
01	External beam, NOS
02	External beam, Photons
03	External beam, Protons
04	External beam, electrons
05	External beam, neutrons
06	External beam, carbon ions
07	Brachytherapy, NOS
08	Brachytherapy, intracavitary, LDR
09	Brachytherapy, intracavitary, HDR
10	Brachytherapy, interstitial, LDR
11	Brachytherapy, interstitial, HDR
12	Brachytherapy, electronic
13	Radioisotopes, NOS
14	Radioisotopes, radium-223
15	Radioisotopes, strontium-89
16	Radioisotopes, strontium-90
98	Radiation therapy administered but treatment modality is not specified or unknown
99	Unknown if radiation treatment administered

### Text Radiation (Beam & Other)

NAACCR Item #	Length	Source of Standard	NAACCR Data Dictionary
2620 & 2630	1000	NPCR	<a href="#">NAACCR Data Dictionary</a>

#### **Description**

Text area for manual documentation of information regarding treatment of the tumor being reported with beam radiation.

#### **Justification**

Text documentation is an essential component of a complete cancer abstract. It is heavily utilized for quality control, special studies and consolidation of information reported from multiple sources.

#### **Coding Instructions**

1. Text documentation is **REQUIRED AND MUST BE PROVIDED BY ALL REPORTING FACILITIES**.
2. All first course radiation, regardless of where it was performed, should be documented in date order.
3. If no radiation was performed or if it is unknown if the recommended or intended radiation was performed, this should be documented.

## RX Summary - Surgery/Radiation Sequence

NAACCR Item #	Length	Source of Standard	Manual
1380	1	SEER/CoC	SEER Program Coding & Staging Manual Standards for Oncology Registry Entry (STORE)

### Description

Records the order in which radiation and surgical procedures were given as part of first course treatment.

### Justification

The sequence of radiation and surgical procedures given as part of the first course of treatment cannot always be determined using the date on which each modality was started or performed. This data item can be used to more precisely evaluate the timing of delivery of treatment to the patient.

### Coding Instructions

- Surgery includes surgery of the primary site, scope of regional lymph node surgery or surgical procedure of other site.
- Assign **code 0** when:
  - Either surgery or radiation was not performed
  - Surgery was performed but not radiation
  - Radiation was performed but not surgery
  - It is unknown if the patient has surgery and/or radiation
    - Death certificate only cases
  - Both radiation and surgery were performed, use codes 2-9
- If multiple first course treatment episodes were given such that both codes 4 and 7 seem to apply, use the code that defines the first sequence that applies.

Code	Label	Definition
0	No radiation therapy and/or surgical procedures	No radiation therapy given or unknown if radiation therapy given; and/or no surgery of the primary site; no scope of regional lymph node surgery; no surgery to other regional site(s), distant site(s), or distant lymph node(s) or it is unknown whether any surgery given.
2	Radiation therapy before surgery	Radiation therapy given before surgery to primary site; scope of regional lymph node surgery, surgery to other regional site(s), distant site(s), or distant lymph node(s).
3	Radiation therapy after surgery	Radiation therapy given after surgery to primary site; scope of regional lymph node surgery, surgery to other regional site(s), distant site(s), or distant lymph node(s).
4	Radiation therapy both before and after surgery	At least two courses of radiation therapy are given before and at least two more after surgery to the primary site; scope of regional lymph node surgery, surgery to other regional site(s), distant site(s), or distant lymph node(s).
5	Intraoperative radiation therapy	Intraoperative therapy given during surgery to primary site; scope of regional lymph node surgery, surgery to other regional site(s), distant site(s), or distant lymph node(s).

6	Intraoperative radiation therapy with other therapy administered before or after surgery	Intraoperative radiation therapy given during surgery to primary site; scope of regional lymph node surgery, surgery to other regional site(s), distant site(s), or distant lymph node(s) with other radiation therapy administered before or after surgery to primary site; scope of regional lymph node surgery, surgery to other regional site(s), distant site(s), or distant lymph node(s).
7	Surgery both before and after radiation	Radiation was administered between two separate surgical procedures to the primary site; regional lymph nodes; surgery to other regional site(s), distant site(s), or distant lymph node(s).
9	Sequence unknown	Administration of radiation therapy and surgery to primary site, scope of regional lymph node surgery, surgery to other regional site(s), distant site(s), or distant lymph node(s) were performed and the sequence of the treatment is not stated in the patient record.

### Reason for No Radiation

NAACCR Item #	Length	Source of Standard	Manual
1430	1	CoC	Standards for Oncology Registry Entry (STORE)

#### Description

Records the reason that no regional radiation therapy was administered to the patient.

#### Justification

When evaluating the quality of care, it is useful to know the reason that various methods of therapy were not used, and whether the failure to provide a given type of therapy was due to the physician’s failure to recommend that treatment, or due to the refusal of the patient, a family member, or the patient’s guardian.

#### Coding Instructions

1. If Regional Treatment Modality Phase I is coded 00, then use the documentation in the record to code the reason no radiation was administered.
2. Assign **code 1** if the treatment plan offered multiple alternative treatment options and the patient chose treatment that did not include radiation therapy.
3. Assign **code 7** if radiation therapy was recommended and the patient refused the treatment specifically, or refused all recommended treatment, or refused all treatment before any was recommended.
4. Assign **code 8** if it is known that a physician recommended radiation therapy but there is no further documentation to confirm that it was administered.
5. Assign **code 9** if multiple treatment options were included in the treatment plan and it is unknown which treatment, if any, was administered.

Code	Label
0	Radiation therapy was administered.
1	Radiation therapy was not administered because it was not part of the planned first course treatment. Diagnosed at autopsy.
2	Radiation therapy was not recommended/administered because it was contraindicated due to other patient risk factors (comorbid conditions, advanced age, progression of tumor prior to planned radiation etc.).



5	Radiation therapy was not administered because the patient died prior to planned or recommended therapy.
6	Radiation therapy was not administered; it was recommended by the patient's physician but was not administered as part of first course treatment. No reason was noted in patient record.
7	Radiation therapy was not administered; it was recommended by the patient's physician, but this treatment was refused by the patient, the patient's family member, or the patient's guardian. The refusal was noted in patient record.
8	Radiation therapy was recommended, but it is unknown whether it was administered.
9	It is unknown if radiation therapy was recommended or administered. Death certificate cases only.

## Date Chemotherapy Started

NAACCR Item #	Length	Source of Standard	Manual
1220	8	CoC	Standards for Oncology Registry Entry (STORE)

### Description

Date of initiation of chemotherapy that is part of the first course of treatment.

### Justification

Collecting dates for each treatment modality allows the sequencing of multiple treatments and aids in the evaluation of time intervals from diagnosis to treatment and from treatment to recurrence.

### Coding Instructions

1. Record the first or earliest date on which chemotherapy was administered at any facility. This date corresponds to the administration of the agents coded in *Chemotherapy*.
2. This data item is required by OCCR for all reporting years.
3. Date format is DDMMYYYY when the full date is known, MMYYYY when only the month and year are known and YYYY when only the year is known.
4. When chemotherapy is not given, or it is unknown if chemotherapy was given, assign code 9

## RX Summ--Chemo

NAACCR Item #	Length	Source of Standard	Manual
1390	2	SEER/CoC	SEER Program Coding & Staging Manual Standards for Oncology Registry Entry (STORE)

### Description

Documents the type of chemotherapy of the first course of treatment at any facility. If chemotherapy is not administered, then this item records the reason it was not administered.

### Justification

Allows for the evaluation of the administration of chemotherapeutic agents as part of the first course of therapy. When evaluating the quality of care, it is useful to know the reason chemotherapy was not administered.

### Coding Instructions

**NOTE: The following drugs changed categories effective with cases diagnosed 01/01/2013 and forward.**

Drug Name/Brand Name	Pre-2013 Category	New Category effective 01/01/2013
Alemtuzumab/Campath	Chemotherapy	BRM/Immunotherapy
Bevacizumab/Avastin	Chemotherapy	BRM/Immunotherapy
Rituximab/Rituxin	Chemotherapy	BRM/Immunotherapy
Trastuzumab/Herceptin	Chemotherapy	BRM/Immunotherapy
Pertuzumab/Perjeta	Chemotherapy	BRM/Immunotherapy
Cetuximab/Erbitux	Chemotherapy	BRM/Immunotherapy

[SEER\\*RX](#) should be used for assistance in coding systemic therapy correctly.

- Assign code 00 when:
  - Chemotherapy was not administered, not recommended, or not indicated for the type of cancer.
  - If there is no information in the medical record regarding chemotherapy and it is typically not administered for this type of cancer or stage.
  - If the treatment offered multiple alternative treatment options and the patient chose treatment that did not include chemotherapy, or the treatment plan was no treatment.
  - Diagnosis is at autopsy.
- Assign codes 82, 85, 86 or 87 when it is known that chemotherapy is usually administered for the type of cancer but was not administered to the patient.
  - Assign code 87 when the patient refuses recommended chemotherapy or refused all treatment before or after treatment recommendations were made.
- Assign code 88 if chemotherapy was recommended but it is unknown if it was administered.
- Assign code 99 when it is unknown if chemotherapy is typically administered for the type and stage of cancer and there is no mention in the medical record if it was recommended or administered. Death certificate only case.
- *Chemoembolization* should be coded to 01, 02 or 03 depending on the number of chemotherapeutic agents involved.
- *Change in chemotherapeutic agent(s)*: If the managing physician changes one of the agents in a combination regimen, and the replacement agent belongs to a different group (chemotherapeutic agents are grouped as alkylating agents, antimetabolites, natural products, or other miscellaneous) than the original agent, the new regimen represents the start of subsequent therapy, and *only the original agent or regimen is recorded as first course therapy*. Refer to SEER\*RX for assistance.
- *Radiosensitizer or radioprotectant*: DO NOT code as chemotherapy treatment. When chemotherapy is given for radiosensitization or radioprotection it is given in low doses that do not affect the cancer. Do not assume that chemotherapy given concurrently with radiation therapy is a radiosensitizer. Look for additional information to clarify the use as comparing the dose given to the dose typically given for treatment.
- *Palliative Care*: If chemotherapy was administered as palliative (provided to prolong a patient's life by controlling symptoms, to alleviate pain, or to make the patient more comfortable) then also record in the item Palliative Care.

Code	Label
00	None, chemotherapy was not part of the planned first course of therapy. Diagnosed at autopsy.
01	Chemotherapy administered as first course therapy, but the type and number of agents is not documented in patient record.
02	Single-agent chemotherapy administered as first course therapy.
03	Multiagent chemotherapy administered as first course therapy.
82	Chemotherapy was not recommended/administered because it was contraindicated due to patient risk factors (i.e., comorbid conditions, advanced age progression of tumor prior to administration, etc.).
85	Chemotherapy was not administered because the patient died prior to planned or recommended therapy.
86	Chemotherapy was not administered. It was recommended by the patient's physician but was not administered as part of the first course of therapy. No reason was stated in patient record.
87	Chemotherapy was not administered. It was recommended by the patient's physician, but this treatment was refused by the patient, a patient's family member, or the patient's guardian. The refusal was noted in patient record.
88	Chemotherapy was recommended, but it is unknown if it was administered.
99	It is unknown whether a chemotherapeutic agent(s) was recommended or administered because it is not stated in patient record. Death certificate only.

## Text Chemo

NAACCR Item #	Length	Source of Standard	Manual
2640	1000	NPCR	NAACCR Data Dictionary Version 23

### Description

Text area for manual documentation of information regarding treatment of the tumor being reported with chemotherapy.

### Justification

Text documentation is an essential component of a complete cancer abstract. It is heavily utilized for quality control, special studies and consolidation of information reported from multiple sources.

### Coding Instructions

1. Text documentation is **REQUIRED AND MUST BE PROVIDED BY ALL REPORTING FACILITIES.**
2. All first course chemotherapy, regardless of where it was administered, should be documented in date order.
3. If no chemotherapy was administered, or if it is unknown if the recommended or intended chemotherapy was administered, this should be documented.

## Date Hormone Therapy Started

NAACCR Item #	Length	Source of Standard	Manual
1230	8	CoC	Standards for Oncology Registry Entry (STORE)

### Description

Date of initiation for hormone therapy that is part of the first course of treatment.

**Justification**

The dates on which different treatment modalities were started are used to evaluate whether the treatments were part of first-course therapy and to reconstruct the sequence of first-course treatment modes.

**Coding Instructions**

1. Record the first or earliest date on which hormone therapy was administered at any facility. This date corresponds to the administration of the agents coded in *Hormone Therapy*.
2. This data item is required by OCCR for all reporting years.
3. Date format is DDMMYYYY when the full date is known, MMYYYY when only the month and year are known and YYYY when only the year is known.
4. When *Hormone Therapy* is not given, or it is unknown if *Hormone Therapy* was given, assign code 9.

**RX Summ – Hormone Therapy**

NAACCR Item #	Length	Source of Standard	
1400	2	NAACCR	SEER Program Coding & Staging Manual Standards for Oncology Registry Entry (STORE)

**Description**

Records whether systemic hormonal agents were administered as first course treatment at any facility, or the reason they were not given. Hormone therapy consists of a group of drugs that may affect the long-term control of a cancer's growth. It is not usually used as a curative measure.

**Justification**

Systemic therapy may involve the administration of one or a combination of agents. This data item allows for the evaluation of the administration of hormonal agents as part of the first course of therapy.

**Coding Instructions**

Code	Label
00	None, hormone therapy was not part of the planned first course of therapy.
01	Hormone therapy administered as first course therapy.
82	Hormone therapy was not recommended/administered because it was contraindicated due to patient risk factors (i.e., comorbid conditions, advanced age).
85	Hormone therapy was not administered because the patient died prior to planned or recommended therapy.
86	Hormone therapy was not administered. It was recommended by the patient's physician but was not administered as part of first course therapy. No reason was stated in the patient record.
87	Hormone therapy was not administered. It was recommended by the patient's physician, but this treatment was refused by the patient, the patient's family member, or the patient's guardian. The refusal was noted in the patient record.
88	Hormone therapy was recommended, but it is unknown if it was administered.
89	It is unknown whether a hormonal agent(s) was recommended or administered because it is not stated in the patient record. Death certificate-only cases.

- When prednisone is given in combination with chemotherapy as part of regimen as first course treatment at any facility, record as hormone therapy.
- If prednisone is administered to treat symptoms or as a single agent, do not code as hormone therapy.
- Assign code 00 when:
  - Hormone therapy was not administered to the patient, and it is known that it is not usually administered for this type and stage of cancer.
  - Diagnosed at autopsy.
  - The treatment plan offered multiple treatment options and the patient selected treatment that did not include hormone therapy or if the option of “no treatment” was accepted by the patient.
- Assign code 01 for thyroid replacement therapy which inhibits TSH ((thyroid-stimulating hormone). TSH is a product of the pituitary gland that can stimulate tumor growth.
- Assign code 82, 85, 86 or 87 to record the reason why no hormone therapy was administered when it is known that hormone therapy is usually administered for this type and stage of cancer but was not administered to the patient.
  - Assign code 87 when the patient refuses recommended hormone or refused all treatment before or after treatment recommendations were made.
- Assign code 88 if hormone therapy was recommended but it is unknown if it was administered.
- Assign code 99 when it is unknown if hormone therapy is typically administered for the type and stage of cancer and there is no mention in the medical record if it was recommended or administered. Death certificate only case.
- *Palliative Care*: If hormone therapy was administered as palliative (provided to prolong a patient’s life by controlling symptoms, to alleviate pain, or to make the patient more comfortable) then also record in the item Palliative Care.

Note: Decadron is coded as hormonal treatment for lymphoid leukemias, lymphomas and multiple myelomas only.

## Text Hormone

NAACCR Item #	Length	Source of Standard	Manual
2650	1000	NPCR	NAACCR Data Dictionary Version 23

### Description

Text area for manual documentation of information regarding treatment of the tumor being reported with hormone therapy.

### Justification

Text documentation is an essential component of a complete cancer abstract. It is heavily utilized for quality control, special studies and consolidation of information reported from multiple sources.

### Coding Instructions

1. Text documentation is **REQUIRED AND MUST BE PROVIDED BY ALL REPORTING FACILITIES.**

2. All first course hormone therapy, regardless of where it was administered, should be documented in date order.
3. If no hormone therapy was administered or if it is unknown if the recommended or intended hormone therapy was administered, this should be documented.

### Date BRM (Immunotherapy) Started

NAACCR Item #	Length	Source of Standard	Manual
1240	8	CoC	Standards for Oncology Registry Entry (STORE)

#### Description

Records the date of initiation of immunotherapy or a biologic response modifier (BRM) that is part of the first course of treatment at any facility.

#### Justification

The dates on which different treatment modalities were started are used to evaluate whether the treatments were part of first course therapy and to reconstruct the sequence of first course treatment modes.

#### Coding Instructions

1. Record the first or earliest date on which immunotherapy or a biologic response modifier was administered by any facility. This date corresponds to the administration of the agents coded in Immunotherapy.
2. This data item is required by OCCR for all reporting years.
3. Date format is DDMMYYYY when the full date is known, MMYYYY when only the month and year are known and YYYY when only the year is known.
4. When immunotherapy is not given, or it is unknown if immunotherapy was given, assign code 9.

### RX Summ – BRM (Immunotherapy)

NAACCR Item #	Length	Source of Standard	Manual
1410	2	SEER/CoC	SEER Program Coding & Staging Manual Standards for Oncology Registry Entry (STORE)

#### Description

Records immunotherapeutic (biological therapy, biotherapy, or biological response modifier) agents administered as first course of therapy. Immunotherapy uses the body's immune system, either directly or indirectly, to fight cancer or to reduce the side effects that may be caused by some cancer treatments. Record only those treatments that are administered to affect the cancer cells.

#### Justification

Systemic therapy may involve the administration of one or a combination of agents. This data item allows for the evaluation of the administration of immunotherapeutic agents as part of the first course

of therapy. In addition, when evaluating the quality of care, it is useful to know the reason if immunotherapy was not administered.

### Coding Instructions

**NOTE: The following drugs changed categories effective with cases diagnosed 01/01/2013 and forward.**

Drug Name/Brand Name	Pre-2013 Category	New Category effective 01/01/2013
Alemtuzumab/Campath	Chemotherapy	BRM/Immunotherapy
Bevacizumab/Avastin	Chemotherapy	BRM/Immunotherapy
Rituximab/Rituxin	Chemotherapy	BRM/Immunotherapy
Trastuzumab/Herceptin	Chemotherapy	BRM/Immunotherapy
Pertuzumab/Perjeta	Chemotherapy	BRM/Immunotherapy
Cetuximab/Erbix	Chemotherapy	BRM/Immunotherapy

[SEER\\*RX](#) should be used for assistance in coding systemic therapy correctly.

- Assign code 00 when:
  - Immunotherapy was not administered, not recommended, or not indicated for the type of cancer.
  - If there is no information in the medical record regarding immunotherapy and it is typically not administered for this type of cancer or stage.
  - If the treatment offered multiple alternative treatment options and the patient chose treatment that did not include immunotherapy, or the treatment plan was no treatment.
  - Diagnosis is at autopsy.
- Assign codes 82, 85, 86 or 87 when it is known that immunotherapy is usually administered for the type of cancer but was not administered to the patient.
  - Assign code 87 when the patient refuses recommended immunotherapy or refused all treatment before or after treatment recommendations were made.
- Assign code 88 if immunotherapy was recommended but it is unknown if it was administered.
- Assign code 99 when it is unknown if immunotherapy is typically administered for the type and stage of cancer and there is no mention in the medical record if it was recommended or administered. Death certificate only case.
- *Palliative Care*: If immunotherapy was administered as palliative (provided to prolong a patient's life by controlling symptoms, to alleviate pain, or to make the patient more comfortable) then also record in the item Palliative Care.

### Text – BRM (Immunotherapy)

NAACCR Item #	Length	Source of Standard	Manual
2650	1000	NPCR	NAACCR Data Dictionary Version 23

#### Description

Text area for manual documentation of information regarding treatment of the tumor being reported with immunotherapy.

#### Justification

Text documentation is an essential component of a complete cancer abstract. It is heavily utilized for quality control, special studies and consolidation of information reported from multiple sources.

### **Coding Instructions**

1. Text documentation is **REQUIRED AND MUST BE PROVIDED BY ALL REPORTING FACILITIES.**
2. All first course immunotherapy, regardless of where it was administered, should be documented in date order.

If no immunotherapy was administered, or if it is unknown if the recommended or intended immunotherapy was administered, this should be documented.

## **RX Summ – Hematologic Transplant/Endocrine Procedure**

NAACCR Item #	Length	Source of Standard	Manual
3250	2	CoC	Standards for Oncology Registry Entry (STORE)

### **Description**

Identifies systemic therapeutic procedures administered as part of the first course of treatment at this and all other facilities. If none of these procedures were administered, then this item records the reason they were not performed. These include bone marrow transplants, stem cell harvests, surgical and/or radiation endocrine therapy.

### **Justification**

Allows the evaluation of patterns of treatment, which involve the alteration of the immune system or change the patient's response to tumor cells, but do not involve the administration of antineoplastic agents. In addition, when evaluating the quality of care, it is useful to know the reason if these procedures were not performed.

### **Coding Instructions**

Code	Label
00	No transplant procedure or endocrine therapy was administered as part of first course therapy. Diagnosed at autopsy.
10	A bone marrow transplant procedure was administered, but the type was not specified.
11	Bone marrow transplant–autologous.
12	Bone marrow transplant–allogeneic.
20	Stem cell harvest and infusion. Umbilical cord stem cell transplant, with blood from one or multiple umbilical cords.
30	Endocrine surgery and/or endocrine radiation therapy.
40	Combination of endocrine surgery and/or radiation with a transplant procedure (Combination of codes 30 and 10, 11, 12, or 20).
82	Hematologic transplant and/or endocrine surgery/radiation was not recommended/administered because it was contraindicated due to patient risk factors (i.e., comorbid conditions, advanced age, progression of disease prior to administration, etc.).
85	Hematologic transplant and/or endocrine surgery/radiation was not administered because the patient died prior to planned or recommended therapy.
86	Hematologic transplant and/or endocrine surgery/radiation was not administered. It was recommended by the patient's physician but was not administered as part of the first course of therapy. No reason was stated in patient record.



87	Hematologic transplant and/or endocrine surgery/radiation was not administered. It was recommended by the patient's physician, but this treatment was refused by the patient, a patient's family member, or the patient's guardian. The refusal was noted in patient record.
88	Hematologic transplant and/or endocrine surgery/radiation was recommended, but it is unknown if it was administered.
99	It is unknown whether hematologic transplant and/or endocrine surgery/radiation was recommended or administered because it is not stated in patient record. Death certificate only.

- **Bone Marrow Transplants:** Code as either autologous (bone marrow originally taken from the patient) or allogenic (bone marrow donated by a person other than the patient). For cases in which the bone marrow transplant was syngeneic (transplanted marrow from an identical twin), the item is coded as allogeneic.
- **Stem Cell Harvest:** involves the collection of immature blood cells from the patient and the reintroduction by transfusion of the harvested cells following chemotherapy or radiation therapy.
- **Endocrine irradiation and/or endocrine surgery:** procedures which suppress the naturally occurring hormonal activity of the patient and thus alter or affect the long-term control of the cancer's growth. These procedures must be bilateral to qualify as endocrine surgery or endocrine radiation. If only one gland is intact at the start of treatment, surgery and/or radiation to that remaining gland qualifies as endocrine surgery or endocrine radiation.
- Assign code 00 when:
  - A transplant or endocrine procedure was not administered, not recommended, or not indicated for the type of cancer.
  - If there is no information in the medical record regarding a transplant or endocrine procedure and it is typically not administered for this type of cancer or stage.
  - If the treatment offered multiple alternative treatment options and the patient chose treatment that did not include a transplant or endocrine procedure, or the treatment plan was no treatment.
  - Diagnosis is at autopsy.
- Assign codes 82, 85, 86 or 87 when it is known that a transplant or endocrine procedure is usually administered for the type of cancer but was not administered to the patient.
  - Assign code 87 when the patient refuses recommended transplant or endocrine procedure or refused all treatment before or after treatment recommendations were made.
- Assign code 88 if a transplant or endocrine procedure was recommended but it is unknown if it was administered.
- Assign code 99 when it is unknown if a transplant or endocrine procedure is typically administered for the type and stage of cancer and there is no mention in the medical record if it was recommended or administered. Death certificate only case.
- **Palliative Care:** If a transplant or endocrine procedure was administered as palliative (provided to prolong a patient's life by controlling symptoms, to alleviate pain, or to make the patient more comfortable) then also record in the item Palliative Care.

## RX Summary Systemic/Surgery Sequence

NAACCR Item #	Length	Source of Standard	Manual
1639	1	CoC	Standards for Oncology Registry Entry (STORE)

### Description

Records the order in which systemic therapy and surgical procedures were given as part of first course treatment.

### Justification

The sequence of systemic therapy and surgical procedures given as part of the first course of treatment cannot always be determined using the date on which each modality was started or performed. This data item can be used to more precisely evaluate the timing of delivery of treatment to the patient.

### Coding Instructions

3. Surgery includes surgery of the primary site, scope of regional lymph node surgery or surgical procedure of other site.
4. Assign **code 0** when:
  - Either surgery or systemic therapy was not performed.
  - Surgery was performed but not systemic therapy.
  - Systemic therapy was performed but not surgery.
  - It is unknown if the patient has surgery and/or systemic therapy.
    - Death certificate only cases
  - Both systemic therapy and surgery were performed, use codes 2-9
5. If multiple first course treatment episodes were given such that both codes 4 and 7 seem to apply, use the code that defines the first sequence that applies.

Code	Label	Definition
0	No systemic therapy and/or surgical procedures	No systemic therapy given or unknown if systemic therapy given; and/or no surgery of the primary site; no scope of regional lymph node surgery; no surgery to other regional site(s), distant site(s), or distant lymph node(s) or it is unknown whether any surgery given.
2	Systemic therapy before surgery	Systemic therapy given before surgery to primary site; scope of regional lymph node surgery, surgery to other regional site(s), distant site(s), or distant lymph node(s).
3	Systemic therapy after surgery	Systemic therapy given after surgery to primary site; scope of regional lymph node surgery, surgery to other regional site(s), distant site(s), or distant lymph node(s).
4	Systemic therapy both before and after surgery	At least two courses of systemic therapy are given before and at least two more after surgery to the primary site; scope of regional lymph node surgery, surgery to other regional site(s), distant site(s), or distant lymph node(s) was performed. This includes cancer treated with neoadjuvant systemic therapy (not bridge therapy) followed by surgery followed by hormone therapy.
5	Intraoperative systemic therapy	Intraoperative therapy given during surgery to primary site; scope of regional lymph node surgery, surgery to other regional site(s), distant site(s), or distant lymph node(s).

6	Intraoperative systemic therapy with other therapy administered before or after surgery	Intraoperative systemic therapy given during surgery to primary site; scope of regional lymph node surgery, surgery to other regional site(s), distant site(s), or distant lymph node(s) with other systemic therapy administered before or after surgery to primary site; scope of regional lymph node surgery, surgery to other regional site(s), distant site(s), or distant lymph node(s).
7	Surgery both before and after systemic therapy	Systemic therapy was administered between two separate surgical procedures to the primary site; regional lymph nodes; surgery to other regional site(s), distant site(s), or distant lymph node(s).
9	Sequence unknown	Administration of systemic therapy and surgery to primary site, scope of regional lymph node surgery, surgery to other regional site(s), distant site(s), or distant lymph node(s) were performed and the sequence of the treatment is not stated in the patient record.

## Date Other Treatment Started

NAACCR Item #	Length	Source of Standard	Manual
1250	8	CoC	Standards for Oncology Registry Entry (STORE)

### Description

Records the date of initiation of other treatment that is part of the first course of treatment at any facility. Other treatment is no treatment already included in surgery, radiation therapy, and systemic treatment.

### Justification

The dates on which different treatment modalities were started are used to evaluate whether the treatments were part of first course therapy and to reconstruct the sequence of first course treatment modes.

### Coding Instructions

1. Record the first or earliest date on which other treatment was administered by any facility.
2. This data item is required by OCCR for all reporting years.
3. Date format is DDMMYYYY when the full date is known, MMYYYY when only the month and year are known and YYYY when only the year is known.
4. When other treatment is not given or it is unknown if other treatment was given, assign code 9.

## Other Treatment

NAACCR Item #	Length	Source of Standard	Manual
1420	1	SEER/CoC	SEER Program Coding & Staging Manual Standards for Oncology Registry Entry (STORE)

### Description

Identifies other treatment that cannot be defined as surgery, radiation, or systemic therapy according to the defined data items in this manual. Treatment for reportable hematopoietic diseases can be supportive care, observation, or any treatment that does not meet the usual definition in which

treatment modifies, controls, removes, or destroys proliferating cancer tissue. Such treatments include phlebotomy, transfusions, and aspirin.

### **Justification**

Information on other therapy is used to describe and evaluate the quality-of-care and treatment practices.

### **Coding Instructions**

- Primary treatment for certain reportable hematopoietic diseases could be supportive care that does not meet the usual definition of treatment that modifies, controls, removes, or destroys proliferating cancer tissue.
- Supportive care may include phlebotomy, transfusion, or aspirin. In order to report the hematopoietic cases in which the patient received supportive care, SEER and the Commission on Cancer have agreed to record treatments such as phlebotomy, transfusion, or aspirin as “Other Treatment” (Code 1) for certain hematopoietic diseases ONLY. Consult the most recent version of the Hematopoietic and Lymphoid Neoplasm Case Reportability and Coding Manual for instructions for coding care of specific hematopoietic neoplasms in this item.

Code	Label	Definition
0	None	All cancer treatment was coded in other treatment fields (surgery, radiation, systemic therapy). Patient received no cancer treatment. Diagnosed at autopsy.
1	Other	Cancer treatment that cannot be appropriately assigned to specified treatment data items (surgery, radiation, systemic therapy).
2	Other-Experimental	This code is not defined. It may be used to record participation in institution-based clinical trials.
3	Other-Double Blind	A patient is involved in a double-blind clinical trial. Code the treatment actually administered when the double-blind trial code is broken.
6	Other-Unproven	Cancer treatments administered by nonmedical personnel.
7	Refusal	Other treatment was not administered. It was recommended by the patient’s physician, but this treatment (which would have been coded 1, 2, or 3) was refused by the patient, a patient’s family member, or the patient’s guardian. The refusal was noted in the patient record.
8	Recommended; unknown if administered	Other treatment was recommended, but it is unknown whether it was administered.
9	Unknown	It is unknown whether other treatment was recommended or administered, and there is no information in the medical record to confirm the recommendation or administration of other treatment. Death certificate only.

- Assign code 1 for:
  - Embolization using alcohol as an embolizing agent.
  - Embolization to a site other than the liver where the embolizing agent is unknown
  - PUVA (psoralen and long-wave ultraviolet radiation).
- Do not code embolization given prior to surgery to shrink the tumor.
- *Palliative Care*: If other treatment was administered as palliative (provided to prolong a patient’s life by controlling symptoms, to alleviate pain, or to make the patient more comfortable) then also record in the item Palliative Care.

- Assign code 8 if it is known that a physician recommended *Other Treatment* but is unknown if it was administered.
- Assign code 0 when diagnosed at autopsy.
- Code 9 for Death Certificate Only cases.

## Text Other Treatment

NAACCR Item #	Length	Source of Standard	Manual
2670	1000	NPCR	NAACCR Data Dictionary Version 23

### Description

Text area for manual documentation of information regarding treatment of the tumor being reported with treatment that cannot be defined as surgery, radiation, or systemic therapy. This includes experimental treatments (when the mechanism of action for a drug is unknown), and blinded clinical trials. If the mechanism of action for the experimental drug is known, code to the appropriate treatment field.

### Justification

Text documentation is an essential component of a complete cancer abstract. It is heavily utilized for quality control, special studies and consolidation of information reported from multiple sources.

### Coding Instructions

1. Text documentation is **REQUIRED AND MUST BE PROVIDED BY ALL REPORTING FACILITIES.**
2. All first course other treatment, regardless of where it was administered, should be documented in date order.

If no treatment defined as other treatment was administered or if it is unknown if the recommended or intended other treatment was administered, this should be documented.

## RX Summ – Treatment Status

NAACCR Item #	Length	Source of Standard	Manual
1285	1	SEER/CoC	SEER Program Coding & Staging Manual Standards for Oncology Registry Entry (STORE)

### Description

This data item summarizes whether the patient received any treatment, or the tumor was under active surveillance.

### Justification

This item documents active surveillance (watchful waiting) and eliminates searching each treatment modality to determine whether treatment was given.

### Coding Instructions

- This item may be left blank for cases diagnosed prior to 2010.
- Treatment given after a period of active surveillance is considered subsequent treatment, and it is not coded in this item.

- Use code 0 when treatment is refused, or the physician decides not to treat for any reason, such as the presence of comorbidities.
- Assign code 0 when the patient does not receive any treatment.
- Scope of Regional Lymph Node Surgery may be coded 0, 1-7, or 9.
- Assign code 1 when the patient receives treatment collected in any of the following data items.
  - a. Surgery of Primary Site
  - b. Surgical Procedure of Other Site
  - c. Radiation Treatment Modality, Phase I, II, III
  - d. Chemotherapy
  - e. Hormone Therapy
  - f. Immunotherapy
  - g. Hematologic Transplant and Endocrine Procedures
  - h. Other Therapy

Code	Label
0	No treatment given
1	Treatment given
2	Active Surveillance (watchful waiting)
9	Unknown if treatment was given

### Date Case Completed

NAACCR Item #	Length	Source of Standard	Manual
2090	8	NAACCR	NAACCR Data Dictionary Version 23

#### **Description**

The date that: (1) the abstractor decided that the tumor report was complete, and (2) the case passed all edits that were applied.

### Abstracted By

NAACCR Item #	Length	Source of Standard	Manual
570	3	CoC	Standards for Oncology Registry Entry (STORE)

#### **Description**

Records the initials of the individual abstracting the case.

#### **Justification**

This item can be used for quality control and management in multi-staffed registries.

#### **Coding Instructions**

Code all three initials of the abstractor.

# **SECTION 10**

# **ABSTRACTING FOLLOW- UP DATA**

## Date of Last Contact or Date of Death

NAACCR Item #	Length	Source of Standard	Manual
1750	8	SEER/CoC	SEER Program Coding & Staging Manual Standards for Oncology Registry Entry (STORE)

### Description

Records the date of last contact with the patient or the date of death.

### Justification

This information is used for patient follow-up and outcomes studies.

### Coding Instructions

Record the last date on which the patient was known to be alive or the date of death.

- This can include the day the patient was last seen at your facility, date of last contact, or date of death.
- Punctuation marks (slashes, dashes, etc.) are not allowed in any date field.
- If patient is known to be deceased, but date of death is not available, date of last contact should be recorded in this field. In the **Remarks** text area, document that the patient is deceased, and the date of death is unavailable.
- If the patient has more than one primary tumor, code each primary with the last date of contact or the date of death of the patient.

## Vital Status

NAACCR Item #	Length	Source of Standard	Manual
1760	8	SEER/CoC	SEER Program Coding & Staging Manual Standards for Oncology Registry Entry (STORE)

### Description

This data element records whether the patient is still living or has expired.

### Justification

This information is related to the *Date of Last Contact or of Death* and will not pass edits without being completed. It is used to evaluate the registry follow-up index and outcome statistics.

### Coding Instructions

- Code the patient's vital status as of the date recorded in the *Date of Last Contact or Death* field. Use the most current and accurate information available.
- If the patient has multiple primaries **simultaneously**, all records should have the same vital status.

Code	Label
0	Dead
1	Alive



## Place of Death – State

NAACCR Item #	Length	Source of Standard	Manual
1942	2	NAACCR	NAACCR Data Dictionary Version 23

### Description

State or Province where the patient died and where certificate of death is filed.

### Justification

This field helps carry out death clearance. When a reporting facility reports a place of death, the information can help in death certificate matching.

### Coding Instructions

- Leave blank if the patient is alive.
- See the SEER Program and Coding Manual Appendix B for proper Country and State Codes.

Code	Label
Blank	Patient is alive
ZZ	Unknown state
State Codes	<a href="https://seer.cancer.gov/tools/codingmanuals/index.html">https://seer.cancer.gov/tools/codingmanuals/index.html</a> Appendix B

## Place of Death – Country

NAACCR Item #	Length	Source of Standard	Manual
1944	3	NAACCR	NAACCR Data Dictionary

### Description

Country in which the patient died and where certificate of death is filed.

### Justification

This field also helps carry out death clearance. When a reporting facility reports a place of death, the information can help in death certificate matching.

### Coding Instructions

- Leave blank if the patient is alive.
- See the SEER Program and Coding Manual Appendix B for proper Country and State Codes.

Code	Label
Blank	Patient is alive
ZZU	Unknown state
State Codes	<a href="https://seer.cancer.gov/tools/codingmanuals/index.html">https://seer.cancer.gov/tools/codingmanuals/index.html</a> Appendix B

## Follow-Up Source

NAACCR Item #	Length	Source of Standard	Manual
1790	3	CoC	Standards for Oncology Registry Entry (STORE)

### Description

Records the source from which the latest follow-up/vital status information was obtained.

### Justification

This data item is used by registries to identify the most recent follow-up source.

### Coding Instructions

Code	Label	Definition
0	Reported Hospitalization	Hospitalization at another institution/hospital or first admission to the reporting facility.
1	Readmission	Hospitalization or outpatient visit at the reporting facility.
2	Physician	Information from a physician.
3	Patient	Direct contact with the patient.
4	Department of Motor Vehicles	The Department of Motor Vehicles confirmed the patient has a current license.
5	Medicare/Medicaid file	The Medicare or Medicaid office confirmed the patient is alive.
7	Death Certificate	Information from the death certificate only.
8	Other	Friends, relatives, employers, other registries, or any sources not covered by other codes.
9	Unknown; not stated in patient record	The follow-up source is unknown or not stated in patient record.

# **SECTION 11**

# **DATA REVIEW GUIDELINES**

### Data Review Guidelines

These simple reviews will help to eliminate common reporting errors:

- Is the **primary site** clearly supported in the text and is it consistent with the code used for primary site?
- Is the **histology code, behavior code and grade codes** correct according to the description in the pathology report?
- If this is a **paired organ**, is the laterality code supported in the text?
- Is **summary stage** clearly documented in stage text in the abstract (tumor size, extension, lymph nodes, distant metastasis)?
- Are **treatment dates, agents and/or procedure codes** supported by text?
- Do dates make sense when compared to the **date of first contact** and **date of diagnosis**?

**BOTTOM LINE:** does the abstract data make sense and **does the text documentation support the coding and dates in the abstract?**

# **APPENDIX A – Reporting Laws and HIPAA**

## FEDERAL LEGISLATION

106 STAT. 3373 Public Law 102-515 - 102d Congress October 24, 1992

<https://www.congress.gov/bill/102nd-congress/senate-bill/3312/text/cps>

## OKLAHOMA LEGISLATION

Oklahoma Statute (OS) Title 63. Public Health and Safety Public Health Code 551.1

§63-1-551.1. Establishment and Maintenance of Tumor Registry.

<https://www.oscn.net/applications/oscn/DeliverDocument.asp?CiteID=98115>

Oklahoma Statute (OS) Title 63. Public Health and Safety Public Health Code 1701.1A and 1701.2

§63-1-1701.1A Violation of rules, regulations, or standards - Orders - Penalties.

§63-1-1701.2 Administrative Warrants.

<https://www.oscn.net/applications/oscn/DeliverDocument.asp?CiteID=98535>

<https://www.oscn.net/applications/oscn/DeliverDocument.asp?CiteID=98537>

Oklahoma Administrative Code

Title 310, Ch 567 State Central Cancer Registry

<https://rules.ok.gov/code?q=>

## HEALTH INSURANCE PORTABILITY AND ACCOUNTABILITY ACT (HIPAA)

<https://www.hhs.gov/hipaa/index.html>

HIPAA resources for Cancer Registrars

<https://www.naaccr.org/hippa/>

[FAQs about HIPAA and Reporting for Hospital Based Cancer Registry](#)

[FAQs about HIPAA and Cancer Registry Revised \(revised 05/19\)](#)

# **APPENDIX B – Instructions for Lymphatic & Hematopoietic Diseases**

## APPENDIX B – Instructions for Lymphatic & Hematopoietic Diseases

Coding leukemia, lymphoma and myeloid malignancies is a complex process. This appendix provides data collection resources for coding these primaries. There are two tools for use with these rules:

1. [Hematopoietic & Lymphoid Neoplasm Database \(Heme DB\)](#)
  - a. A tool to assist in screening for reportable cases and determining reportability requirements.
  - b. The database contains abstracting and coding information for all hematopoietic and lymphoid neoplasm (9590/3-9992/3).
2. [Hematopoietic & Lymphoid Neoplasm Coding Manual](#) (PDF, 1.0 MB)
  - a. Reportability instructions and rules for determining the number of primaries, the primary site and histology, and the cell lineage or phenotype.
  - b. The introduction to the manual has an updated Steps in Priority Order for using the Hematopoietic and Lymphoid Neoplasm Coding Manual & Database.

### General Instructions

The Heme DB and Manual enable registrars to identify and understand hematopoietic and lymphoid neoplasms as well as to correctly and consistently abstract and code cases. Briefly, the steps for using these resources are as follows:

1. Identify the working (preliminary) histology code(s).
2. Use the Multiple Primary Rules to determine the number of primaries using the working histology code(s).
3. Verify or revise the working histology code(s) using the Primary Site and Histology (PH) Rules.
4. Determine primary site using the Primary Site and Histology Rules in this manual (see Note on next page).

There are many sub-topics that need to be reviewed for the above steps. Abstractors **must** review the coding rules, guidelines, and instructions in the opening chapters of the Hematopoietic & Lymphoid Neoplasm Coding Manual prior to abstracting these disease processes.

### Education

[SEER\\*Educate](#) provides training on how to use the Heme Manual and DB. Step-by-step instructions are provided for each case scenario to learn how to use the application and manual to arrive at the answer provided.



**Citation**

Ruhl J, Adamo M, Dickie L., Negoita, S. (September 2020). *Hematopoietic and Lymphoid Neoplasm Coding Manual*. National Cancer Institute, Bethesda, MD, 2020.

The rules, guidelines, and the Hematopoietic Database follow the *World Health Organization (WHO) Classification of Tumours of Haematopoietic and Lymphoid Tissues*. Revised 4th ed. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, eds. WHO Classification of Tumours, Volume 2. IARC Press; 2016.

# **APPENDIX C – SEER Country and State Codes**

**SEER Country and State Codes***For Coding Place of Birth and Place of Death*<https://seer.cancer.gov/tools/codingmanuals/index.html> Appendix B**ALPHABETICAL LISTING**

Name of Country/State	ISO Country Code	USPS State Code
Afghanistan	AFG	XX
Africa, NOS <sup>1</sup>	ZZF	YY
Alabama	USA	AL
Aland Islands	ALA	XX
Alaska	USA	AK
Albania	ALB	XX
Alberta	CAN	AB
Algeria	DZA	XX
American Samoa	ASM	AS
Andorra	AND	XX
Angola	AGO	XX
Anguilla	AIA	XX
Antarctica	ATA	XX
Antigua and Barbuda	ATG	XX
Argentina	ARG	XX
Arizona	USA	AZ
Arkansas	USA	AR
Armed Forces Americas (except Canada)	USA	AA
Armed Forces Europe, the Middle East, and Canada	USA	AE
Armed Forces Pacific	USA	AP
Armenia	ARM	XX
Aruba	ABW	XX
Asia, NOS <sup>1</sup>	ZZA	YY
Australia	AUS	XX
Austria	AUT	XX
Azerbaijan	AZE	XX
Bahamas (the)	BHS	XX
Bahrain	BHR	XX
Bangladesh	BGD	XX
Barbados	BRB	XX
Belarus	BLR	XX
Belgium	BEL	XX
Belize	BLZ	XX

Name of Country/State	ISO Country Code	USPS State Code
Benin	BEN	XX
Bermuda	BMU	XX
Bhutan	BTN	XX
Bolivia (Plurinational State of)	BOL	XX
Bonaire, Saint Eustatius and Saba	BES	XX
Bosnia and Herzegovina	BIH	XX
Botswana	BWA	XX
Bouvet Island	BVT	XX
Brazil	BRA	XX
British Columbia	CAN	BC
British India	IOT	XX
Brunei Darussalam	BRN	XX
Bulgaria	BGR	XX
Burkina Faso	BFA	XX
Burundi	BDI	XX
California	USA	CA
Cabo Verde (formerly Cape Verde)	CPV	XX
Cambodia	KHM	XX
Cameroon	CMR	XX
Canada	CAN	CD
Cayman Islands (the)	CYM	XX
Central African Republic (the)	CAF	XX
Central America, NOS <sup>1</sup>	ZZC	YY
Chad	TCD	XX
Chile	CHL	XX
China	CHN	XX
Christmas Island	CXR	XX
Cocos (Keeling) Islands (the)	CCK	XX
Colombia	COL	XX
Colorado	USA	CO
Comoros (the)	COM	XX
Congo (the)	COG	XX
Congo (the Democratic Republic of)	COD	XX
Connecticut	USA	CT
Cook Islands (the)	COK	XX
Costa Rica	CRI	XX
Cote d'Ivoire (formerly Ivory Coast)	CIV	XX
Croatia	HRV	XX

Name of Country/State	ISO Country Code	USPS State Code
Cuba	CUB	XX
Curacao	CUW	XX
Cyprus	CYP	XX
Czechia (formerly Czech Republic)	CZE	XX
Czechoslovakia <sup>1</sup>	CSK	YY
Delaware	USA	DE
Denmark	DNK	XX
District of Columbia	USA	DC
Djibouti	DJI	XX
Dominica	DMA	XX
Dominican Republic (the)	DOM	XX
Ecuador	ECU	XX
Egypt	EGY	XX
El Salvador	SLV	XX
England	ENG	XX
Equatorial Guinea	GNQ	XX
Eritrea	ERI	XX
Estonia	EST	XX
Eswatini (formerly Swaziland)	SWZ	XX
Ethiopia	ETH	XX
Europe, NOS <sup>1</sup>	ZZE	YY
Falkland Islands (the)	FLK	XX
Faroe Islands (the)	FRO	XX
Fiji	FJI	XX
Finland	FIN	XX
Florida	USA	FL
France	FRA	XX
French Guiana	GUF	XX
French Polynesia	PYF	XX
French Southern Territories (the)		
Gabon	GAB	XX
Gambia (the)	GMB	XX
Georgia	USA	GA
Georgia	GEO	XX
Germany	DEU	XX
Ghana	GHA	XX
Gibraltar	GIB	XX
Greece	GRC	XX

Name of Country/State	ISO Country Code	USPS State Code
Greenland	GRL	XX
Grenada	GRD	XX
Guadeloupe	GLP	XX
Guam	GUM	GU
Guatemala	GTM	XX
Guernsey	GGY	XX
Guinea	GIN	XX
Guinea-Bissau	GNB	XX
Guyana	GUY	XX
Haiti	HTI	XX
Hawaii	USA	HI
Heard Island and McDonald Islands		
Holy See (the)		
Honduras	HND	XX
Hong Kong	HKG	XX
Hungary	HUN	XX
Iceland	ISL	XX
Idaho	USA	ID
Illinois	USA	IL
India	IND	XX
Indiana	USA	IN
Indonesia	IDN	XX
Iowa	USA	IA
Iran (Islamic Republic of)		
Iraq	IRQ	XX
Ireland	IRL	XX
Isle of Man	IMN	XX
Israel	ISR	XX
Italy	ITA	XX
Jamaica	JAM	XX
Japan	JPN	XX
Jersey	JEY	XX
Jordan	JOR	XX
Kansas	USA	KS
Kazakhstan	KAZ	XX
Kentucky	USA	KY
Kenya	KEN	XX
Kiribati	KIR	XX

Name of Country/State	ISO Country Code	USPS State Code
Korea (the Democratic People's Republic of) (used for North Korea)		
Korea (the Republic of) (used for South Korea)		
Kuwait	KWT	XX
Kyrgyzstan	KGZ	XX
Lao People's Democratic Republic (the)		
Latvia	LVA	XX
Lebanon	LBN	XX
Lesotho	LSO	XX
Liberia	LBR	XX
Libya	LBY	XX
Liechtenstein	LIE	XX
Lithuania	LTU	XX
Louisiana	USA	LA
Luxembourg	LUX	XX
Macao	MAC	XX
Madagascar	MDG	XX
Maine	USA	ME
Malawi	MWI	XX
Malaysia	MYS	XX
Maldives	MDV	XX
Mali	MLI	XX
Malta	MLT	XX
Manitoba	CAN	MB
Marshall Islands (the)	MHL	MH
Martinique	MTQ	XX
Maryland	USA	MD
Massachusetts	USA	MA
Mauritania	MRT	XX
Mauritius	MUS	XX
Mayotte	MYT	XX
Mexico	MEX	XX
Michigan	USA	MI
Micronesia (Federal States of)		
Minnesota	USA	MN
Mississippi	USA	MS
Missouri	USA	MO
Moldova (the Republic of)		
Monaco	MCO	XX

Name of Country/State	ISO Country Code	USPS State Code
Mongolia	MNG	XX
Montana	USA	MT
Montenegro	MNE	XX
Montserrat	MSR	XX
Morocco	MAR	XX
Mozambique	MOZ	XX
Myanmar (formerly Burma)	MMR	XX
Namibia	NAM	XX
Nauru	NRU	XX
Nebraska	USA	NE
Nepal	NPL	XX
Netherlands (the)	NLD	XX
Nevada	USA	NV
New Brunswick	CAN	NB
New Caledonia	NCL	XX
New Hampshire	USA	NH
New Jersey	USA	NJ
New Mexico	USA	NM
New York	USA	NY
New Zealand	NZL	XX
Newfoundland and Labrador	CAN	NL
Nicaragua	NIC	XX
Niger (the)	NER	XX
Nigeria	NGA	XX
Niue	NIU	XX
Non-US/Canada NOS <sup>1</sup>	ZZX	YY
Norfolk Island	NFK	XX
North America, NOS <sup>1</sup>	ZZN	YY
North Carolina	USA	NC
North Dakota	USA	ND
North Korea	PRK	XX
North Macedonia	MKD	XX
Northern Ireland	NIR	XX
Northern Mariana	MNP	MP
Northwest Territories	CAN	NT
Norway	NOR	XX
Nova Scotia	CAN	NS
Nunavut	CAN	NU



Name of Country/State	ISO Country Code	USPS State Code
Ohio	USA	OH
Oklahoma	USA	OK
Oman	OMN	XX
Ontario	CAN	ON
Oregon	USA	OR
Pacific, NOS <sup>1</sup>	ZZP	YY
Pakistan	PAK	XX
Palau	PLW	PW
Palestine (State of)	PSE	XX
Panama	PAN	XX
Papua New Guinea	PNG	XX
Paraguay	PRY	XX
Pennsylvania	USA	PA
Peru	PER	XX
Philippines (the)	PHL	XX
Pitcairn	PCN	XX
Poland	POL	XX
Portugal	PRT	XX
Prince Edward Island	CAN	PE
Puerto Rico	PRI	PR
Qatar	QAT	XX
Quebec	CAN	QC
Réunion	REU	XX
Rhode Island	USA	RI
Romania	ROU	XX
Russian Federation (the)	RUS	XX
Rwanda	RWA	XX
Saint Barthelemy	BLM	XX
Saint Helena, Ascension and Tristanda Cunha		
Saint Kitts and Nevis	KNA	XX
Saint Lucia	LCA	X
Saint Martin (French part)	MAF	XX
Saint Pierre and Miquelon	SPM	XX
Saint Vincent the Grenadines	VCT	XX
Samoa	WSM	XX
San Marino	SMR	XX
Sao Tome	STP	XX
Saskatchewan	CAN	SK

Name of Country/State	ISO Country Code	USPS State Code
Saudi Arabia	SAU	XX
Scotland	SCT	XX
Senegal	SEN	XX
Serbia	SRB	XX
Seychelles	SYC	XX
Sierra Leone	SLE	XX
Singapore	SGP	XX
Sint-Maarten (Dutch part)	SXM	XX
Slovakia	SVK	XX
Slovenia	SVN	XX
Solomon Islands	SLB	XX
Somalia	SOM	XX
South Africa	ZAF	XX
South America, NOS <sup>1</sup>	ZZS	YY
South Carolina	USA	SC
South Dakota	USA	SD
South Georgia and the South Sandwich Islands	SGS	XX
South Korea (see Korea (the Republic of))	KOR	XX
South Sudan	SSD	XX
Spain	ESP	XX
Sri Lanka	LKA	XX
Sudan (the)	SDN	XX
Suriname	SUR	XX
Svalbard and Jan Mayen	SJM	XX
Sweden	SWE	XX
Switzerland	CHE	XX
Syrian Arab Republic (the)	SYR	XX
Taiwan (Province of China)	TWN	XX
Tajikistan	TJK	XX
Tanzania, the United Republic of	TZA	XX
Tennessee	USA	TN
Texas	USA	TX
Thailand	THA	XX
Timor-Leste	TLS	XX
Togo	TGO	XX
Tokelau	TKL	XX
Tonga	TON	XX
Trinidad, and Tobago	TTO	XX

Name of Country/State	ISO Country Code	USPS State Code
Tunisia	TUN	XX
Turkey	TUR	XX
Turkmenistan	TKM	XX
Turks and Caicos Islands (the)	TCA	XX
Tuvalu	TUV	XX
Uganda	UGA	XX
Ukraine	UKR	XX
United Arab Emirates (the)	ARE	XX
United Kingdom of Great Britain and Northern Ireland (the)	GBR	XX
United States Minor Outlying Islands (the)	UMI	XX
United States of America (the)	USA	US
Unknown1	ZZU	ZZ
Uruguay	URY	XX
Utah	USA	UT
Uzbekistan	UZB	XX
Vanuatu	VUT	XX
Venezuela (Bolivarian Republic of)	VEN	XX
Vermont	USA	VT
Viet Nam	VNM	XX
Virgin Islands (British)	VGB	XX
Virgin Islands (U.S.)	VIR	VI
Virginia	USA	VA
Wales	WLS	XX
Wallis and Futuna	WLF	XX
Washington	USA	WA
West Virginia	USA	WV
Western Sahara	ESH	XX
Wisconsin	USA	WI
Wyoming	USA	WY
Yemen	YEM	XX
Yugoslavia1	YUG	YY
Yukon Territory	CAN	YT
Zambia	ZMB	XX
Zimbabwe	ZWE	XX

# **APPENDIX D – Common Abbreviations**

[NAACCR Abbreviations and Acronyms](#)

Abbreviation/Symbol	Word/Term(S)
^	Above or elevated
&	And
≈	Approximately
@	At
=	Equals
>	Greater than, more, or more than
<	Less or less than
-	Negative or minus
#	Number or pound(s)
+	Plus or positive
X	Times
<b>A</b>	
A FIB	Atrial fibrillation
A/P	Abdomen/Pelvis
AA	African American
ABD	Abdomen (abdominal)
ABG	Arterial blood gases
ABN	Abnormal
ABNL	Abnormal
ABS	Absent/Absence
ABST	Abstract/Abstracted
ABX	Antibiotics
ACH	Adrenal cortical hormone
ACID PHOS	Acid phosphatase
A-COLON	Ascending Colon
ACTH	Adrenocorticotrophic hormone
ADENOCA	Adenocarcinoma

Abbreviation/Symbol	Word/Term(S)
ADENOP	Adenopathy
ADH	Antidiuretic hormone
ADJ	Adjacent
ADL	Activities of daily living
ADM	Admission/Admit
ADR	Adverse drug reaction
AFP	Alpha-fetoprotein
AG	Antigen
AGL	Acute granulocytic leukemia
AI	Aromatase inhibitor
AIDS	Acquired Immune Deficiency Syndrome
AIHA	Autoimmune hemolytic anemia
AIN III or AIN 3	Anal intraepithelial neoplasia, grade III
AK(A)	Above knee (amputation)
AKA	Also known as
ALB	Albumin
ALK PHOS	Alkaline phosphatase
ALL	Acute lymphocytic leukemia
ALND	Axillary Lymph node dissection
AM	Before noon
AMA	Against medical advice
AMB	Ambulatory
AMI	Acute myocardial infarction
AML	Acute myelogenous leukemia
AMP	Amputation
AMT	Amount
ANAP	Anaplastic
ANGIO	Angiography/Angiogram

Abbreviation/Symbol	Word/Term(S)
ANS	Autonomic nervous system
ANT	Anterior
AP	Abdominal perineal
A-P	Anteroposterior
APP	Appendix
APPL'Y	Apparently
ARDS	Acute Respiratory Distress (Disease) Syndrome
ARF	Acute renal failure
ART	Artery (ial)
ASA	Aspirin, Acetylsalicylic acid
ASAP	As soon as possible
ASP	Aspiration
ASSOC	Associated
ATP	Adenosine triphosphate
AUT	Autopsy
AVG	Average
AVM	Arteriovenous malformation
AX	Axilla(ry)
AXLND	Axillary Lymph node dissection
<b>B</b>	
B/F	Black female
B/L	Bilateral
B/M	Black male
BCC	Basal cell carcinoma
BCG	Bacillus Calmette-Guerin
BD	Bile duct
BF	Black female
BID	Twice a day (daily)

Abbreviation/Symbol	Word/Term(S)
BIL	Bilateral
BK(A)	Below knee (amputation)
B/L	Bilateral
BM	Black Male
BM	Bone marrow
BM	Bowel movement
BMBX	Bone marrow biopsy
BMI	Body mass index
BMT	Bone marrow transplant
BOT	Base of tongue
BP	Blood pressure
BPH	Benign prostatic hypertrophy/hyperplasia
BR	Bloom-Richardson
BRACHY	Brachytherapy
BRBPR	Bright red blood per rectum
BRCA 1 and BRCA 2	Breast cancer susceptibility gene
BRM	Biological response modifier
BRO	Brother
BSA	Body surface area
BSC	Bone scan
BSO	Bilateral salpingo-oophorectomy
BT	Bladder tumor or Brain tumor
BUN	Blood urea nitrogen
BX	Biopsy
<b>C</b>	
C/A/P	Chest, abdomen, pelvis
C/O	Complaint (-ning) of
C/W	Consistent with



Abbreviation/Symbol	Word/Term(S)
C1-C7	Cervical vertebrae
CA	Carcinoma
CA 125	Cancer antigen 125
CA 19-9	Carbohydrate antigen 19-9
CABG	Coronary artery bypass graft
CAD	Coronary artery disease
CALC(S)	Calcification(s)
CBC	Complete blood count
CC	Chief complaint or Cubic centimeter
CCU	Coronary care unit
CEA	Carcinoembryonic antigen
CF	Cystic fibrosis
CFN	Centimeters from nipple
CGA	Serum chromogranin A
CGL	Chronic granulocytic leukemia
CGY	Centigray
CHD	Congenital heart disease
CHEMO	Chemotherapy
CHF	Congestive heart failure
CHG	Change
CHR	Chronic
CIG	Cigarettes
CIN	Cervical intraepithelial neoplasia
CIN III or CIN 3	Cervical intraepithelial neoplasia, grade III
CIS	Carcinoma <i>in situ</i>
CISH	Chromogenic in situ hybridization
CLL	Chronic lymphocytic leukemia
CLR	Clear

Abbreviation/Symbol	Word/Term(S)
CM	Centimeter
CML	Chronic myeloid (myelocytic) leukemia
CNS	Central nervous system
CO60	Cobalt 60
COLD	Chronic obstructive lung disease
CONT	Continue/continuous
CONTRA	Contralateral
COPD	Chronic obstructive pulmonary disease
CRF	Chronic renal failure
CRM	Circumferential resection margin
CS	Collaborative stage
CSF	Cerebrospinal fluid
C-SPINE	Cervical spine
CT	CAT/CT scan/Computerized axial tomography
CTC	Circulating tumor cells
CUC	Chronic ulcerative colitis
CVA	Cerebrovascular accident
CVD	Cardiovascular disease
CXR	Chest X-ray
CYSTO	Cystoscopy
CYTO	Cytology
<b>D</b>	
D&C	Dilatation and curettage
D/C	Discharge
D/T	Due to
DC	Discontinue(d)
DCIS	Ductal carcinoma in situ
D-COLON	Descending colon

Abbreviation/Symbol	Word/Term(S)
DDX	Differential diagnosis
DECR	Decrease(d)
DERM	Dermatology
DIAM	Diameter
DIFF	Differentiated/differential
DISCH	Discharge
DJD	Degenerative joint disease
DK	Don't/Doesn't know
DM	Diabetes mellitus
DNA	Deoxyribonucleic acid
DOA	Dead on arrival
DOB	Date of birth
DOD	Date of death
DOE	Dyspnea on exertion
DRE	Digital rectal examination
DTC	Disseminated tumor cells
DVT	Deep vein thrombosis
DX	Diagnosis
DZ	Disease
<b>E</b>	
E.G.	For example
E/O	Evidence of
EBRT	External beam radiotherapy
ECG/EKG	Electrocardiogram
ED	Emergency department
EEG	Electroencephalogram
EENT	Eye, ear, nose, throat
EGD	Esophagogastroduodenoscopy

Abbreviation/Symbol	Word/Term(S)
EGFR	Epidermal growth factor receptor
ELEV	Elevated
EMG	Electromyogram
ENL	Enlarged
ENLGD	Enlarged
ENT	Ears, nose, and throat
ER	Emergency room
ER(A)	Estrogen receptor (assay)
ERCP	Endoscopic retrograde cholangiopancreatography
ESRD	End stage renal disease
ETOH	Alcohol
EUA	Exam under anesthesia
EV	Electron volt
EVAL	Evaluation
EXAM	Examination
EXC(D)	Excision/excised
EXP	Expired
EXP LAP	Exploratory laparotomy
EXPL	Exploratory
EXPL LAP	Exploratory laparotomy
EXT	Extend/extension
<b>F</b>	
FAP	Familial adenomatous polyposis
FCOT	First course of treatment
FHX	Family History
FISH	Fluorescence in situ hybridization
FL	Fluid
FLIPI	Follicular lymphoma international prognostic index

Abbreviation/Symbol	Word/Term(S)
FLOW CYTO	Flow cytometry
FLURO	Fluoroscopy
FNA	Fine needle aspiration
FNAB	Fine needle aspiration biopsy
FOM	Floor of mouth
FREQ	Frequent/Frequency
FS	Frozen section
FTSG	Full thickness skin graft
FU	Follow-up
FUO	Fever of unknown origin
FX	Fracture
FX(S)	Fractions(s)
<b>G</b>	
GB	Gallbladder
GE	Gastroesophageal
GEN	General/Generalized
GERD	Gastroesophageal reflux disease
GI	Gastrointestinal
GIST	Gastrointestinal stromal tumors
GR	Grade
GU	Genitourinary
GY	Gray
GYN	Gynecology
<b>H</b>	
H&E	Hematoxylin and Eosin
H&P	History and physical
H/H	Hemoglobin and hematocrit
H/O	History of

Abbreviation/Symbol	Word/Term(S)
HAV	Hepatitis A (virus)
HBV	Hepatitis B (virus)
HCG	Human chorionic gonadotropin
HCT	Hematocrit
HCV	Hepatitis C (virus)
HDR	High dose rate
HDV	Hepatitis D (virus)
HEM/ONC	Hematology/Oncology (ist)
HEP A	Hepatitis A (virus)
HEP B	Hepatitis B (virus)
HEP C	Hepatitis C (virus)
HEP D	Hepatitis D (virus)
HER2	Human epidermal growth factor receptor 2
HF	Hispanic female
HGB	Hemoglobin
HGSIL	High grade squamous intraepithelial lesion
HIV	Human Immunodeficiency Virus
HM	Hispanic male
HORM	Hormone
HOSP	Hospital
HPI	History of present illness
HPV	Human Papilloma Virus
HR(S)	Hour/Hours
HRT	Hormone replacement therapy
HSM	Hepatosplenomegaly
HTLV	Human T-Lymphotropic Virus, (Type III)
HTN	Hypertension
HX	History

Abbreviation/Symbol	Word/Term(S)
HYST	Hysterectomy
I	
I&D	Incision & drainage
I-131	Iodine 131
IBD	Inflammatory bowel disease
ICB	Intracavitary brachytherapy
ICM	Intercostal margin
ICS	Intercostal space
ICU	Intensive care unit
IDC	Infiltrating/invasive ductal carcinoma
IDDM	Insulin-dependent diabetes mellitus
IG	Immunoglobulin
IHC	Immunohistochemical
ILD	Interstitial lung disease
IM	Intramuscular
IMP	Impression
IMRT	Intensity modulated radiation therapy
INCL	Includes/Including
INCR	Increase(d)
INF	Inferior
INFIL	Infiltrating
INFILT	Infiltrating
INPT	Inpatient
INT	Internal
INV	Invade(s)/invading/invasion
INVL	Involve(s)/involvement/involving
IP	Inpatient
IPI	International prognostic index (for lymphoma)

Abbreviation/Symbol	Word/Term(S)
IPS	International prognostic score
IPSI	Ipsilateral
IRREG	Irregular
IT	Intrathecal
ITC	Isolated tumor cells
ITP	Idiopathic thrombocytopenia
IV	Intravenous
IVC	Inferior vena cava
IVCA	Intravenous cholangiogram
IVP	Intravenous pyelogram
<b>J</b>	
JAK2	Janus kinase 2
JRA	Juvenile rheumatic arthritis
JVD	Jugular venous distention
<b>K</b>	
KG	Kilogram
KS	Kaposi sarcoma
KUB	Kidneys, ureters, bladder
KV	Kilovolt
<b>L</b>	
L1-L5	Lumbar vertebra
LAB	Laboratory
LAD	Lymphadenopathy
LAN	Lymphadenopathy
LAP	Laparotomy
LAT	Lateral
LAV	Lymphadenopathy-associated virus
LB(S)	Pound(s)



Abbreviation/Symbol	Word/Term(S)
LCIS	Lobular carcinoma in situ
LCM	Left costal margin
LDH	Lactic dehydrogenase
LDR	Low dose rate
LE	Lower extremity
LFT	Liver function test
LIN	Laryngeal intraepithelial neoplasia
LINAC	Linear accelerator
LIQ	Lower inner quadrant
LLE	Left lower extremity
LLL	Left lower lobe
LLQ	Left lower quadrant
LMP	Last menstrual period
LN(S)	Lymph node(s)
LND	Lymph node dissection
LOQ	Lower outer quadrant
LRG	Large
LS	Lumbosacral
LSO	Left salpingo-oophorectomy
L-SPINE	Lumbar spine
LS SCAN	Liver/spleen scan
LT	Left
LUE	Left upper extremity
LUL	Left upper lobe
LUOQ	Left upper outer quadrant
LUQ	Left upper quadrant
LVI	Lymph/vascular invasion / Lymphovascular invasion
<b>M</b>	

Abbreviation/Symbol	Word/Term(S)
M/DIFF	Moderately differentiated
MAL	Malignant
MALIG	Malignant
MAMMO	Mammogram
MAND	Mandible/mandibular
MAX	Maximum
MC	Medical center
MC(H)	Millicurie (hours)
MCG	Microgram
MCN	Mucinous cystic neoplasm
MCTD	Mixed connective tissue disease
MD	Moderately differentiated
MDS	Myelodysplastic syndrome
MED	Medication
MED ONC	Medical oncology (ist)
METS	Metastatic/Metastasis
MEV	Million electron volts
MG	Myasthenia gravis
MG(H)	Milligram (hours)
MGF	Maternal grandfather
MGM	Maternal grandmother
MGUS	Monoclonal gammopathy of uncertain significance
MI	Myocardial infarction
MIBB	Minimally invasive breast biopsy
MICRO	Microscopic
MIN	Minimum
MIN	Minute
MIS	Melanoma in situ

Abbreviation/Symbol	Word/Term(S)
ML	Middle lobe
ML	Milliliter
MM	Millimeter
MMG	Mammogram
MO(S)	Months
MOD	Moderate(ly)
MOD DIFF	Moderately differentiated
MRCP	Magnetic resonance cholangiopancreatography
MRI	Magnetic resonance imaging
MRM	Modified radical mastectomy
MRSA	Methicillin Resistant Staphylococcus Aureus
MS	Multiple sclerosis
MSB	Main stem bronchus
MSI	Microsatellite instability
MULT	Multiple
MV	Megavolt
<b>N</b>	
N&V	Nausea and vomiting
N/A	Not applicable
N/V	Nausea and vomiting
NA	Not applicable
NE	No evidence
NEC	Not elsewhere classified
NED	No evidence of disease
NEG	Negative
NEOPL	Neoplasm
NET	Neuroendocrine tumor
NEURO	Neurology

Abbreviation/Symbol	Word/Term(S)
NH	Nursing home
NHL	Non-Hodgkin lymphoma
NIDDM	Non-insulin dependent diabetes mellitus
NML	Normal
NORM	Normal
NOS	Not otherwise specified
NR	Not recorded
NR	Not reportable
NSCCA	Non-small cell carcinoma
NSCLC	Non-small cell lung carcinoma
NSF	No significant findings
<b>O</b>	
OB	Obstetrics
OBS	Organic brain syndrome
OBST	Obstructed (-ing, -ion)
ONC	Oncology (ist)
OP	Outpatient
OP RPT	Operative report
OR	Operating room
ORTHO	Orthopedics
OTO	Otology
OUTPT	Outpatient
OZ	Ounce
<b>P</b>	
P/DIFF	Poorly differentiated
P32	Phosphorus 32
PAC	Premature atrial contraction
PALP	Palpated (-able)

Abbreviation/Symbol	Word/Term(S)
PAP	Papanicolaou smear
PAP	Papillary
PATH	Pathology
PBSCT	Peripheral blood stem cell transplant
PCP	Primary care physician
PCV	Polycythemia vera
PD	Poorly differentiated
PE	Physical examination
PEDS	Pediatrics
PERC	Percutaneous
PET	Positron emission tomography
PGF	Paternal grandfather
PGM	Paternal grandmother
PIN III or PIN 3	Prostatic intraepithelial neoplasia, grade III
PLT	Platelets
PMH	Past/personal (medical) history
PMP	Primary medical physician
PNS	Peripheral nervous system
POOR DIFF	Poorly differentiated
POS	Positive
POSS	Possible
POST	Posterior
POST OP	Postoperative(-ly)
PPD	Packs per day
PR	Per rectum
PR(A)	Progesterone receptor (assay)
PRE-OP	Preoperative(-ly)
PREV	Previous

Abbreviation/Symbol	Word/Term(S)
PROB	Probable (-ly)
PROCTO	Proctoscopy
PS	Performance status
PSA	Prostatic specific antigen
PT	Patient
PT	Physiotherapy/Physical therapy
PTA	Prior to admission
PTC	Percutaneous transhepatic cholecystogram
PTCC	Papillary transitional cell carcinoma
PUD	Peptic ulcer disease
PULM	Pulmonary
PVD	Peripheral vascular disease
P VERA	Polycythemia vera
PY	Pack years
<b>Q</b>	
Q	Every
QD	Every day
QUAD	Quadrant
<b>R</b>	
R/O	Rule out
RA	Rheumatoid arthritis
RAD	Radiation absorbed dose
RAD ONC	Radiation Oncology
RAEB	Refractory anemia with excess blasts
RAI	Radioactive iodine
RAIU	Radioactive iodine uptake
RAL	Robotic assisted laparoscopy
RARP	Robotic assisted radical prostatectomy

Abbreviation/Symbol	Word/Term(S)
RBBB	Right bundle branch block
RBC	Red blood cells (count)
RCC	Renal cell carcinoma
RCM	Right costal margin
RCS	Reticulum cell sarcoma
RE	Regarding
REC	Recommend
REC'D	Received
REFRACT ANEM	Refractory anemia
REG	Regional
REG	Regular
RESEC	Resection (ed)
RIA	Radioimmunoassay
RIQ	Right inner quadrant
RLE	Right lower extremity
RLL	Right lower lobe
RLQ	Right lower quadrant
RMC	Regional medical center
RML	Right middle lobe
ROF	Review of outside films
RONC	Radiation Oncology
ROQ	Right outer quadrant
ROS	Review of outside slides
RRP	Radical retropubic prostatectomy
RSO	Right salpingo-oophorectomy
RT	Radiation therapy
RT	Right
RUE	Right upper extremity

Abbreviation/Symbol	Word/Term(S)
RUL	Right upper lobe
RUQ	Right upper quadrant
RX	Prescription
RXT	Radiation therapy
<b>S</b>	
S/P	Status post
S1-S5	Sacral vertebra
SATIS	Satisfactory
SB	Small bowel
SCC	Squamous cell carcinoma
SCF	Supraclavicular fossa
SCID	Severe combined immunodeficiency syndrome
S-COLON	Sigmoid colon
SCT	Stem cell transplant
SCV	Supraclavicular
SGOT	Serum glutamic oxaloacetic transaminase
SGPT	Serum glutamic pyruvic transaminase
SH	Social history
SHX	Social history
SIG COLON	Sigmoid colon
SIN III or SIN 3	Squamous intraepithelial neoplasia
SLE	Systemic lupus erythematosus
SLL	Small lymphocytic lymphoma
SLN	Sentinel lymph node
SLNBX	Sentinel lymph node biopsy
SM	Small
SmCC	Small cell carcinoma
SO	Salpingo-oophorectomy



Abbreviation/Symbol	Word/Term(S)
SOB	Short(ness) of breath
SPEC	Specimen
SPEP	Serum protein electrophoresis
SQ	Squamous
SS	Summary stage
S-SPINE	Sacral spine
SSS	Sick sinus syndrome
STSG	Split thickness skin graft
SQCC	Squamous cell carcinoma
SUBCU	Subcutaneous
SUBQ	Subcutaneous
SUGG	Suggestive
SURG	Surgery/Surgical
SUSP	Suspicious/suspected
SVC	Superior vena cava
SX	Symptoms
<b>T</b>	
T1-T12	Thoracic vertebra
TAH	Total abdominal hysterectomy
TAH-BSO	Total abdominal hysterectomy- bilateral salpingo-oophorectomy
TB	Tuberculosis
TB	Tumor board
TCC	Transitional cell carcinoma
T-COLON	Transverse colon
TIA	Transient ischemic attack
TNM	Tumor, node, metastasis
TOB	Tobacco
TRANS-COLON	Transverse colon

Abbreviation/Symbol	Word/Term(S)
TRUS	Transrectal ultrasound
TS	Tumor size
T-SPINE	Thoracic spine
TTP	Thrombotic thrombocytopenia purpura
TUR	Transurethral resection
TURB	Transurethral resection bladder
TURP	Transurethral resection prostate
TVC	True vocal cord
TVH	Total vaginal hysterectomy
TX	Treatment
<b>U</b>	
UE	Upper extremity
UGI	Upper gastrointestinal (series)
UIQ	Upper inner quadrant
UNDIFF	Undifferentiated
UNK	Unknown
UOQ	Upper outer quadrant
URI	Upper respiratory infection
US	Ultrasound
UTI	Urinary tract infection
<b>V</b>	
VAG	Vagina/Vaginal
VAG HYST	Vaginal hysterectomy
VAIN III or VAIN 3	Vaginal intraepithelial neoplasia (grade III)
VIN III or VIN 3	Vulvar intraepithelial neoplasia (grade III)
VGP	Vertical growth phase
VGR	Vertical growth rate
VS	Vital signs

Abbreviation/Symbol	Word/Term(S)
<b>W</b>	
W/	With
W/DIFF	Well differentiated
W/F	White female
W/M	White male
W/O	Without
W/U	Work-up
WBC	White blood cells (count)
WD	Well differentiated
WELL DIFF	Well differentiated
WF	White female
WK(S)	Week(s)
WL	Weight loss
WM	White male
WNL	Within normal limits
WPW	Wolff-Parkinson-White syndrome
WT	Weight
<b>X</b>	
XR	X-ray
XRT	External radiation therapy
<b>Y</b>	
Y/O	Year old
YO	Year old
YR(S)	Year(s)
Y-90	Yttrium-90

# **APPENDIX E – 2024 Changes and Updates**

## 2024 New Data Items and Changes Oklahoma Central Cancer Registry

*Applicable for cases diagnosed January 1, 2024 and forward, NAACCR version 24*

### New Data Items

#### Site Specific Data Items

NAACCR Item #	SSDI Name	Schema
<b>3964</b>	<b>Brain Primary Tumor Location</b>	<b>Brain V9* (09721)</b>
<p><b>This SSDI is effective for diagnosis years 2024+</b>  <b>For cases diagnosed 2018-2023, leave this SSDI blank</b>                      Brain Primary Tumor Location [3964] is added to Brain V9 to distinguish between the Pons and all other subsites within the brain stem.</p>		

#### NPCR Data Items

NAACCR Item #	Item Name
No new NPCR required data items for 2024 not already identified in Site Specific Data Items above.	

### Changed Data Items

Site Specific Data Items		
<p>Some SSDI codes and code descriptions are changed to reflect changes in clinical management and/or staging and to improve clarity or to address questions that were raised in the various forums. <b>Code changes for SSDIs are applicable to cases diagnosed January 1, 2018, and forward, but registrars will not be required to update previously coded information.</b></p>		
NAACCR Item #	SSDI Name	Schema
<b>3816</b>	<b>Brain Molecular Markers</b>	<b>Brain V9 (09721) CNS Other V9 (09722)</b>
Codes 10-23 are added to incorporate new terms for various histologies. Code 85 is revised to include all histologies applicable for this data item.		
NAACCR Item #	SSDI Name	Schema
<b>3956</b>	<b>p16</b>	<b>Cervix V9 (09520) Anus V9 (09210) Vulva V9 (09500)</b>
p16 which is an existing SSDI for the Cervix V9 (09520) and Anus V9 (09210) schemas, is added to the Vulva V9 schema (09500). For cases diagnosed prior to January 1, 2024, Vulva cases would be in Vulva 8th and p16 would not be captured.		

#### NPCR Sponsored Data Item Changes

The description and rationale for the following NPCR-sponsored data item has been updated.	
NAACCR Item #	Data Item
344	Tobacco Use Smoking Status
<p>The following coding instructions are implemented for Tobacco Use Smoking Status [344]:</p> <ul style="list-style-type: none"> <li>Record cigarette, cigar, and/or pipe use only. Tobacco Use Smoking Status does not include marijuana, chewing tobacco, e-cigarettes, or vaping devices.</li> <li>Tobacco smoking history can be obtained from sections such as the Nursing Interview Guide, Flow Chart, Vital Stats or Nursing Assessment section, or other available sources from the patient's hospital medical record or physician office record.</li> <li>Use <b>code 1</b> if there is evidence in the medical record that the <i>patient quit smoking within 30 days prior to diagnosis</i>. The 30 days prior information is intended to differentiate patients who may have quit recently due to symptoms that led to a cancer diagnosis.</li> <li>Use <b>code 2</b> if medical record indicates patient smoked tobacco in the past but does not smoke now. <i>Patient must have quit 31 or more days prior to cancer diagnosis</i> to be coded as 'Former smoker.'</li> <li>Use <b>code 3</b> if it cannot be determined whether the patient currently smokes or formerly smoked. For example, the medical record only indicates "Yes" for smoking without further information.</li> </ul>	

<ul style="list-style-type: none"> <li>Use <b>code 9</b> (Unknown if ever smoked) rather than code 0 (Never smoker), if the medical record only indicates “No” for tobacco use; smoking status is not stated or provided; or the method (cigarette, pipe, cigar) used cannot be verified in the chart.</li> <li>This data item can be left blank for cases diagnosed prior to 1/1/2022.</li> </ul>		
Retired Data Items		
NAACCR Item #	Item Name	Current Data Items
250	Birthplace	Replaced in 2013 with Birthplace-State [252] and Birthplace-Country [254]
1940	Place of Death	Replaced in 2013 with Place of Death-State [1942] and Place of Death-Country [1944]
2390	Name-Maiden	Replaced in 2021 with Name-Birth Surname [2232]
3884	LN Status Femoral-Inguinal, Para-aortic, Pelvic	Replaced in 2022 with LN Status Para-aortic [3958], LN Status Pelvic [3957], and LN Status Femoral-Inguinal [3959]
ICD-O-3		
<p>Beginning with cases diagnosed January 1, 2021, ICD-O-3.2 is the preferred morphology coding reference manual. This manual should be used jointly with the 2024 ICD-O Histology and Behavior Code Update tables, Hematopoietic and Lymphoid Neoplasm Database, and Solid Tumor rules. Edits will enforce the new codes/behaviors.</p> <p><b>The IARC/WHO ICD-O Committee has indicated they will not be developing or publishing a print or downloadable .pdf version of ICD-O-3.2. Please use the coding table, linked below, available on the NAACCR website.</b>  <a href="https://www.naacr.org/wp-content/uploads/2020/10/Copy-of-ICD-O-3.2_MFin_17042019_web.xls">https://www.naacr.org/wp-content/uploads/2020/10/Copy-of-ICD-O-3.2_MFin_17042019_web.xls</a></p> <p><b>Coding Guidelines, tables 1-2 and the annotated list are located here</b> <a href="https://www.naacr.org/icdo3/">https://www.naacr.org/icdo3/</a>  <b>Note: Use of these guidelines is required for determining reportability and accurate coding.</b>  <b>Table 1:</b> lists all changes for 2024 including five new ICD-O codes and terms, one code with changes to behavior, and new preferred or related terms, in numerical order by ICD-O number.  <b>Table 2:</b> lists all changes for 2024 including five new ICD-O codes and terms, one code with changes to behavior, and new preferred or related terms, in alpha order by histology term.</p> <p>For 2024, no major changes have been identified during review of the 5th Editions WHO Urinary and Male Genital Tumors. Majority of changes for 2024 are new related terms for existing codes, five new ICD-O codes, four reportable and one non-reportable, and one histology that has changed behaviors and is now reportable.</p>		
<p><b>IMPORTANT REMINDERS</b></p> <p>Please check the 2024 ICD-O-3 Update Table 1 or 2 to determine if the histology is listed. If the histology is not included in the update, then review ICD-O-3.2 and/or Hematopoietic and Lymphoid Database and/or Solid Tumor Rules (MP/H).</p> <p>ICD-O-3.2 included changes from all 4th Ed WHO Classification of Tumors books. New editions released following the publication of 4th editions are not included in 3.2. A new ICD-O version will be released once all 5th Ed Blue Books are published.</p>		
<p><b>2024 Cancer PathCHART ICD-O-3 Site Morphology and Validation List</b></p> <p>The SEER Site/Histology Validation List is now replaced by the 2024 Cancer PathCHART ICD-O-3 Site Morphology and Validation List and has been updated to include the new ICD-O-3.2 histology codes and behaviors identified in the 2024 ICD-O-3 Update guidelines. It is posted on the SEER website at <a href="https://seer.cancer.gov/cancerpathchart/products.html">https://seer.cancer.gov/cancerpathchart/products.html</a></p>		
Solid Tumor Rules		
<p>The content of the Solid Tumor Rules will be made consistent with the Cancer PathCHART tumor site and morphology standards as outlined in the 2024 Cancer PathCHART ICD-O-3 Site Morphology Validation List.</p> <p><b>General</b></p> <p>The addition of new terminology, clarifications to equal/equivalent terms, and clarifications to terms that are not equal/equivalent comprise most of the changes for 2024.</p> <p>New site-specific modules are not planned for 2024 at this time, pending the publication of the remaining 5th Edition WHO Classification of Tumours books.</p>		

Reportability
Reportability for cases diagnosed in 2024 is based on the ICD-O Third Edition, Second Revision Morphology (ICD-O-3.2) plus the ICD-O-3.2 updates posted on the NAACCR website. There are no changes to reportability for 2024 diagnosis.
Surgery Codes
The Site-Specific Surgery Codes for <b>Lung (C34), Pancreas (C25), Thyroid (C73), Colon (C18), and Breast (C50)</b> are updated to align with the Synoptic Operative Report for cases diagnosed January 1, 2024, and forward. These surgery codes are in Appendix A of the 2024 <a href="#">STORE Manual</a> and Appendix C of the 2024 <a href="#">SEER Manual</a> . Valid values are based on year of diagnosis. Pay close attention to these specific instructions.
Surgery Code Crosswalks
<a href="#">Crosswalks of surgery codes</a> for the data items RX Summ--Surg Prim Site 03-2022 [1290] and RX Summ-Surg Prim Site 2023 [1291] have been developed for sites where significant changes occurred to the surgery codes and code definitions. <a href="https://www.naacccr.org/crosswalks-interoperability/">https://www.naacccr.org/crosswalks-interoperability/</a>  These crosswalks are intended to be used for quality control, by registry software vendors, and by data analysts interested in reviewing surgery codes over time.
Summary Stage 2018
OCCR continues to require directly assigned Summary Stage 2018 for cases diagnosed on or after January 1, 2018. <a href="https://seer.cancer.gov/tools/ssm/">https://seer.cancer.gov/tools/ssm/</a> Older cases still require Summary Stage 1977, Summary Stage 2000 or CS Derived Summary Stage 2000 depending on the diagnosis year.  Notes for prostate are updated similarly to the EOD fields to improve clarity. Registrars are not required to update previously coded information.
Hematopoietic and Lymphoid Neoplasm Manual and Database
The Hematopoietic and Lymphoid Neoplasms Manual and Database ( <a href="#">Heme manual</a> ) is effective for cases diagnosed 2010+. There are no changes to the Heme manual or to the Heme database for 2024.
Cancer PathCHART
The Cancer Pathology Coding Histology and Registration Terminology (Cancer PathCHART) initiative is a groundbreaking collaboration of North American and global registrar, registry, pathology, and clinical organizations, including tumor and histology cancer data standard setters.  Cancer PathCHART aims to improve cancer surveillance data quality by updating standards for tumor site, histology, and behavior code combinations and associated terminology.  Updated standards will be implemented as follows: <ul style="list-style-type: none"> <li>• For cases diagnosed in 2023 and earlier, 2023 tumor site and morphology standards will be used; <i>standards will not be applied retroactively, no review of cases diagnosed prior to 2024 will be required.</i></li> <li>• For cases diagnosed in 2024 at topographical sites that have undergone the Cancer PathCHART review processes, updated 2024 standards will be used.</li> <li>• For all other cases diagnosed in 2024 at topographical sites that have yet to be reviewed, 2023 tumor site and morphology standards will be used.</li> </ul> For more information about Cancer PathCHART see the <a href="#">NAACCR 2024 Implementation Guidelines</a> or the <a href="#">NCI SEER Cancer PathCHART webpage</a> .
v24 Edits
Changes to edits for cases diagnosed 2018 through 2023 address fixes to edit logic as well as updates necessary to accommodate changes to existing data items for 2024. You may view the changes in the <a href="#">NAACCR v24 Change Spreadsheet</a>  Not sure how to correct an edit error? Use the <a href="#">Edit Detail Report</a> to find the edit error and its details.

The OCCR uses the standard NAAACR edit metafile released for each NAACCR version update. Within this edit metafile, the OCCR requires use of the Central: VsYY State Example – Incoming Abstracts edit set. All commercial cancer registry software vendors will be provided with this information, as required, by October prior to the implementation date 01/01/YYYY.

#### 2024 NAACCR Implementation

##### **Webinar**

The NAACCR December 13, 2023, webinar “2024 Update: ICD O, Solid Tumor Rules, SSDIs” can be viewed here <https://education.naacr.org/updates-implementation>

##### **Summary for Hospital Registrars and Reporting Facilities**

<https://www.naacr.org/implementation-guidelines/> Section 12, page 29

\*V9 refers to AJCC Version 9 Protocols

Information listed in this document pertains exclusively to the OCCR reporting requirements as mandated by the CDC NPCR. ACoS CoC accredited hospitals have additional updates and changes beyond the scope of this document. Please refer to the [NAACCR implementation guidelines](#) for updates and changes from all standard setters or contact the ACoS for CoC accredited hospital questions.



# **APPENDIX F – Required Data Items**

**NPCR Required Data Items, current and historical per the NAACCR Data Dictionary v24 Required Status Table**

OCCR Reference year: 1997

Diagnosis years required to be reported to the OCCR: 1997-2024

Codes for Requirements	
R	Required
R#	Required; central registries may code available data using either SEER or CoC data items and associated rules
R*	Required, when available
R^	Required, these text requirements may be met with one or several text block fields
RH	Historically collected and currently transmitted
RH*	Historically collected and currently transmitted when available
RS*	Required, site specific; when available

NAACCR Data Item Number	Data Item Name	Section Name	NPCR Collect
70	Addr at DX--City	Demographic	R
80	Addr at DX--State	Demographic	R
90	County at DX Reported	Demographic	R
100	Addr at DX--Postal Code	Demographic	R
160	Race 1	Demographic	R
161	Race 2	Demographic	R
162	Race 3	Demographic	R
163	Race 4	Demographic	R
164	Race 5	Demographic	R
190	Spanish/Hispanic Origin	Demographic	R
220	Sex	Demographic	R
230	Age at Diagnosis	Demographic	R
240	Date of Birth	Demographic	R
252	Birthplace--State	Demographic	R*
254	Birthplace--Country	Demographic	R*
272	Census Ind Code 2010 CDC	Demographic	R*
282	Census Occ Code 2010 CDC	Demographic	R*
310	Text--Usual Occupation	Demographic	R*
320	Text--Usual Industry	Demographic	R*
344	Tobacco Use Smoking Status	Demographic	R*
390	Date of Diagnosis	Cancer Identification	R
400	Primary Site	Cancer Identification	R
410	Laterality	Cancer Identification	R
501	Casefinding Source	Cancer Identification	R*

NAACCR Data Item Number	Data Item Name	Section Name	NPCR Collect
522	Histologic Type ICD-O-3	Cancer Identification	R
523	Behavior Code ICD-O-3	Cancer Identification	R
540	Reporting Facility	Hospital-Specific	R
545	NPI--Reporting Facility	Hospital-Specific	R*
580	Date of 1st Contact	Hospital-Specific	R*
610	Class of Case	Hospital-Specific	R
630	Primary Payer at DX	Hospital-Specific	R*
756	Tumor Size Summary	Stage/Prognostic Factors	R
764	Summary Stage 2018	Stage/Prognostic Factors	R
820	Regional Nodes Positive	Stage/Prognostic Factors	R
830	Regional Nodes Examined	Stage/Prognostic Factors	R
1068	Grade Post Therapy Clin (yc)	Stage/Prognostic Factors	R*
1182	Lymphovascular Invasion	Stage/Prognostic Factors	R*
1200	RX Date Surgery	Treatment-1st Course	R*
1210	RX Date Radiation	Treatment-1st Course	R*
1220	RX Date Chemo	Treatment-1st Course	R*
1230	RX Date Hormone	Treatment-1st Course	R*
1240	RX Date BRM	Treatment-1st Course	R*
1250	RX Date Other	Treatment-1st Course	R*
1270	Date 1st Crs RX CoC	Treatment-1st Course	R#*
1285	RX Summ--Treatment Status	Treatment-1st Course	R#
1291	RX Summ--Surg Prim Site 2023	Treatment-1st Course	R
1292	RX Summ--Scope Reg LN Sur	Treatment-1st Course	R
1294	RX Summ--Surg Oth Reg/Dis	Treatment-1st Course	R
1340	Reason for No Surgery	Treatment-1st Course	R
1380	RX Summ--Surg/Rad Seq	Treatment-1st Course	R
1390	RX Summ--Chemo	Treatment-1st Course	R
1400	RX Summ--Hormone	Treatment-1st Course	R
1410	RX Summ--BRM	Treatment-1st Course	R
1420	RX Summ--Other	Treatment-1st Course	R
1430	Reason for No Radiation	Treatment-1st Course	R
1506	Phase I Radiation Treatment Modality	Treatment-1st Course	R
1639	RX Summ--Systemic/Sur Seq	Treatment-1st Course	R
1750	Date of Last Contact	Follow-up/Recurrence/ Death	R
1760	Vital Status	Follow-up/Recurrence/ Death	R
1910	Cause of Death	Follow-up/Recurrence/Death	R
1920	ICD Revision Number	Follow-up/Recurrence/Death	R

NAACCR Data Item Number	Data Item Name	Section Name	NPCR Collect
1942	Place of Death--State	Demographic	R
1944	Place of Death--Country	Demographic	R*
1990	Over-ride Age/Site/Morph	Edit Overrides/Conversion History/System Admin	R
2000	Over-ride SeqNo/DxConf	Edit Overrides/Conversion History/System Admin	R
2010	Over-ride Site/Lat/SeqNo	Edit Overrides/Conversion History/System Admin	R
2020	Over-ride Surg/DxConf	Edit Overrides/Conversion History/System Admin	R
2030	Over-ride Site/Type	Edit Overrides/Conversion History/System Admin	R
2040	Over-ride Histology	Edit Overrides/Conversion History/System Admin	R
2050	Over-ride Report Source	Edit Overrides/Conversion History/System Admin	R
2060	Over-ride Ill-define Site	Edit Overrides/Conversion History/System Admin	R
2070	Over-ride Leuk, Lymphoma	Edit Overrides/Conversion History/System Admin	R
2071	Over-ride Site/Behavior	Edit Overrides/Conversion History/System Admin	R
2074	Over-ride Site/Lat/Morph	Edit Overrides/Conversion History/System Admin	R
2078	Over-ride Name/Sex	Edit Overrides/Conversion History/System Admin	R
2152	CoC Accredited Flag	Edit Overrides/Conversion History/System Admin	R
2230	Name--Last	Patient-Confidential	R
2232	Name--Birth Surname	Patient-Confidential	R
2240	Name--First	Patient-Confidential	R
2250	Name--Middle	Patient-Confidential	R
2280	Name--Alias	Patient-Confidential	R
2300	Medical Record Number	Patient-Confidential	R
2315	Medicare Beneficiary Identifier	Patient-Confidential	R*
2320	Social Security Number	Patient-Confidential	R
2330	Addr at DX--No & Street	Patient-Confidential	R
2335	Addr at DX--Supplementl	Patient-Confidential	R
2520	Text--DX Proc--PE	Text-Diagnosis	R^
2530	Text--DX Proc--X-ray/Scan	Text-Diagnosis	R^
2540	Text--DX Proc--Scopes	Text-Diagnosis	R^
2550	Text--DX Proc--Lab Tests	Text-Diagnosis	R^
2560	Text--DX Proc--Op	Text-Diagnosis	R^
2570	Text--DX Proc--Path	Text-Diagnosis	R^
2580	Text--Primary Site Title	Text-Diagnosis	R^
2590	Text--Histology Title	Text-Diagnosis	R^
2600	Text--Staging	Text-Diagnosis	R^
2610	RX Text--Surgery	Text-Treatment	R^
2620	RX Text--Radiation (Beam)	Text-Treatment	R^
2630	RX Text--Radiation Other	Text-Treatment	R^

NAACCR Data Item Number	Data Item Name	Section Name	NPCR Collect
2640	RX Text--Chemo	Text-Treatment	R^
2650	RX Text--Hormone	Text-Treatment	R^
2660	RX Text--BRM	Text-Treatment	R^
2670	RX Text--Other	Text-Treatment	R^
3170	RX Date Mst Defn Srg	Treatment-1st Course	R*
3250	RX Summ--Transplnt/Endocr	Treatment-1st Course	R
3816	Brain Molecular Markers	Stage/Prognostic Factors	RS
3817	Breslow Tumor Thickness	Stage/Prognostic Factors	RS
3827	Estrogen Receptor Summary	Stage/Prognostic Factors	RS
3829	Esophagus and EGJ Tumor Epicenter	Stage/Prognostic Factors	RS
3835	Fibrosis Score	Stage/Prognostic Factors	RS
3838	Gleason Patterns Clinical	Stage/Prognostic Factors	RS
3839	Gleason Patterns Pathological	Stage/Prognostic Factors	RS
3840	Gleason Score Clinical	Stage/Prognostic Factors	RS
3841	Gleason Score Pathological	Stage/Prognostic Factors	RS
3842	Gleason Tertiary Pattern	Stage/Prognostic Factors	RS*
3843	Grade Clinical	Stage/Prognostic Factors	R
3844	Grade Pathological	Stage/Prognostic Factors	R
3845	Grade Post Therapy Path (yp)	Stage/Prognostic Factors	R*
3855	HER2 Overall Summary	Stage/Prognostic Factors	RS
3890	Microsatellite Instability (MSI)	Stage/Prognostic Factors	RS*
3915	Progesterone Receptor Summary	Stage/Prognostic Factors	RS
3920	PSA (Prostatic Specific Antigen) Lab Value	Stage/Prognostic Factors	RS
3926	Schema Discriminator 1	Stage/Prognostic Factors	RS
3927	Schema Discriminator 2	Stage/Prognostic Factors	RS
3932	LDH Lab Value	Stage/Prognostic Factors	RS
3956	p16	Stage/Prognostic Factors	RS
3960	Histologic Subtype	Stage/Prognostic Factors	RS*
3964	Brain Primary Tumor Location	Stage/Prognostic Factors	RS

# **APPENDIX G – Texting Table**

The <b>OCCR Required Text</b> column indicates text which <b>must</b> be included in an abstract submitted to the Oklahoma Central Cancer Registry (OCCR).		
NAACCR Item #	Field Name, (NAACR Field Name) and Field Length	<b>OCCR <u>Required</u> Text</b>
2570	<p><b>Pathology Text</b></p> <p>(Text-DX Proc-Path)</p> <p>Length: 4000</p>	<p><b>Chronologically</b> (using date the specimen was obtained) record all relevant pathology and/or cytology results from all <b>diagnostic and surgical procedures</b>, including:</p> <ul style="list-style-type: none"> <li>• <b>Date specimen(s) Obtained (Date of Procedure)</b></li> <li>• <b>Location/Place</b> where specimen was obtained.</li> <li>• <b>Pathology and/or Cytology Report Number(s)</b></li> <li>• <b>Origin and Description</b> of specimens or tissue examined (e.g., biopsy, smear, surgical specimen, FNA, etc.)</li> <li>• <b>Final Histologic Diagnosis and Additional Details</b> including (but not limited to):                             <ul style="list-style-type: none"> <li>○ Morphology (cell type), behavior &amp; grade of tumor</li> <li>○ Primary tumor size, all dimensions when given</li> <li>○ Description of tumor invasion from gross, microscopic and/or final diagnosis</li> <li>○ Lymph node information</li> <li>○ Surgical margins</li> </ul> </li> <li>• <b>Additional Impressions from the Pathologist</b> (Including addendums, differential diagnoses considered/ruled out/favored, and consults that confirm or change the diagnosis)</li> <li>• <b>Include information from the synoptic report, when available</b></li> </ul>
2520	<p><b>Physical Exam Text</b></p> <p>(Text-DX Proc-PE)</p> <p>Length: 4000</p>	<p><b>Synoptic narrative</b> of any pertinent findings from the patient’s inpatient and outpatient visits, including:</p> <ul style="list-style-type: none"> <li>• <b>Date of visit.</b> Must substantiate the date of first contact and the date of diagnosis (if not substantiated elsewhere in the abstract)</li> <li>• <b>Place of Visit/Provider’s Name, Impression and Treatment Plan.</b></li> <li>• <b>Symptoms at Diagnosis.</b> If asymptomatic or incidentally diagnosed, state reason for presenting to medical care.</li> <li>• <b>Pertinent Personal Medical History</b> related to the current cancer diagnosis, including prior history of cancer(s) if any.</li> <li>• <b>Physical exam findings at initial diagnosis</b>, including date of exam, where exam was performed, age, sex and race of patient and pertinent findings.                             <ul style="list-style-type: none"> <li>○ <b>All prostate primaries</b> must include results of DRE prior to any needle biopsies of the prostate.</li> <li>○ <b>All lymphoma primaries</b> must include PE evaluation of lymph nodes &amp; presence or absence of ‘B symptoms.</li> </ul> </li> </ul>

The **OCCR Required Text** column indicates text which **must** be included in an abstract submitted to the Oklahoma Central Cancer Registry (OCCR).

NAACCR Item #	Field Name, (NAACR Field Name) and Field Length	<b>OCCR <u>Required</u> Text</b>
2530	<b>X-ray/Scan Text</b>  (Text-DX Proc-Xrays/Scans)  Length: 4000	<b>Chronologically</b> (using date of imaging) enter all relevant <b>film/imaging report results</b> done to diagnose and/or detail the extent of tumor involvement: <ul style="list-style-type: none"> <li>• <b>Date</b> films taken</li> <li>• <b>Place</b> where films were taken</li> <li>• <b>Imaging modality &amp; body part</b> being imaged (CT C, MRI Abd, TBBS, etc.)</li> <li>• <b>Description</b> of tumor, tumor invasion, lymph node status, tumor size (if mentioned) and presence or absence of metastatic disease. Record both positive and negative findings, with positive findings first.</li> <li>• <b>Results, findings and/or conclusions</b> from appropriate report(s) including differential diagnoses considered/ruled out/favored</li> </ul>
2550	<b>Lab Tests Text</b>  (Text-DX Proc-Lab Tests)  Length: 4000	<b>Chronologically</b> (using date specimen obtained) enter all relevant <b>lab tests or tumor markers</b> : <ul style="list-style-type: none"> <li>• <b>Date and place</b> lab tests or tumor markers taken</li> <li>• <b>Pathology or cytology report number</b> (if obtained from a histologic or cytologic pathology specimen)</li> <li>• <b>Type/Name</b> of lab test performed                             <ul style="list-style-type: none"> <li>○ Narrative documentation to support values coded in SSDIs, unless documented in another field</li> </ul> </li> <li>• <b>Test Results</b>, including normal test reference range or value, and/or physician interpretation</li> </ul>
2540	<b>Scopes Text</b>  (Text-DX Proc-Scopes)  Length: 4000	<b>Chronologically</b> (using date of exam) enter all <b>endoscopic examinations</b> relevant to the initial diagnosis, staging and/or treatment of this primary: <ul style="list-style-type: none"> <li>• <b>Date and place</b> of endoscopic exam</li> <li>• <b>Type or name</b> of endoscopic exam performed (including site scoped)</li> <li>• <b>Results, findings and/or conclusions</b> from endoscopic exam including:                             <ul style="list-style-type: none"> <li>○ Primary site and histology (if given)</li> <li>○ Tumor size</li> <li>○ Lymph node evaluation</li> <li>○ Tumor location (e.g., esophageal tumor extends from 32 cm to 40 cm from the incisors)</li> </ul> </li> </ul>



The <b>OCCR Required Text</b> column indicates text which <b>must</b> be included in an abstract submitted to the Oklahoma Central Cancer Registry (OCCR).		
NAACCR Item #	Field Name, (NAACR Field Name) and Field Length	OCCR <u>Required</u> Text
2560	DX Procedures Text  (Text-DX Proc-OP)  Length: 4000	<b>Chronologically</b> (using date of procedure) enter the observations of the surgeon or other appropriate physician from all diagnostic and surgical procedures, including: <ul style="list-style-type: none"> <li>• <b>Date and place</b> of all diagnostic and surgical procedure(s)</li> <li>• <b>Name or type</b> of diagnostic and surgical procedure(s)</li> <li>• <b>Description</b> of tumor, tumor invasion, lymph node status and tumor size (if mentioned). Record both positive and negative findings.</li> <li>• <b>Note:</b> Do not enter information from the pathology report here; information from pathology reports is texted in Text-DX Proc-Path.</li> </ul>
2600	Text Staging (Text-Staging)  Length: 4000	<b>Synoptic narrative</b> of rationale to support <b>SEER Summary Stage</b> <ul style="list-style-type: none"> <li>• Codes <b>must</b> include a narrative documentation of extent of disease</li> <li>• A brief description is acceptable (e.g., “cancer confined to prostate” or “SS2018 7/Distant mets to liver”)</li> <li>• Facilities may use this area to also document AJCC TNM stage</li> </ul>
2580	Primary Site Text (Text Primary Site) Length: 100	<b>Synoptic narrative of:</b> <ul style="list-style-type: none"> <li>• <b>Primary site</b>, and</li> <li>• <b>Laterality</b> (for all paired sites)</li> </ul>
2590	Histology Text (Text-Histology Title) Length: 100	<b>Synoptic narrative of:</b> <ul style="list-style-type: none"> <li>• <b>Histologic (cell) type and behavior</b>,</li> </ul>
2610	Text Surgery  (RX Text-Surgery)  Length: 4000	<b>Chronologically</b> (using date of surgical ablation or resection) enter all relevant <b>surgical ablations or resections</b> done to provide cancer-directed treatment, including: <ul style="list-style-type: none"> <li>• <b>Date</b> of surgical ablation or resection</li> <li>• <b>Location/place</b> where surgical ablation or resection was performed</li> <li>• <b>Name or description</b> of surgical ablation or resection performed</li> <li>• <b>Tissues removed</b>, including <b>lymph nodes, regional or adjacent tissues and metastatic sites</b> (as applicable)</li> <li>• <b>Note:</b> The preferred text placement of observations by the surgeon(s) during the procedure is Text-DX Proc-OP</li> </ul>

The OCCR Required Text column indicates text which <b>must</b> be included in an abstract submitted to the Oklahoma Central Cancer Registry (OCCR).		
NAACCR Item #	Field Name, (NAACR Field Name) and Field Length	OCCR <u>Required Text</u>
2620	Text Radiation Beam  (RX Text-Radiation Beam)  Length: 4000	<b>Chronologically</b> (using radiation start date) enter all relevant <b>beam radiation treatments</b> administered as cancer-directed treatment including: <ul style="list-style-type: none"> <li>• <b>Date</b> beam radiation started for Phase 1 Radiation</li> <li>• <b>Place</b> where beam radiation was administered for Phase 1 Radiation</li> <li>• <b>Treatment details</b> for Phase 1 Radiation such as:                             <ul style="list-style-type: none"> <li>○ <b>Treatment modality (type of beam radiation)</b> such as photon, proton, electron, etc.)</li> </ul> </li> <li>• Documentation of <b>patient refusal or reason why</b> beam radiation was not administered</li> </ul>
2630	Text Radiation Other  (RX Text-Radiation Other)  Length: 4000	<b>Chronologically</b> (using radiation start date) enter all relevant <b>brachytherapy, systemic or other radiation treatments</b> administered as cancer-directed treatment including: <ul style="list-style-type: none"> <li>• <b>Date brachytherapy, systemic or other radiation treatment</b> was administered for Phase 1 radiation</li> <li>• <b>Place</b> where brachytherapy, systemic or other radiation treatment was administered for Phase 1 Radiation</li> <li>• <b>Treatment details</b> for Phase 1 Radiation such as:                             <ul style="list-style-type: none"> <li>○ <b>Type of radiation</b> (including <b>modality</b> such as brachytherapy, etc.)</li> </ul> </li> <li>• Documentation of <b>patient refusal or reason why</b> beam radiation was not administered</li> </ul>
2640	Text Chemotherapy  (RX Text-Chemotherapy)  Length: 4000	<b>Chronologically</b> (using chemotherapy start date) enter all relevant chemotherapy treatment details administered as cancer-directed treatment such as: <ul style="list-style-type: none"> <li>• <b>Date(s)</b> chemotherapy agents were administered</li> <li>• <b>Place(s)</b> where chemotherapy was administered</li> <li>• <b>Treatment details</b> including names of all chemotherapy agents administered</li> <li>• Documentation of <b>patient refusal or reason why</b> chemotherapy was not administered</li> </ul>

The <b>OCCR Required Text</b> column indicates text which <b>must</b> be included in an abstract submitted to the Oklahoma Central Cancer Registry (OCCR).		
NAACCR Item #	Field Name, (NAACR Field Name) and Field Length	OCCR <u>Required Text</u>
2650	Text Hormone (RX Text-Hormone Therapy)  Length: 4000	<p><b>Chronologically</b> (using hormone therapy start date) enter all relevant hormone therapy treatment details administered as cancer-directed treatment such as:</p> <ul style="list-style-type: none"> <li>• <b>Date(s)</b> hormone therapy agents were administered</li> <li>• <b>Place(s)</b> where hormone therapy was administered</li> <li>• <b>Treatment details</b> including names of all hormone therapy agents administered</li> </ul> <p>Documentation of <b>patient refusal or reason why</b> hormone therapy was not administered</p>
2660	Text BRM (RX Text-BRM)  Length: 4000	<p><b>Chronologically</b> (using immunotherapy start date) enter all relevant immunotherapy treatment details administered as cancer-directed treatment such as:</p> <ul style="list-style-type: none"> <li>• <b>Date(s)</b> immunotherapy agents were administered</li> <li>• <b>Place(s)</b> where immunotherapy was administered</li> <li>• <b>Treatment details</b> including names of all immunotherapy agents administered</li> <li>• Documentation of <b>patient refusal or reason why</b> immunotherapy was not administered</li> </ul> <p><b>Hematologic Transplants and Endocrine Procedures</b> documentation:</p> <ul style="list-style-type: none"> <li>• RX Text-BRM is also used to document hematologic transplants and endocrine procedures</li> <li>• Hematopoietic transplants should include the source (bone marrow, peripheral blood, cord, etc.)</li> </ul>
2670	Text Other Treatment (RX Text-Other)  Length: 4000	<p><b>Chronologically</b> (using other therapy start date) enter all relevant other therapy treatment details administered as cancer-directed treatment, including experimental treatments and blinded clinical trials such as:</p> <ul style="list-style-type: none"> <li>• <b>Date(s)</b> other therapy agents were administered</li> <li>• <b>Place(s)</b> where other therapy was administered</li> <li>• <b>Treatment details</b> including names of all other therapy agents administered</li> <li>• Documentation of <b>patient refusal or reason why</b> other therapy was not administered</li> </ul>

The **OCCR Required Text** column indicates text which **must** be included in an abstract submitted to the Oklahoma Central Cancer Registry (OCCR).

NAACCR Item #	Field Name, (NAACR Field Name) and Field Length	<u>OCCR Required Text</u>
2680	Text, Remarks  (Text Remarks)  Length: 4000	<p><b>Record all other known primary tumors</b>, including:</p> <ul style="list-style-type: none"> <li>• Sequence number of additional primaries (e.g., seq. 01)</li> <li>• <b>Primary site and laterality</b></li> <li>• <b>Histology and behavior</b></li> <li>• <b>Date of diagnosis</b></li> <li>• <b>Location of diagnosis</b> (if known)</li> </ul> <p><b>Additional information</b> could include:</p> <ul style="list-style-type: none"> <li>• Solid Tumor Rules used to determine number of primaries, recurrent disease, primary site and/or histology codes</li> <li>• Native American tribal affiliation (if known)</li> <li>• Place of death, date of death and where information was obtained</li> <li>• Pertinent family medical history</li> <li>• Social history (smoking, alcohol use, etc.) if not documented in Text, PE</li> </ul>
310	Text-Usual Occupation  Length: 100	<p><b>Synoptic narrative</b> of the patient’s usual occupation (usual type of job or work)</p> <ul style="list-style-type: none"> <li>• Record the patient’s usual occupation (e.g., the kind of work performed during most of the patient’s working life before diagnosis of this tumor). Do not record “retired” or NA (N/A or not available). If the usual occupation is not available or is unknown, record the patient’s current or most recent occupation, or any available occupation. If no occupational history is known or available, record “unknown”.</li> </ul>
320	Text-Usual Industry  Length: 100	<p><b>Synoptic narrative</b> of the patient’s usual occupation (usual type of business/industry)</p> <ul style="list-style-type: none"> <li>• Record the primary type of activity carried on by the business/industry at the location where the patient was employed for the most number of years before diagnosis of this tumor. The information for industry should be based on the information listed in the “Occupation” field.</li> </ul>

<b>Texting Notes</b>
NAACCR approved abbreviations should be used (see the NAACCR Data Dictionary <a href="#">Appendix G</a> ).
Do not repeat information from other fields.
Do not include irrelevant information; also do not include information that the registry is not permitted to collect.
With the increase in field length, there should not be overflow text; however, in the rare instance this should occur, overflow text from other fields can be placed in Text, Remarks. For text documentation that is continued from one field to another, use asterisks or other symbols to indicate the connection with preceding text.
Text pertinent positive and negative findings. Text pertinent positive findings first followed by a simply stated summary of negative findings.
Text must substantiate all codes for that treatment type.
If a specific treatment or treatment modality has been recommended as part of a treatment plan <b>or</b> is typically administered as standard of care for the type and stage of disease but was <b>not</b> administered, document reason why it was not given (i.e., patient refused, etc.)
Information should be entered manually from the medical record and <b>should not be generated automatically from coded values.</b>

<b>Text Examples – Case #1 (Skin primary)</b>	
<b>Field Name</b>	<b>Text Example</b>
<b>Pathology Text</b>	<p>11/1/2023 Downtown Derm Shave bx skin of Lt foot ABC23-123456: Invasive melanoma, acral type, Breslow's thickness 3.3 mm; 5 mitoses per mm<sup>2</sup>; LVI pos; PNI neg. Margins pos. pT3a</p> <p>11/17/2023 ABC Hosp Wide excision skin of L foot w/SLN ABD23-234567: Malignant melanoma, acral type. Residual tumor thickness 2.2 mm. Margins neg. BRAF neg. 2/3 sentinel inguinal LNs w/mets melanoma, 0.3 mm. pT3a pN2a</p>
<b>Physical Exam Text</b>	<p>11/1/2023 Downtown Derm 54 y/o WF c/o skin lesion between her toes on Lt foot, present approx. 6 years, recently began increasing in size and bleeding. PE: Extensively sun damaged skin. An approx. 0.75 mm dark brown ulcerated lesion on webspace between the first and second toes on Lt. Recommended shave biopsy, performed. Remainder of exam WNL.</p> <p>11/17/2023 ABC Hosp H&amp;P: Pt presents for wide excision of previously diagnosed melanoma between her toes on Lt. She is also to have a sentinel lymph node biopsy.</p>
<b>X-ray/Scan Text</b>	None
<b>Lab Texts Text</b>	11/5/2023 Downtown Derm LDH: 293 U/L (normal)
<b>Scopes Text</b>	None
<b>DX Procedures Text</b>	11/17/2023 ABC Hosp Wide excision skin of Lt foot w/SLN: NSF; greater than 1 cm margins were obtained.
<b>Text Staging</b>	SS2018: 3/LN Mets to 2 of 3 sentinel (Lt inguinal) lymph nodes
<b>Primary Site Text</b>	Skin of Lt foot
<b>Histology Text</b>	Melanoma, acral type
<b>Text Surgery</b>	<p>11/1/2023 Downtown Derm Shave biopsy of Lt foot</p> <p>11/17/2023 ABC Hosp Wide excision skin of Lt foot w/SLN</p>
<b>Text Radiation (Beam)</b>	None
<b>Text Radiation Other</b>	None
<b>Text Chemotherapy</b>	None
<b>Text Hormone</b>	None
<b>Text BRM (Immunotherapy)</b>	12/29/2023 ABC Oncology Nivolumab
<b>Text Other Treatment</b>	None
<b>Text, Remarks</b>	
<b>Text Usual Occupation</b>	Unknown
<b>Text Usual Industry</b>	Unknown

<b>Text Examples – Case #2 (Lung primary)</b>	
<b>Field Name</b>	<b>Text Example</b>
<b>Pathology Text</b>	<p>4/2/2023 ABC Med Ctr RUL bx w/FNA of stations 4R &amp; 7 LNs ABC23-1234: Pulmonary adenocarcinoma w/solid predominant growth pattern. No evidence of mets in sampled LNs.</p> <p>5/14/2023 ABC Med Ctr RUL Lobectomy w/MLND ABC23-3456 Synoptic report: Unifocal 5.7x3.5x2.1 cm solid adenocarcinoma poorly diff invading visceral pleura w/LVI. Peribronchial margin positive; bronchial &amp; vascular margins neg. STAS not id'd. 1/3 10R LNs, 1/2 peribronchial LNs &amp; 0/1 interlobar LN w/mets. pT4 pN1</p>
<b>Physical Exam Text</b>	1/31/2023 ABC Med Ctr 67 y/o Hispanic male presents for evaluation of Rt shoulder pain and abnormal x-ray. Admits to mild SOB/DOE. No other significant PMH. Current smoker. PE: Decreased range of motion in Rt shoulder. Remainder of PE: NSF. Will order CT scan.
<b>X-ray/Scan Text</b>	<p>2/5/2023 ABC Med Ctr CT C/A/P: 6.4 cm spiculated mass RUL abuts mediastinum, obstructs RUL airway w/suspected post obstructive pneumonia. Add'l nodule measures up to 1.5 cm. Findings almost certainly represent malignancy. Soft tissue fullness extends to Rt hilum. Mediastinal LNs are seen but not enlarged by size criteria. Remainder neg for mets.</p> <p>3/8/2023 ABC Med Ctr PET: RUL malignancy measures 5.6 cm. No other malig uptake.</p>
<b>Lab Texts Text</b>	ALK & EGFR not performed.
<b>Scopes Text</b>	4/2/2023 ABC Med Ctr Bronchoscopy w/bx, lavage & EBUS LN sampling: Complete occlusion of RUL apical segment. Station 4R & station 7 enlarged LNs, sampled.
<b>DX Procedures Text</b>	5/14/2023 ABC Med Ctr Robotic assisted converted to open RUL lobectomy w/MLND: NSF.
<b>Text Staging</b>	SS2018: 4/DE&RLN Direct extension to visceral pleura w/mets to hilar & peribronchial LNs
<b>Primary Site Text</b>	RUL Lung
<b>Histology Text</b>	Solid adenocarcinoma
<b>Text Surgery</b>	5/14/2023 ABC Med Ctr Robotic assisted converted to open RUL lobectomy w/MLND
<b>Text Radiation (Beam)</b>	5/28/2023 ABC Rad: Recommended combined chemoradiation but pt decided they did not want to proceed.
<b>Text Radiation Other</b>	None.
<b>Text Chemotherapy</b>	5/28/2023 ABC Onc: Recommended combined chemoradiation w/Cisplatin & Alimta x4 cycles but pt decided they did not want to proceed.
<b>Text Hormone</b>	Not recommended.

<b>Text BRM (Immunotherapy)</b>	Not recommended.
<b>Text Examples – Case #2 (Lung primary)</b>	
<b>Field Name</b>	<b>Text Example</b>
<b>Text Other Treatment</b>	Not recommended.
<b>Text, Remarks</b>	
<b>Text Usual Occupation</b>	Truck driver
<b>Text Usual Industry</b>	Transportation